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Oral motor performance refers to the daily-life execution of oral motor tasks in a person’s 
natural environment. This thesis focuses on complex oral motor activities in seriously 
impaired children: eating and drinking, swallowing, and saliva control. 
In normal circumstances, eating and drinking are daily activities that guarantee sufficient 
food and liquid intake, but also create opportunities for children and their caregivers to 
communicate and socially interact, which forms a basis for normal development.1 However, 
in children with neurodevelopmental disabilities, e.g. due to cerebral palsy (CP), it may be 
challenging to eat, drink, swallow, and control saliva in an efficient and safe way, which 
jeopardizes their intake and social development. Quite often, oral motor problems in 
these children are associated with other CP-related conditions such as epilepsy, cognitive 
impairments, behavioral problems, and/or perception and sensation disorders. Furthermore, 
possible impairments of the oral region show a large variation and complex association 
with other sensorimotor impairments, leading to diminished oral motor performance. 
For example, difficulties with swallowing can be associated with excessive drooling,2 and 
difficulties with eating and drinking can arise when intake is disturbed by poor gross motor 
function or intellectual impairment.3 
The limited oral motor performance in children with neurodevelopmental disabilities 
inevitably results in feeding difficulties caused by the interaction of (1) dysfunctional oral 
motor control (weak sucking, persistent tongue protrusion or thrusting, poor lip closure, 
poor bolus formation), (2) abnormal neurological maturation (presence of oral pathological 
reflexes like biting, gagging), and (3) low level of motor ability and poor seating posture during 
feeding.4 In the child with neurodevelopmental disability, body posture and the sequence 
of essential oral events may be compromised by abnormal tone and movement patterns. It 
is important to secure correct postural alignment in order to achieve safe swallowing and 
sufficient feeding. Effective oral functioning for feeding begins with attaining head stability 
to ensure jaw control. Head stability, however, is influenced by trunk alignment, which in 
turn is dependent on the stability of the pelvic area.5 
Besides the oral motor problems, the feeding process can be disrupted by gastro-
intestinal problems like gastroesophageal reflux, vomiting, constipation, and dysmotility 
disorders.6 In addition, children with neurodevelopmental disabilities have difficulties 
expressing themselves because of speech problems or cognitive impairments. In this 
respect, it can be hard for the child to make clear to the environment his/her food preference 
or the need of food and liquid in the first place. Side effects of medication can also have 
a serious impact. For example, spasmolytic, anticholinergic and anti-epileptic drugs may 
affect appetite and/or gastrointestinal motility.7 
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Due to the complexity of these children, organized care during their development 
is needed. For this reason, since 2000, forces have been joined at the Radboud university 
medical center by forming an interdisciplinary, outpatient saliva control and swallowing 
team. Over the past two decades, hundreds of children have been referred to this team. 
The team includes a pediatric neurologist, an ear-nose-throat (ENT) specialist, a pediatric 
rehabilitation specialist, a psychologist, and speech-language therapists (SLTs). Parents 
are part of the team as the primary caregivers and decision makers of their child. There 
is collaboration ‘on demand’ with other disciplines such as dentistry, gastroenterology, 
pediatrics, dietetics, physiotherapy, and occupational therapy. In addition, the department 
of radiology can perform video fluoroscopic swallow studies (VFSS). The team members are 
armed with knowledge about the (patho)physiology of swallowing and are experienced in 
assessing and treating dysphagia and drooling. A well structured approach to diagnosis and 
treatment is followed and children are consistently monitored before and after any (proposed) 
intervention. The outcomes of all measurements are registered in a database. The mission 
of the team is to improve health-related quality of life in children with neurodevelopmental 
disabilities and their caregivers and to enhance meaningful participation in everyday life. 
SLTs take care of accurate assessment of eating and drinking abilities and advise about long-
term treatment of dysphagia and drooling. As the nature of eating, drinking and swallowing 
problems is multifactorial, all levels of the international classification of functioning, disability 
and health: children and youth version (ICF-CY)8 (i.e., impairments, activity limitations, 
participation restrictions) are addressed in a comprehensive assessment. Not only ‘capacity’, 
describing what a child is able to do in an optimal situation, but also ‘performance’, 
representing what a child actually does in his/her natural environment, are assessed. 
Despite the apparent increase in the number of children with feeding and swallowing 
disorders, validated classification systems, assessment tools, and outcome measures are 
largely lacking.1 These gaps in the clinical work-up of assessing oral motor performance and 
managing dysphagia and drooling form the inspiration for this thesis.
Dysphagia
The term dysphagia is derived from Greek and means ‘problematic’(dys) – eating (phagein). 
It refers to problems in any or all of the four phases of swallowing. Swallowing is a complex 
process during which saliva, liquid, and (chewed) food are transported from the mouth 
into the stomach while keeping the airway protected.9 For safe feeding and swallowing the 
integrity of five nerves and more than 30 muscles is needed to make voluntary movements 
and generate effective oral and pharyngeal reflexes.10 The ‘oral preparatory phase’ is 
initiated when food is taken into the mouth to process it and mix it with saliva to form 
a bolus. The ‘oral transit phase’ consists of the posterior propulsion of the bolus through 
the oral cavity, whereby jaw-closing muscles stabilize the mandible in a closed position. 
The ‘pharyngeal phase’ begins when the swallowing reflex is triggered and has two crucial 
biological features: (1) food passage, propelling the food through the pharynx and upper 
13
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from the pharynx during passage of food or saliva to prevent aspiration.10 The ‘esophageal 
phase’ starts with relaxation of the UES during a swallow and allows the bolus passage 
through the esophagus to the stomach.
In pathologic conditions three syndromes of chronic pulmonary aspiration have been 
described: aspiration of toxic contents (i.e. gastric acid); aspiration of pathogenic bacteria 
transmitted by saliva; and aspiration of inert substances.11 Chronic aspiration of saliva is 
the least common form of aspiration and is often not diagnosed prior to the development 
of lung injury. Aspiration can be caused by swallowing dysfunction, anatomic or dynamic 
abnormalities of the airways, and/or circumstances that overrule the child’s capacity to 
protect the airway (for example during vomiting).12 
Figure 1. Phases of the swallowing process
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The estimated international prevalence of pediatric dysphagia in patients with 
neurodevelopmental disabilities ranges from 27 to 99%. These prevalence estimates should 
be viewed with caution since they depend on the description of the feeding difficulties 
or dysphagia, the characteristics of the study population, and the diagnostic instruments 
selected.3, 13-15 The rate of newly diagnosed cases of pediatric dysphagia is unknown but 
there is general agreement that the occurrence of feeding and swallowing dysfunction is 
increasing, probably because of the improved survival rates of premature born children and 
children with complex medical conditions.16 In children with CP or other neurodevelopmental 
disabilities, oropharyngeal dysphagia is a major risk factor for morbidity and mortality.17 It 
leads to the inability to safely consume sufficient food and liquid and is associated with 
prolonged mealtimes, poor growth and malnutrition, and with respiratory consequences 
due to oropharyngeal aspiration.18 These swallowing problems cause a significant distress to 
affected children and their caregivers and have a great impact on the health and well being 
of the children and their families.19 In a study of children with severe CP (severe mobility 
problems, wheelchair depended) and intellectual disability (IQ<55)) parents tended to 
underestimate the severity of dysphagia probably due to habituation or low expectations of 
the feeding performance of their child.15 
Feeding is the process that involves all aspects of eating and drinking, including gathering 
and preparing food and liquid for intake, sucking and chewing, and swallowing.9 A feeding 
disorder is identified when a child is unable or refuses to eat or drink a sufficient quantity 
or variety of food to maintain proper nutrition. To get a grip on identifying feeding and 
swallowing difficulties, Arvedson proposed four key questions to assist parents in identifying 
children who require comprehensive evaluation.20 These questions cover mealtime duration, 
mealtime stress, and concerns about growth and respiratory conditions with corresponding 
indicators for referral (‘red flags’). The answers help determine if a comprehensive clinical 
feeding and swallowing assessment is needed, even though the answers do not necessarily 
define the problem.
1. How	 long	 do	mealtimes	 typically	 take? If more than about 30 minutes on any regular basis, 
there is a problem. Prolonged feeding times are major red flags pointing to the need for further 
investigation.
2. Are	mealtimes	stressful	to	the	child	or	the	parent? Regardless of factors that underlie the stress, 
further investigation is needed. It is very common for parents to state that they “just dread 
mealtimes”.
3. Does	the	child	show	any	signs	of	respiratory	stress? Red flags may include rapid breathing, gurgling 
voice quality, nasal congestion that increases as the meal progresses, or respiratory illness. 
4. Has	the	child	gained	insufficient	weight	in	the	past	2	to	3	months? In the first 2 years of life, steady 
and sufficient weight gain is particularly important for brain development and general growth. A 
lack of weight gain in a young child is a red flag, like weight loss in an older child or adult. 
15
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eating? and Does	your	child	have	difficulty	drinking?), which are scored on a Visual Analogue 
Scale (VAS), to detect children with feeding and swallowing difficulties and malnutrition. 
Both methods may be valuable to improve adequate and timely referral to an SLT. 
The clinical evaluation of a child with neurodevelopmental disabilities related to feeding 
and swallowing includes a thorough history, physical examination, and feeding observation. 
Instrumental assessments of swallowing may be needed when there are concerns regarding 
pharyngeal phase physiology and increased risk of aspiration during oral feeding. A VFSS 
is the preferred method to evaluate the swallowing process, as it allows visualization of 
all phases of swallowing. In this way, different patterns of dysphagia can be determined in 
children with central and peripheral neurological disorders.22 Unfortunately, there are only 
few validated observation instruments to assess eating and drinking problems in children with 
neurodevelopmental disabilities. Benfer et al.23 evaluated nine oral-pharyngeal observation 
instruments and concluded that only two instruments (Schedule for Oral Motor Assessment 
(SOMA)24 and Functional Feeding Assessment modified25 (FFAm)) had good psychometric 
properties. Regrettably, there are no Dutch versions of these instruments available. Only the 
Dysphagia Disorder Survey (DDS)26, the Mastication Observation and Evaluation (MOE)27, 
and the 6-min mastication test (6 MMT)28, 29 are available in Dutch. Recently, the Test of 
Masticating and Swallowing Solids in Children (TOMASS-C)30 has been developed as a 
quantitative assessment of discrete oral stage components of solid bolus ingestion. The 
TOMASS-C has (internationally) proven to be a reliable diagnostic tool in preschoolers up 
to young adults that are able to follow instructions. To classify the functional performance, 
Sellers et al.31 developed a valid and reliable functional eating and drinking ability 
classification system (EDACS) for children with CP as an addition to already existing functional 
CP classification systems for general movement32, 33, manual ability34 and communication.35 
However, a reliable Dutch classification system for eating and drinking abilities in children 
with CP is lacking. We, therefore, aimed to assess the reliability and validity of the translated 
EDACS in Dutch children with CP (chapter 4).
After adequate assessment, the ultimate goal of feeding and swallowing interventions 
is to provide the child with a stable airway, and with adequate nutrition and hydration 
during a safe, pleasant and relaxed mealtime. Because there is a growing awareness among 
clinicians that, already in early stages, particular attention should be paid to the importance 
of dysphagia, we considered it useful to write a review with recommendations for the 
assessment and treatment of dysfunctional swallowing in children with CP (chapter 3).
Drooling
Drooling or lack of saliva control is a normal phenomenon in the growing child, although 
it is unknown up to what age and to what extent drooling occurs in healthy children. For 
this reason, the development of saliva control was investigated in healthy children (normal 
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development, age 0 – 4 years) (chapter 2). In children with neurodevelopmental disabilities, 
drooling may persist due to a swallowing disorder in the oral and/or oral-pharyngeal phase. 
Hypersalivation is not considered to be a significant cause of drooling in children with CP, 
however, there may be arguments for increased salivary flow in children particular with 
dyskinetic CP.36 By far the largest saliva production in humans comes from the paired parotid, 
submandibular and sublingual glands. The submandibular glands are responsible for the 
production of approximately 65-70% of all saliva in rest.37 The parotid glands are mainly 
active following tactile or gustatory stimulation. At rest, they are responsible for about 20% 
of all saliva but, when stimulated, this may well amount to over 50%. 
From a clinical point of view, it makes sense to distinguish between ‘anterior’ and 
‘posterior’ drooling.6 ‘Anterior drooling’ is the visible consequence of lack of oromotor 
control and refers to unintentional loss of saliva from the mouth. ‘Posterior drooling’ refers 
to saliva that is spilled over the tongue through the faucial isthmus. Normally, the sensation 
of saliva in the hypopharynx initiates a swallowing reflex. However, when the trigger to 
swallow is impaired or missing, pooled saliva may lead to posterior drooling, which may lead 
to alarming congested breathing, coughing, gagging, vomiting and at times saliva aspiration 
into the trachea.38 Up to 78% of the children with neurodevelopmental disabilities may have 
complaints of anterior drooling, with a mean prevalence of about 40%.3, 13, 14, 39 The prevalence 
of posterior drooling is unknown, but estimated to be 10-15% in the population with severe 
neurodevelopmental disabilities. Drooling negatively affects physical health and well-being 
and also has an adverse effect on social and emotional functioning.40, 41 To understand the 
multifactorial nature and impact of drooling, it is important to assess underlying factors and 
to evaluate the effects of treatment. A combination of measures is often recommended 
focusing on modifying (1) underlying factors of drooling, (2) severity and frequency of 
drooling,42, 43 and (3) impact of drooling on the child and family.40, 44 The severity of drooling 
can be quantified by a range of objective and subjective measures. Objective measures 
include the salivary flow rate and the drooling quotient (DQ),43 which are assessed by the 
SLT. To develop a more accurate and time-efficient instrument we reassessed the time span 
of the existing drooling quotient (chapter 5). Subjective scales include the Drooling Severity 
and Frequency Scale (DSFS),42 the Teacher Drool Scale (TDS),45 a parent questionnaire to 
assess the impact of drooling, and scaling the severity by a Visual Analogue Scale (VAS);41, 46 
scales that are mostly rated by the children themselves, their parents or caregivers. Despite 
all these available outcome measures, there is no international consensus on a definition of 
an ‘adequate treatment response’ nor on the question ‘how to define change?’. Therefore, 
these issues are addressed in this thesis (chapter 9). 
The goal of any intervention to treat drooling is a reduction of visible spill of saliva or 
a decrease in posterior drooling to improve the child’s quality of life and to make caregivers’ 
lives easier. Various non-invasive and invasive treatment strategies for the improvement of 
oral motor control and reduction of drooling are available. Non-invasive therapies can be 
categorized into (1) oral (sensory)motor therapies to optimize oral sensation and awareness 
17
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self-management) techniques, and (4) oral drugs to reduce salivary to increase swallowing 
frequency and efficacy flow (e.g. anti-cholinergic medication). Invasive interventions 
comprise (1) intra-glandular injections with botulinum neurotoxin type-A (BoNT-A), and 
(2) surgical interventions (e.g. duct ligation, gland excision, and redirection of saliva to 
the posterior part of the mouth).47 Unfortunately, there is no (international) consensus on 
the hierarchy of these interventions, when or how to start treatment, or how to continue 
with treatment in the long run. In collaboration with saliva control teams from the USA, 
Australia, UK, and the Netherlands, we composed a first, evidence-informed approach to 
the management of drooling in children and youth with CP (chapter 6).
Previous research
Since 2001, several PhD projects have been completed at the Radboud university medical 
center addressing different aspects of drooling. Our salivary control and swallowing team 
was able to proof that BoNT-A in the submandibular glands reduces the salivary flow and 
anterior drooling in approximately half of the children with neurodevelopmental disabilities 
for about 22 weeks (median duration).48-50 In addition, surgery (i.e., submandibular duct 
relocation, submandibular gland excision and submandibular duct ligation) appeared to be 
effective and safe to diminish visible drooling.51-55 We provided evidence that salivary flow 
reduction has a significant impact on daily life and care, with positive consequences for social 
interaction and self-esteem.41, 46, 56 Possible side effects of treatment were also investigated, 
revealing that after BoNT-A injections for drooling there is a risk of thickened saliva.57 Non-
medical treatment options, e.g. behavioral interventions,58, 59 were also studied and a self 
management program for children with appropriate motivation and learning abilities was 
developed and evaluated.60, 61 Besides anterior drooling, we were able to show that posterior 
drooling can just as well be treated by an intervention aimed at saliva reduction.38, 51 Specific 
interest in the cause of drooling led to evidence that dysfunctional oral motor control is 
most likely to be responsible for drooling, because hypersalivation does not occur except 
in children with a dyskinetic movement disorder.38 Lastly, our team provided evidence that 
the outcome of BoNT-A treatment cannot be predicted based on the type of CP, nor on 
other functional characteristics such as head position, lip seal, tongue control, mental age, 
or control of voluntary movement.62, 63 
Outline of this thesis
Although significant progress in the treatment of drooling, eating and drinking problems, 
and dysphagia has been made, there are still substantial gaps in our knowledge to assess, 
treat, and monitor children with neurodevelopmental disabilities who suffer from drooling 
and/or dysphagia. In this thesis we address both the assessment of oral motor performance 
(part one) and a personalized approach to the treatment of drooling (part two).  
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Part one: towards refined assessment of oral motor performance:
Chapter 2 describes the development and validation of a parent questionnaire to quantify 
drooling severity and frequency in young children (the DRIPS). Based on this questionnaire 
the development of saliva control in typically developing infants and preschoolers is 
described and sex-specific reference charts are constructed to compare and visualize saliva 
control with peers. These charts allow clinicians to timely initiate individually targeted 
interventions if children outperform.
Chapter 3 describes the clinical practice of swallowing problems in cerebral palsy, based 
on a literature review. A plan for an integrated approach to investigation and treatment of 
swallowing problems in CP is presented.
Chapter 4 assesses the reliability, validity and usability of a functional classification system 
for eating and drinking abilities of Dutch children with CP. Use of EDACS by SLTs and parents 
is investigated and forms the basis for increased awareness of safety and efficiency of eating 
and drinking abilities in children with CP. 
Chapter 5 examines if the 10-minute drooling quotient and the 5-minute drooling quotient 
are interchangeable. The agreement between measurements of 162 children with 
neurodevelopmental disabilities and their accuracy in classifying drooling severity were 
used to develop a time-efficient clinical, objective drooling assessment. 
Part two: towards a personalized approach to the treatment of drooling
Chapter 6 reports an evidence-informed approach for the treatment of sialorrhea in 
children and youth with CP, based on the AACPDM (American Academy of Cerebral Palsy 
and Developmental Medicine) care pathway.
Chapter 7 presents a case series of children with Megdel syndrome and anterior and posterior 
drooling. The need for a stepwise and personalized treatment approach is emphasized.
Chapter 8 describes adverse effects of submandibular BoNT-A injections on oral motor 
function in children with drooling and developmental disabilities due to central neurological 
disorders. We also tried to identify independent predictors of adverse effects in this 
population.
In Chapter 9 we discuss our definition of a clinical response to treatment and critically reflect 
on what should be considered a meaningful change after BoNT-A treatment. Changes in the 
impact of drooling on daily life and care, social interaction and self-esteem after BoNT-A 
treatment are analyzed.
Chapter 10 comprises the summary and general discussion.
19
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Abstract
Objectives: To develop and validate a parent questionnaire to quantify drooling severity 
and frequency in young children (the Drooling Infants and Preschoolers Scale – the 
DRIPS). To investigate development of saliva control in typically developing young 
children in the age of 0–4 years. To construct sex-specific reference charts presenting 
percentile curves for drooling plotted for age to monitor the development of saliva 
control in infancy and preschool age.
Study design: The DRIPS was developed consisting of 20 items to identify severity and 
frequency of drooling during meaningful daily activities. Factor analysis was performed 
to test construct validity. A piecewise logistic regression was followed by a piecewise 
linear regression to construct sex-specific reference charts.
Results: We obtained 652 completed questionnaires from parents of typically developing 
children. The factor analysis revealed four discriminating components: drooling during 
Activities,	Feeding,	Non	nutritive	sucking,	and	Sleep. To illustrate the development of 
saliva control, eight sexspecific reference curves were constructed to plot the scores of 
the DRIPS by age group, at the 15th, 50th, 85th and 97th percentile. About 3–15% of 
the preschoolers in our cohort did not acquire full saliva control at the age of 4 years.
Conclusions: With the DRIPS it is possible to validly compare and visualize the 
development of saliva control in an individual infant or preschooler and allow clinicians 
to timely initiate individually targeted interventions if children outperform.
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Introduction
Drooling is the unintentional loss of saliva from the mouth and is considered to be a normal 
phenomenon in the growing child.1 In general, drooling starts when infants keep up their 
head in prone position (mean age 2.3 months SD 0.8) or when children start to bring toys 
to their mouth (mean age 3.3 months SD 1).2 In typically developing children drooling 
decreases as a result of maturation of the oral sensory-motor functions.3 The development 
of saliva control might be considered as a process of perception-action coupling.4 Sensory 
experiences like feeling saliva in the oral cavity or running down the lips or chin, and sensory-
based motor actions like learning to slurp a drop from the lips into the mouth and form a 
saliva bolus before swallowing are considered crucial in the early development of saliva 
control. Infants and preschoolers have to learn how to couple these perceptual experiences 
to adequate motor action to change their (drooling) behavior. This process takes place in a 
responsive environment where social feedback on the negative consequences of drooling is 
also important to motivate the child to attain saliva control.
Swallowing saliva is a complex function that includes volitional and reflexive actions, 
needing the integrity of five nerves and 30 muscles.5 The average saliva flow varies between 
0.5–1.5 l per day and flow variation may be dependent on environmental stimuli and 
conditions like temperature and humidity.6, 7 It is assumed that salivary flow during infancy is 
also influenced by teeth eruption, dietary changes, and age (higher flow in older children).8 
In addition, salivary flow is modulated by chewing and increases during the introduction 
of solid food.9 As stated before, the growing child will usually adapt to these salivary flow 
changes by ‘implicit motor learning’: acquiring skills through practice and refinement. In the 
end the desired movement (spontaneous saliva swallow) is made automatically during an 
increasing number of daily activities.10
Underlying causes of pathological drooling in young children can be a combination of  (1) 
oral motor difficulties when swallowing, (2) sensory processing problems in the mouth 
region related to saliva, and (3) insufficient coupling between sensations that arise when 
the saliva ‘spills’ and the active swallowing process.11
From preschool age on, problems with saliva control may lead to embarrassment 
in the child and avoidance by peers.1 Visible drooling is not a medical condition, but 
it can lead to socio-emotional burden for the child and its parents if it still exists at an 
older age. The frequently used developmental screening tools and clinical assessment 
tests in our country (such as the Dutch van Wiechen classification scheme12 and 
Bayleys-III-NL13) do not document any developmental stages of saliva control in typically 
developing children. In addition, there is no consensus about the age at which saliva 
control should be achieved. Some authors argue that it is physiological to drool up to the 
age of 18 months and that up to the age of 4 years drooling can be tolerated.1, 14 Others 
conclude that healthy, typically developing children might have troublesome drooling 
up to 6 years of age.15 Yet, Crysdale stated that drooling after the age of 4 years, while 
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the child is awake, should be considered as abnormal.16 This is why saliva control teams 
accept children from the age of 3–4 years for drooling assessment and treatment.15, 17 It 
must be concluded that a valid instrument for assessment of the development of saliva 
control in young children is lacking and that there is no consensus about the age limit at 
which drooling must be considered  problematic. To gain better insight in these issues, 
the primary objective of this study was to develop and validate a questionnaire for parents 
to quantify drooling severity and frequency in their young children (the Drooling Infants 
and Preschoolers Scale – the DRIPS). With the DRIPS, our second goal was to investigate 
the course of development of saliva control in typically developing children between the 
age of 0–4 years. The third goal was to construct sex-specific reference charts presenting 
percentile curves plotted for age to monitor saliva control in infancy and preschool age.
Materials and methods
Development of the DRIPS
Initially, a questionnaire about drooling for parents and other caregivers of young children 
was developed in Dutch, based on common knowledge about drooling, children’s 
psychomotor development, and the development of saliva control. The first part of the 
questionnaire consisted of items concerning demographic and health characteristics (items 
1–7). Questions about drooling frequency and severity in meaningful situations were 
included in the second part of the questionnaire (items 8–16). In this part, parents were 
asked to rate their child’s drooling in the following nine context-related situations: in prone 
position, during supported sitting, during gross motor activities, fine motor activities, eating 
and drinking, non-nutritive sucking on thumb or pacifier at daytime and night- time, while 
sleeping, and while babbling or talking. Answers were classified in accordance with the 
ordinal distribution of the Drooling Frequency and Severity Scale (DFSS).18 Dichotomous 
answers about drooling during teething and (nose) colds (items 17–20) were collected in 
the third part of the questionnaire.
The initial Dutch questionnaire was piloted and its readability for parents was 
improved on the basis of a study including 119 typically developing children and their 
parents in 2008, after which consensus for adaptations was reached in the research group. 
The final Dutch version of the DRIPS was developed in 2009 with the aim to be able to 
complete the questionnaire in 15 min.
Procedure
Data from postal questionnaires were collected from 2009 to 2012 in convenience sample 
by sending the questionnaires to day nursery’s, child health clinics, playgroups, and parents 
of young children in the Netherlands. In addition, from 2011 to 2013, data from digital 
questionnaires were collected via internet home pages and forums for parents with young 
children in the Netherlands. For the aim of the current paper, an English translation of the 
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Dutch questionnaire was created using the method of Eremenco et al.19 (see Appendix A). 
The following exclusion criteria were applied with regard to sample selection: age > 4;00 
years, any diagnosis of oral or facial (anatomical) deficits, any known congenital syndromes 
or confirmed neurological problems.
Statistics
Descriptive statistics were used to report the demographic data. To evaluate the construct 
validity of the questionnaire, an exploratory factor analysis was performed to test the 
underlying dimensions of the DRIPS. Principal component analysis (PCA) was applied as 
the extraction method. Orthogonal rotation (varimax) with Kaiser’s criterion, eigenvalues 
> 1.0, was used to determine the final number of extracted factors. The Kaiser-Meyer-
Olkin (KMO) measure was performed to verify the sampling adequacy for the analysis. 
In addition, Bartlett’s test of sphericity was applied to test if correlations between items 
were sufficiently large for PCA. A full factor loading matrix for the final solution is presented 
together with percentages of variance explained by each factor. Cronbach’s alpha of items 
with factor loading ≥ 0.60 were calculated to measure the internal consistency of each factor 
found. Values of 0.70–0.95 were accepted.20 To control for the relationship between the 
four factors, the Pearson product-moment coefficients of correlation  between  the  factor 
sum-scores  were  calculated.  A  moderate  to weak relationship (r < 0.70) was expected 
to establish that each factor addressed a separate concept within the total construct.20 All 
questionnaire items on drooling were scored on an ordinal scale and finally a sum score for 
each factor was calculated by adding up the frequency and severity score. A pooled multiple 
imputation method in SPSS was used to deal with missing values and values coded as “not 
applicable” (in total < 5% of all answers).
To determine the reference values for girls and boys, two stages were used to 
construct the sex-specific reference values of each of the sum scores belonging to the 
factors found in the factor analysis. The large number of zero scores on the factors makes an 
analysis that assumes normal distributions of scores probably invalid. Therefore, we used 
two stages to construct the sex-specific reference values for each of the factors.
At first, drooling variables were characterized by an age-specific (large) number of 
zero values indicating no drooling. Specifically, the theoretical pattern for the first 8 months 
(0.7 Y) is different from the period thereafter, because then children start crawling, sit 
without support, while the first teeth occurs, solid food is introduced and children show 
self-feeding behaviors.2 Following this reasoning, a piece-wise logistic regression was used, 
with a change point at the age of 8 months to describe the probability of non-drooling 
as a function of age. The independent variables were the continuous age variable and a 
continuous, transformed age variable equal to zero for age < 8 months, and equal to the 
actual age minus 8 months for the age of 8 months or older.
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Second, a piece-wise linear regression was used to study the pattern in non-zero 
scores of each drooling variable, separately. The dependent variable was the (non-zero) 
score of the drooling variable of interest. The independent variables were the continuous 
age variable and a continuous transformed age variable equal to zero for age < 24 months 
(2.0 Y), and equal to the actual age minus 24 months for age 24 months or older. The change 
point for the piecewise regression was chosen at 2 years of age, based on the idea that 
most of the gross, fine and oral motor behaviors should have been developed by that time. 
Likewise, the eruption of the primary teeth should have been finished.21
The age-specific point estimate of the percentage zero of the first stage and the 
age-specific percentiles in the second stage were combined to calculate the eight-specific 
reference values. The 15th-, 50th-, 85th- and 97th-percentile are visualized in a graph.
Initially, a wide range of models on drooling variables were studied, namely: first 
to third degree polynomials in age, piece-wise regression in age, and untransformed and 
logarithmically transformed values of the drooling variables. The Likelihood-Ratio test was 
used to test the differences between the models for their goodness of fit to the data.
Statistical analyses were carried out using SPSS 20.0 for Windows (IBM Corp., 
Armonk, NY, USA) and SAS 9.2 for Windows (SAS Institute, Cary, NC).
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Table 1: Demographic and health characteristics of the study population (n=652).
Child characteristics n (%)
Sex
Male
Female
314
338
(48.2)
(51.8)
Age groups in months (Male/Female)
0–3 (23/18)
3–6 (21/15)
6–9 (23/25)
9–12 (28/27)
12–15 (21/24)
15–18 (22/23)
18–21 (17/17)
21–24 (13/22)
24–27 (24/26)
27–30 (15/19)
30–33 (24/34)
33–36 (16/19)
36–39 (16/18)
39–42 (23/15)
42–45 (12/19)
45–48 (16/17)
41
36
48
55
45
45
34
35
50
34
58
35
34
38
31
33
(6.3)
(5.5)
(7.4)
(8.4)
(6.9)
(6.9)
(5.2)
(5.4)
(7.7)
(5.2)
(8.9)
(5.4)
(5.2)
(5.8)
(4.8)
(5.1)
Region of residence in the Netherlands
North
East
South
West
87
232
183
150
(13.3)
(35.6)
(28.1)
(23.0)
Gestational age at birth
≤37 weeks
>37 weeks
Missing
43
606
3
(6.6)
(92.9)
(0.5)
Attendance of a physician or allied health professional
Pediatric neurologist
Pediatriciana
Ear Nose Throat specialista
Speech Language Therapista
Physiotherapista
No attendance
Missing
171
7
102
51
27
30
478
3
(26.2)
(1.1)
(15.6)
(7.8)
(4.1)
(4.6)
(73.3)
(0.5)
Medication useb
Yes
No
72
580
(11.0)
(89.0)
a Attendance of more than one physician or allied health professional is possible.
b Medication for allergic reactions, gastric reflux, or respiratory.
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Table 2: Summary of exploratory factor analysis of the DRIPS (n=652).
Does drooling occur in your child 
during/in:
Rotated Factor Loadings
Activities Feeding Non Nutritive 
Sucking
Sleep
Tummy	position
Severity level
Sitting	up	and	supported
Severity level
Moving	around
Severity level
Using	fine-motor	materials
Severity level
Babbling/talking
Severity level
Eating and drinking
Severity level
Sucking	a	pacifier	or	thumb	(daytime)
Severity level
Sucking	a	pacifier	or	thumb	(nighttime)
Severity level
Sleeping
Severity level when sleeping on back
Severity level when sleeping on side
Severity level when sleeping on 
tummy
Eigenvaluesa
% of variancea
Cronbach’s αb
0.87
0.89
0.86
0.87
0.85
0.86
0.81
0.83
0.67
0.69
0.30
0.33
0.25
0.24
0.08
0.14
0.06
0.14
0.01
0.04
8.68
43.38
0.95
0.09
0.05
0.13
0.11
0.17
0.12
0.12
0.39
0.35
0.89
0.88
0.12
0.18
−0.01
0.01
0.05
0.00
0.10
0.07
1.35
6.75
0.88
0.09
0.09
0.18
0.18
0.08
0.08
0.14
0.12
0.16
0.14
0.11
0.14
0.86
0.86
0.65
0.60
0.18
0.11
−0.01
−0.01
1.63
8.16
0.82
0.04
0.04
0.02
0.02
0.11
0.08
0.11
0.09
0.07
0.08
0.11
0.07
0.03
0.02
0.56
0.55
0.90
0.73
0.85
0.86
3.48
17.42
0.84
In bold: Rotated factors matrix shows largest loading for each variable per factor.
a Values before rotation.
b Cronbach’s alpha of items with factorloading ≥0.60. 
Results
Data collection and participants
In total 676 questionnaires were returned, of which 296 questionnaires were obtained by 
post (response rate 32.9%) and 380 web-based. Twenty-four questionnaires were excluded 
based on the pre-set exclusion criteria or because forms were incomplete or filled in with 
invalid data. Hence, the final study population consisted of 652 typically developing children 
between 0–4;00 years old (314 boys, 338 girls; see for demographic and health characteristics 
Table 1). Children were divided in 16 age groups of three months with a minimum of 30 
children in each group. There were on average 40.8 children per age group (range 31–58). 
The total sample was representative for sex, age and region of residence in the Netherlands 
(see Table 1). To obtain a fair representation of a ‘normal’ population of typically developing 
children, we accepted preterm born infants (6.6%), children using medication (11%), and 
children who attended a physician or allied health professional (26.2%). A small proportion 
of these children (7%) were treated by more than one physician or allied health professional 
(7%).
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Factor analysis
A principal component analysis (PCA) was conducted on the 20 items with orthogonal 
rotation (varimax). The Kaiser-Meyer-Olkin measure of sampling adequacy was 0.83, 
above the recommended value, and Bartlett’s test of sphericity was significant (χ² (190)= 
13521.96, p < .01) indicating that correlations between items were sufficiently large for PCA.
An initial analysis was run to obtain eigenvalues for each component in the data. 
Four components had eigenvalues over Kaiser’s criterion of 1 and in combination explained 
75.7% of the variance. Table 2 shows the factor loadings after rotation. The items that cluster 
on the same components suggest that factor 1 represents drooling during Activities (prone 
position, sitting with assistance, gross motor activities, fine motor activities, and babbling/
talking (items 8–11 and item 16)), factor 2 represents drooling during Feeding (item 12), 
factor 3 drooling during Non	nutritive	sucking during day and night (items 13–14), and factor 
4 drooling while Sleeping in different positions (item 15). All factors showed high reliability 
(all Cronbach’s α–values > 0.82) and the Pearson’s correlation coefficients between the 
factors were significant, though moderate to weak (factor 1–2: r
p
=0.52, factor 1–3: r
p
=0.40, 
factor 1–4: r
p
=0.15, factor 2–3: r
p
=.35, factor 2–4: r
p
=0.15, factor 3–4: r
p
=0.39)
Sex-specific reference charts
As a result of the combined regression analysis, percentile curves for all factors were 
calculated for each sex-specific age group and presented in Fig. 1. The curves for the factors 
Activities,	 Feeding and Non	nutritive	 sucking showed a descending trend; older children 
drool less than younger children. Curves for the factor Sleep showed a rising trend.
Drooling during activities
At the age of 35 months, 50% of the boys achieved a sum score of 0 (no drooling) during 
Activities, whereas girls reached that score already at the age of 30 months. Fifteen percent 
of the boys still had some drooling (DRIP score ≥ 5) at the age of 4 years, whereas this score 
was ≥ 2 for the girls. At the age of 4 years drooling still occurred in 3% of the boys and girls 
with respective sum scores of ≥ 15 and ≥ 11.
Drooling during feeding
In 50% of the cases (boys and girls) drooling during Feeding stopped at the age of 21–22 
months and only 3% of the preschoolers drooled during mealtimes with a score of 3–4 at 
the age of 4 years. In 85% of the girls, drooling during feeding ended before the age of 4 
years, whereas 15% of the boys still drooled with a score ≥ 2 at the age of 4 years.
36
Chapter 2
Drooling during non nutritive sucking
Drooling during Non	nutritive	sucking on thumb or pacifier stopped in 50% of the boys at 36 
months and in 50% of the girls at 29 months. Both boys and girls still drooled in 15% of the 
cases during Non	nutritive	sucking with a score ≥ 3–5 at the age of 4 years and 3% persisted 
drooling during Non	nutritive	sucking at that age (score ≥ 6–7).
Drooling during sleep
The curves of drooling during Sleep have an ascending line. Still 50% of the children drooled 
at the age of 4 years with scores ≥ 5 for boys and ≥ 3 for girls.
Figure 1. Sex-specific reference charts with percentile curves (P15th, P50th, P85th, P97th) for the factors drooling 
during Activities,	Feeding,	Non	nutritive	sucking and Sleep.
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Discussion
To the best of our knowledge this is the first study that analyzed drooling and the 
development of saliva control in a large representative cohort of typically developing infants 
and preschoolers up to 4;00 years. Data were collected with a newly developed parent 
questionnaire, the Drooling Infants and Preschoolers Scale – DRIPS. In addition, sex-specific 
percentile curves for drooling in four situations were developed for children in different age 
groups. These can be easily used in clinical practice to compare children of the same sex and 
age with their peers regarding the severity and frequency of problems with saliva control.
Although Crysdale16 stated that drooling must be considered abnormal after the age 
of 4 years, we found that a substantial part (3–15%) of the typically developing preschoolers 
are still drooling to a certain extent at 4 years of age. We speculate that not all these 
children suffer from abnormal pathological drooling, but that drooling in a small group of 
children older than 4 years is within the range of normal variability. Special attention and 
monitoring should be given to the 3% children with a percentile > P97 who could be at risk 
of pathological drooling.
Differences were found between boys and girls in the course of the development of 
saliva control. For example, half of the female population stopped drooling earlier than their 
male peers during Activities. Miller et al.22 already found significant prenatal sex differences 
for laryngeal and pharyngeal motor activity and oral-lingual movements, suggesting a sex-
dependent trajectory of oral motor development. Other studies have also suggested that 
there are maturational sex differences in motor skills of preschoolers and that preschool 
boys and girls should not be compared to each other, but to children of the same age and 
sex.23, 24 Because we anticipated that sex differences in motor skill development between 
preschool boys and girls might also influence children’s drooling behavior, we presented 
sex-specific references charts. At the age of 4 years, however, sex differences in drooling 
behavior tends to taper off, as is demonstrated in these curves.
Saliva control was first achieved during Feeding, even though it is known that salivary 
flow rates increase during eating. During normal development, children from 12 to 36 
months of age refine their oral motor skills during feeding and become more effcient in 
moving the jaw, lips and tongue to gain oral motor control and to form a bolus.25 The oral 
phase of swallowing during feeding or saliva swallowing takes place in two stages: a suction 
or collecting stage and a propulsion stage.26 Lespargot et al. found that the oral suction 
stage of saliva swallowing in healthy children is characterized by intra-oral pressure.26 This 
intra-oral pressure is generated by combined movements of the tongue and mandible and 
is necessary to collect saliva or small volumes of liquid and to form a bolus. These findings 
were confirmed by a study of Bourdiol et al. who identified three different saliva swallowing 
patterns.27 In all patterns, intra-oral negative pressure played an important role in gathering 
saliva above the tongue and in the propulsion of the saliva bolus into the pharynx. The same 
mechanism of suction, food bolus formation and propulsion to clean the oral cavity is seen 
during eating and drinking. Probably, because swallowing saliva and swallowing food tend 
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to develop synchronously, saliva control during Feeding is the first factor achieved in 50% of 
the children aged 21–23 months.
Our data show that drooling still exists in 15% of 4-year-old boys and girls during 
Non	nutritive	sucking on their thumb or pacifier. The percentile curves P85th and P97th stay 
rather flat, which implies that these children do not achieve full saliva control when they 
continue thumb or pacifier sucking. To our knowledge, limited data are available concerning 
the relation between thumb or pacifier sucking and drooling in typically developing infants 
and preschoolers. In a study of Szynkiewicz et al., the rate of non nutritive swallowing during 
awake state in infants while sucking 10 min on their pacifier was compared with the swallow 
rate without pacifier.28 In both the younger group (age 2–4 mo) and the older infants (age 
7–9 mo), the use of the pacifier doubled the rate of swallows. This is in accordance with 
our data. The curves for Non	nutritive	sucking show an upward trend during the first nine 
months, which implies that children suck and swallow saliva frequently during thumb or 
pacifier sucking. After that period, non nutritive sucking seems to maintain drooling behavior 
in young children. This is probably because they habituate to the pacifier or thumb without 
a trigger to collect and swallow saliva. During non nutritive sucking the lips are slightly 
opened, the tongue is in a low position, and swallow efficiency (in terms of making intra-
oral pressure and collecting saliva) is limited. As a consequence, children do not practice 
saliva control during non nutritive sucking. As repetitions are essential for the acquisition of 
(oral) motor skills10, this is an important reason for health professionals to advice parents of 
children who still drool to stop their child’s habit of thumb or pacifier sucking.
Although salivary flow is low during sleep,7 all drooling curves (of boys and girls) 
during Sleep in different positions rise during the first 4 years. From this, we conclude that 
drooling during Sleep may not subside with age and may not be related to the development 
of saliva control. This makes the factor Sleep different from the others that all are clearly 
related to development.
A strength of this study is the use of factor analysis to test construct validity of a 
parent questionnaire, allowing the identification of constructs underlying saliva control 
development. The sample size of this cross-sectional study is large and the participants 
are reasonably representative of the Dutch population of 0–4 years of age. Indeed, the 
percentage of preterm born children in this study (6.6%) is close to the percentage of 
preterm born infants in the Dutch population (7.4%).29
A limitation of this study is the fact that the assessment of drooling behavior is only 
based on parent questionnaires. However, it has been proven that parent-report observations 
can be used to monitor the child’s (gross) motor development.30 In addition, our participant 
inclusion may have been biased if parents of children with troublesome drooling felt more 
need to fill in and return the questionnaire than parents of children without troublesome 
saliva loss.
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Conclusion
The acquisition of saliva control should be considered as an integral part of normal 
development during childhood. It is associated with physical growth and maturation of 
the oral sensory and motor functions, by motor learning based on perception-action 
coupling, and by increasing cognitive and social-emotional awareness. Knowledge about 
the development of saliva control and the availability of reference charts for drooling 
severity in infants and preschoolers is important for pediatric physicians, therapists, and 
multidisciplinary saliva control teams. The DRIPS enables communication with parents 
about the impact of their child’s drooling and the development of saliva control compared 
to peers. In the event of delayed saliva control a proper treatment can be started. 
The sexspecific reference charts of the DRIPS from our study allow health professionals 
to monitor the developmental stages of drooling behavior up to the age of 4 years and 
timely initiate individually targeted interventions. Percentile curves derived from DRIPS 
scores of children developing typically may be useful for screening. We suggest to 
use the 97th percentile as the outer most percentile cutoff value indicating pathological 
drooling. Children with DRIPS scores above the 85th percentile could be considered 
as ‘at risk’.
If a child drools significantly more than his peers, individual advice can be given to 
train specific skills. For example, high scores on drooling during Activities are possibly related 
to immature motor skills and referral to a pediatric physiotherapist may be beneficial. If a 
child shows excessive drooling during Feeding, there may be underlying oral-motor problems 
for which it is wise to consult a speech-language therapist. When a child scores high on all 
factors, a general health issue (e.g. ear-nose-throat pathology) or an overall developmental 
delay may be an underlying cause. However, whether the DRIPS is a useful instrument to 
improve clinical practice, needs to be proven in further longitudinal studies, testing the 
stability of the percentile curves including both typically developing children and children 
with excessive pathological drooling behavior.
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Appendix A. DRIPS questionnaire
	
	
Drooling	Infant	and	Preschooler	Scale	(DRIPS)	
	
Parent	section	
	
	
To	the	parents/guardians,	
You	are	asked	to	complete	this	survey	because	drooling	occurs	in	your	child.	The	purpose	of	this	questionnaire	is	to	find	out	
what	elements	may	be	a	factor	to	drooling.	Kindly	fill	out	this	questionnaire	based	on	the	past	two	weeks.	
Each	question	is	made	up	of	two	parts.	The	first	part	contains	a	question	about	when	drooling	occurs	in	your	child,	the	second	
part	covers	the	level	of	drooling.	If,	for	example,	your	child	never	plays	in	a	tummy	position	(question	8),	you	may	tick	N/A	(not	
applicable).		
	
Part	1.	
	
1.	Your	child’s	name:	____________________________________________________________	
	
2.	Date	of	completion:____-____-________	
	
3.	What	is	your	child’s	date	of	birth?	
____-____-________	
	
4.	What	is	your	child’s	gender?	
□	 Boy	
□	 Girl	
	
5.	Was	your	child	born	before	week	37	of	your	pregnancy?	
□	 Yes	
□	 No	
	
6.	Has	your	child	visited:	(several	answers	possible)	
□	 The	(pediatric)	neurologist	 concerning:____________________________.	
□	 The	pediatrician	 											 	 concerning:____________________________.	 																
□	 The	Ear	Nose	Throat	specialist	 concerning:____________________________.		
□	 The	speech	therapist	 	 concerning:____________________________.		
□	 The	physiotherapist	 	 concerning:____________________________.	
□	 None	of	the	above	
	
7.	Does	your	child	take	any	medication?	 	 	 		
□	 Yes,	i.e.:____________________________________________.	
□	 No	
	
Part	2.	
	
8.	Does	drooling	occur	in	your	child	while	in	a	tummy	position	and	awake,	e.g.	when	playing	on	the	floor?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	9)	 	 																																																						(Proceed	to	question	9)	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
9.	Does	drooling	occur	in	your	child	while	sitting	up	and	supported	(supported	by	the	parent	or	sitting	in	a	chair	with	a	back)?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	10)	 	 																																																						(Proceed	to	question	10)	
	
What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
	
zie voor bestand: 
www.radboudumc.nl/drips
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		10.	Does	drooling	occur	in	your	child	while	moving	around,	e.g.	rolling	over,	crawling,	walking,	jumping	or	doing	sports?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	11)	 	 																																																						(Proceed	to	question	11)	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
11.	Does	drooling	occur	in	your	child	while	using	fine-motor	materials	such	as	a	rattle,	blocks,	while	drawing,	stringing	beads?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	12)	 	 																																																						(Proceed	to	question	12)	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
12.	Does	drooling	occur	in	your	child	while	eating	and	drinking?	
					□	Never													□	Occasionally									□	Often													□Always														
(Proceed	to	question	13)	 	 	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
13.	Does	drooling	occur	in	your	child	while	sucking	on	a	teat,	thumb,	finger,	lip	or	pacifier	during	the	day?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	14)	 	 																																																						(Proceed	to	question	14)	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
	
14.	Does	drooling	occur	in	your	child	while	sucking	on	a	teat,	thumb,	finger,	lip	or	dummy	during	the	night?	
□	Never													□	Occasionally									□	Often													□	Always													□	N/A	
(Proceed	to	question	15)	 	 	 	 																								(Proceed	to	question	15)	
	
	What	is	the	level	of	drooling?	
□	Wet	lips			□	Wet	lips	and	chin/cheeks			□	Also	wet	clothes			□	Also	wet	pillows,	sheets	and	cuddly	toys	
	
15.	Does	drooling	occur	in	your	child	while	it	is	asleep?	
□	Never													□	Occasionally									□	Often													□	Always														
(Proceed	to	question	16)		
	
What	is	the	level	of	drooling	when	your	child	sleeps	on	its	back?	□	N/A	
What	is	the	level	of	drooling	when	that’s	the	case?	
□	Wet	lips			□	Wet	lips	and	chin/cheeks			□	Also	wet	clothes			□	Also	wet	pillows,	sheets	and	cuddly	toys	
	 	 									
What	is	the	level	of	drooling	when	your	child	sleeps	on	its	side?	□	N/A	
What	is	the	level	of	drooling	when	that’s	the	case?	
□	Wet	lips			□	Wet	lips	and	chin/cheeks			□	Also	wet	clothes			□	Also	wet	pillows,	sheets	and	cuddly	toys	
	
What	is	the	level	of	drooling	when	your	child	sleeps	on	its	tummy?	□	N/A	
What	is	the	level	of	drooling	when	that’s	the	case?	
□	Wet	lips			□	Wet	lips	and	chin/cheeks			□	Also	wet	clothes			□	Also	wet	pillows,	sheets	and	cuddly	toys	
	
16.	Does	drooling	occur	in	your	child	when	babbling/talking?	
					□	Never													□	Occasionally									□	Often													□Always													□	N/A	
(Proceed	to	question	17)	 	 																																																						(Proceed	to	question	17)	
	
What	is	the	level	of	drooling	when	that’s	the	case?	
□	Wet	lips			□	Wet	lips	and	chin		□	Also	wet	clothes/bib			□	Wet	clothes,	hands,	table,	floor	and	items	
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Part	3.	
	
17.	Has	your	child	had	(new)	teeth	eruptions	over	the	past	two	weeks?	
□	 Yes	
□	 No	(Proceed	to	question	19)	
	
18.	Would	you	have	completed	the	survey	differently	if	your	child	had	not	had	(new)	teeth	eruptions	over	the	past	two	weeks?		
□	 Yes,	my	child	tends	to	suffer	more	from	drooling.	
□	 Yes,	my	child	tends	to	suffer	less	from	drooling.	
□	 No	
	
19.	Has	your	child	had	a	cold	(in	the	nose)	over	the	past	two	weeks?		
□	 Yes	
□	 No	(End	of	survey)	
	
20.	Would	you	have	completed	the	survey	differently	if	your	child	had	not	had	a	cold	(in	the	nose)	over	the	past	two	weeks?	
□	 Yes,	my	child	tends	to	suffer	more	from	drooling.	
□	 Yes,	my	child	tends	to	suffer	less	from	drooling.	
□	 No	
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Swallowing problems in cerebral palsy
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Abstract 
Cerebral palsy (CP) is the most common physical disability in early childhood. The 
worldwide prevalence of CP is approximately 2–2.5 per 1,000 live births. It has been 
clinically defined as a group of motor, cognitive, and perceptive impairments secondary 
to a non-progressive defect or lesion of the developing brain. Children with CP can have 
swallowing problems with severe drooling as one of the consequences. Malnutrition 
and recurrent aspiration pneumonia can increase the risk of morbidity and mortality. 
Early attention should be given to dysphagia and excessive drooling and their substantial 
contribution to the burden of a child with CP and his/her family. This review displays 
the important functional and anatomical issues related to swallowing problems in 
children with CP based on relevant literature and expert opinion. Furthermore, based 
on our experience, we describe a plan for approach of investigation and treatment of 
swallowing problems in cerebral palsy.
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Introduction
Cerebral palsy (CP) is the most common physical disability in early childhood. The worldwide 
prevalence of CP is approximately 2–2.5 per 1,000 live births.27 It has been clinically defined 
as a group of motor, cognitive, and perceptive impairments secondary to a non-progressive 
defect or lesion of the developing brain.4 Epilepsy is a common problem in patients with CP.27 
Up to 80% of CP cases arise from antenatal factors; birth asphyxia contributes approximately 
10% of CP cases.16 Acquired cases in the postnatal period are usually related to central nervous 
system infection, trauma, strokes, and severe hypoxic events such as neardrowning. Genetic 
disorders and acquired insults follow a pattern of selective vulnerability during early brain 
development. For example, the neonatal neuropathological correlates of hypoxic–ischemic 
encephalopathy include specific and well-known patterns of brain injury12, 51 (see Table 1) 
that interfere with the frontal/insular–basal ganglia–brainstem swallowing pathway.6, 10, 
13, 15, 19–21, 23, 24, 26, 39, 52 We propose that an understanding of paediatric dysphagia might be 
facilitated by a heightened awareness of the topography pertaining to the neuronal damage. 
This article focuses on the pathophysiology, clinical features, assessment, and management 
of swallowing problems in children with CP.
Members of the Multidisciplinary Outpatient Swallowing/ Drooling Clinic at the 
Radboud University Nijmegen Medical Center in the Netherlands continually review 
literature on dysphagia and drooling in neurologically affected patients. References for 
this review were obtained from personal reprint files, supplemented by PubMed and 
Scopus searches with varying search periods. The search terms “drooling,” “sialorrhoea,” 
“swallowing,” “dysphagia,” “cerebral palsy,” “children,” “brain regions,” “fMRI,” “MEG,” 
and “EMG” were used. Only English-language articles, published from 1970 up to 2011, 
were included. The final reference list was generated based on originality and relevance to 
the topics covered in the review.
Table 1: Regions with a predilection for hypoxic–ischemic neuronal injury to swallowing.
Site of lesion 12, 51 Swallowing elementsa
Oral Pharyngeal GOR
Periventricular leucomalacia (preterm babies) + +/− +/−
Cortical and subcortical injury in a watershed parasagittal distribution (term 
babies and prolonged partial hypoxic events)
+ +/− +/−
Relatively selective injury to the putamen, thalamus, and peri-rolandic 
cerebral cortex, and often including injury to the brainstem (term babies 
and acute anoxic events)
+ ++ +/−
GOR gastro-oesophageal reflux, +/− probably present, + very likely present, ++ evident
a Expert opinion
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Neural control of swallowing 
Normal swallowing is a goal-directed sequential behaviour that requires the coordinated 
action and inhibition of the muscles located around the oropharynx and oesophagus. 
The swallowing process is controlled in a complex manner involving the brainstem 
as well as cortical and subcortical central pathways. In addition, it requires a higher 
level of fine-tuning between the central circuits and the enteric nervous systems (ENS) 
(see Fig. 1).
Efficient swallowing relies on sensory input from the oropharynx that triggers 
bilateral afferents in specific regions of the trigeminal sensory nuclei. Subsequently, 
the inputs reach the brainstem regions responsible for the patterned motor actions of 
swallowing. Sequential and rhythmic patterns of swallowing are formed and organized by a 
central pattern generator (CPG) located in the medulla oblongata. The CPG consists of two 
hemi-CPGs which, under physiological conditions, are tightly synchronized. The swallowing 
motor sequence is primarily generated in the ipsilateral hemi-CPG which transfers premotor 
neuron signals to the contralateral CPG.17 The CPG itself is organized into two groups of 
neurons: the dorsal swallowing group (DSG) in and around the nucleus of tractus solitarius 
(NTS) and the ventral swallowing group (VSG) just cranial to the nucleus ambiguus. The 
DSG contains the generator neurons involved in the triggering, shaping, and timing of the 
sequential or rhythmic swallowing pattern. The DSG activates all VSG premotor neurons, 
which in turn distribute the swallowing drive to the various motor neuron pools involved 
in swallowing. The multifunctional pattern-generating circuits of the brainstem allow 
rapid modulation of orofacial behaviours (swallowing, respiration, chewing, coughing, and 
vomiting).5
Although our knowledge of the cortical regions involved in swallowing has grown 
substantially through functional magnetic resonance imaging studies, the exact central 
control mechanism for swallowing is still not fully understood. The involvement of 
many functionally and spatially different cortical sites suggests multilevel control for the 
swallowing pathways. It has been proposed that the control system consists of parallel 
loops which are able to coordinate and integrate the complex, sequentially based 
activation for swallowing.26 The primary motor area and cingulate and insular cortices 
might all have essential roles in the coordination of the entire swallowing process.21, 24, 52 
Some investigators assume a functional dominance in swallowing8 or a time-dependent 
shift of cortical activation from the left to the right sensorimotor cortex during voluntary 
swallowing.45
In summary, voluntary and reflexive swallowing are controlled by widely distributed 
bilateral and multifocal cortical networks which apparently involve overlapping cortical 
regions. The primary sensory, motor, and cingulate cortices have a major role in these 
networks. The execution of the sensorimotor aspects related to swallowing relies on 
functionally connected pathways between (extra) pyramidal cortical motor planning 
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The brain–gut axis
Normal gastrointestinal tract (GI) function results from a balanced interaction between 
the enteric nervous system (ENS) and the central nervous system (CNS) which is called 
“the brain–gut axis”. Both neural and hormonal ENS communications have important 
integrative functions. A detailed discussion of the hormonal pathways is beyond the scope 
of this article. The ENS neural communications consist of the intrinsic afferent and motor 
neurons distributed along the gut wall (located in the mesenteric Auerbach and submucosal 
Meissner plexuses).
Afferent (vagal) sensory fibres terminate in the NTS of the hindbrain. The preganglionic 
motor innervations to the plexus arise from the dorsal motor nucleus of the vagus in the 
brainstem. The NTS and the vagal dorsal motor nucleus together comprise the dorsal vagal 
complex, important in the coordination of the muscular gut activity (by the vago-vagal 
reflex).1
The oesophagus consists of a proximal striated muscle portion (upper oesophageal 
sphincter, UOS) and a distal smooth muscle portion (lower oesophageal sphincter, LOS). At 
rest both sphincters are tonically contracted. Relaxation of the UOS (glossopharyngeal and 
vagal nerves) is initiated in the swallowing center located in the medulla. Relaxation and 
contraction of the LOS (vagal and splanchic nerves) are initiated through local peristaltic 
activity of the oesophagus or distension of the gastric wall.
Figure 1. Overview of the swallowing pathway. DSG dorsal swallowing group, NTS nucleus of tractus solitarius, 
VSG ventral swallowing group, NA nucleus ambiguus.
Cortex (premotor opercular
areas)
and
Basal Ganglia Thalamus
Swallowing
Centre (CPG)
in medulla
oblongata
Cranial nerves
V, VII, IX, X, XIIGastrointessnal tract
DSG - NTS
VSG - NA
regions, centers controlling the brainstem and cranial nerves, as well as lower motor 
neurons.
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Thus far, the exact coupling of distinct interneurons (also called local circuit neurons 
or connector neurons) in the NTS is not known. Also, it is not totally clear which cortical 
regions are mainly involved in processing information to the GI tract. It has been suggested 
that the anterior insular cortex (called “visceral cortex”), the prefrontal and sensory/motor 
regions, the cingulate gyrus, as well as the limbic regions, all participate in the integration of 
neuronal information to the GI tract.18
Swallowing problems in cerebral palsy
A recent epidemiological study among 1,357 children recorded by the Northern Ireland 
Cerebral Palsy Register between 1992 and 2009 showed a dysphagia prevalence of 43% in 
children with CP in any degree.29 Results from speech pathology testing and video fluoroscopic 
swallowing studies in CP children demonstrate the relationship between typically affected 
brain regions and the associated characteristic patterns of dysfunctional swallowing (see 
Table 1). Usually, clinical features such as delayed initiation and segmented swallowing 
during attempted volitional movement might be determined by cortical neuronal networks, 
while dysfunctional pharyngeal components of swallowing (i.e. automatic components of 
deglutition, such as throat clearing, laryngeal closure tasks) suggest subcortical brain injury 
and/or basal ganglia necrosis.23 In CP, dysphagia is often characterized by problems in both 
the volitional oral movements and the more reflexive pharyngeal phase of swallowing. 
Moreover, impaired ability to plan and coordinate swallowing with ventilation (e.g. 
greater propensity to swallow at abnormal times within the respiratory cycle, such as early 
inspiration after a thin liquid swallow and variable duration of the deglutition apnoea) 
are consistent with brainstem involvement.6 A clinico-pathological correlation between 
differences in the breath–swallow pattern and the risk for aspiration is likely. Clinically, 
aspiration or episodic aspiration manifests as frequent coughing and occasional pneumonia. 
The overall incidence of pulmonary aspiration in CP due to oral motor dysfunctions is not 
known precisely. Admission to the hospital for presumed aspiration pneumonia in children 
with CP is common. An earlier study among 238 children with recurrent pneumonia 
showed that 48% had oropharyngeal incoordination with an aspiration syndrome 
whereas 50% of these children were diagnosed with CP.28 Video fluoroscopic study of 
swallowing (VFSS) has demonstrated pulmonary aspiration in 38%32 to over 70% of the 
cases25, and frequently, the aspiration occurred without coughing, referred to as “silent”.32, 
38 Repeated pulmonary aspiration leads to chronic coughing, sleep-disordered breathing, 
impaired clearance of airway secretions, colonization of the respiratory tract by pathogenic 
bacteria, and a high risk of progressive lung parenchymal damage. This process may be 
lethal.14, 22
Besides dysphagia, chronic pulmonary aspiration may also occur as a result of 
the gastro-oesophageal reflux (GOR).53 The incidence of GOR has been estimated at 
approximately 50%40 and might be explained by lesions in the neuronal-anatomic swallowing 
center located in the medulla oblongata leading to dysfunction of the vago-vagal reflex. In 
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Table 2: Recommendations for evaluation of dysfunctional swallowing (expert opinion)
The paediatric neurologist, paediatrician, rehabilitation specialist, speech pathologist, ENT specialist, pedagogue, dentist, nurse 
practitioner, occupational therapist, physiotherapist, plastic surgeon may be involved in the multidisciplinary swallowing/
drooling teams.
Assessments:
Medical and social–emotional history of the patient. Does the child suffer from intractable seizures?
Medication, benzodiazepines or neuroleptic-induced drooling?
Respiratory status (cough, wheezing, recurrent pneumonia) → Consider examination by the paediatric pulmonologist.
Comment: although common practice, the prophylactic use of antibiotics with suspected or proven aspiration is not 
recommended.
Presence of gastro-oesophageal reflux, which, if severe, can be associated with hyperstimulation of the salivary glands or 
indirect aspiration → Consider GOR treatment.
Nutrition and hydration. Safe feeding programme? Does the feeding result in normal  
growth? → Consider nasotube feeding, laxative.
Comment: see www.LifeExpectancy.org/articles/GrowthCharts.shtml and 9
Neurological examination (consciousness, cranial nerves, general motor skills/posture, and tone)
Orofacial examination (nasal breathing, upper airways obstruction) → Consider examination by the ENT specialist.
Oral hygiene, occlusion, and dental examination
Assessment by a speech pathologist → objective: modify food bolus such as consistency, size and texture, positioning of the 
patient, and examining compensatory swallow manoeuvres:
Posture and head control; mouth closure, lip seal
Oral sensorimotor examination (tongue lateralisation, sensation, tone, strength, (pathological) reactions)
Oropharyngeal stage of swallowing during eating and drinking (swallow on demand, oral control, frequency/efficiency/safety)
Speech (dysarthria/dyspraxia) and communication skills
Management of secretions → Consider drooling treatment 31.
VFSS confirms silent aspiration and defines the pathophysiology of oropharyngeal swallow with various types of bolus
Comments: VFSS is the study of choice for complete evaluation of the feeding and swallowing process; aspiration is suspected 
in case of recurrent pneumonia and in children who are prone to gagging and coughing; silent aspirators do not exhibit 
overt symptoms of aspiration; aspiration risk is increased in non-ambulant children with CP (Gross Motor Functioning 
Classification System III or higher). See also 2
Table 3: Drooling treatment (expert opinion)
Severe anterior drooling
• <3 years: oral motor therapy for training motor skills
• >4 years: botulinum toxin therapy (submandibular glands) 36
If no response or developmental progress → Consider
1. Injection of the submandibular and parotid glands concurrently
2. Intense behavioural treatment 47
3. Surgery: submandibular duct relocation 37
Comment: Behavioural therapy is not given nor indicated in adults because no research is done in this field: no evidence exists 
that it is effective.
Posterior drooling
• <3 years: oral motor therapy, feeding advices for safer swallowing
• >4 years: botulinum toxin therapy (submandibular and/or parotid glands)
If no response → Consider surgery (duct ligation or gland removal, no submandibular duct relocation)
Comment: Consider anticholinergic medication for drooling control in case of contraindications to botulinum toxin therapy or 
surgery. Glycopyrrolate (glycopyrronium bromide) appears to be a more acceptable anticholinergic drug in the management 
of drooling in children. Randomized controlled trials with this drug in children with CP are warranted. Dosage: oral 
suspension 40–100 μg/kg per day with a maximum of 175 μg/kg per day, dosage given once daily 42
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addition, GOR in children with CP may also result from direct lesions in cortical areas that 
modulate brainstem activity.1, 3
Constipation, a common dysmotility disorder of the gut in children with CP, is often 
overlooked. More than half of the children with severe generalized CP are constipated.50 
The high incidence of the dysmotility disorders emphasizes the defective integration and 
modulation of information in the brain–gut axis in CP,30, 34, 35, 41, 43, 49 for which some investigators 
had proposed the term “Dysphagia–GOR complex” with a central role for the vagal nerve.33, 
34 It is reasonable to assume that vagal disruption is responsible for defective feedback to 
the distinct cortical regions and to the brainstem, those features being associated with 
swallowing disorders, defective ventilation, as well as dysmotility problems. At this time, 
more studies are needed to investigate the clinical relevance of integrated breathing, GI and 
swallowing function on the health and nutritional outcomes of children with CP.
Drooling is caused by the swallowing disorder and occurs in 10–58% of children with 
CP.11, 44, 46 From a clinical point of view, it makes sense to distinguish between “anterior” and 
“posterior” drooling. Anterior drooling is the unintentional loss of saliva from the mouth; it 
can impose a significant disability on children with CP, leading to psycho-social, physical, and 
educational consequences. The most severely affected children may be rejected by their 
peers and even by their caregivers. Excessive anterior drooling damages books, computer, 
and keyboards and as such threatens essential tools for education and communication 
in neurologically disabled patients. In addition to cosmetic effects, drooling can produce 
peri-oral infections and can impair dentition. In contrast to anterior drooling, the so-called 
“posterior drooling” refers to the spill of saliva over the tongue through the faucial isthmus.18 
In particular, the children with most severe pharyngeal dysphagia are at medical risk due to 
saliva aspiration to the lungs. As mentioned above, aspiration in a child with CP often occurs 
without obvious coughing or choking (i.e. silent), and therefore, chronic aspiration of saliva 
might not be diagnosed prior to development of significant lung injury.
In case of chemical irritation such as that caused by GOR, salivary secretion is 
increased to protect the oral, pharyngeal, and oesophageal mucosa mediated by the vago-
vagal complex in the brainstem. Unfortunately, in children with oral motor dysfunction, this 
protective increased saliva volume may accumulate in the pharynx and/or oesophagus, 
leading to an increased risk for aspiration. It is still a matter of debate whether GOR can 
cause severe drooling and whether or not treatment of pathological GOR diminishes 
drooling in children with CP.
Assessment and management of swallowing problems in CP
The investigation and treatment of swallowing problems in children with CP are challenging. 
Individualized care plans should be formulated accounting for the degree of oral motor 
impairment, feeding ability, aspiration, epilepsy, and ambulation. Generally, swallowing 
is more problematic in non-ambulatory children with CP. Furthermore, marked disturbed 
consciousness such as drug overdose and seizures interfere with the voluntary swallowing 
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act and is a common cause of aspiration. Some children develop aspiration in association 
with GOR. Some anti-epileptics, such as clobazam and clonazepam, and neuroleptic drugs 
will induce the drooling risk.
In short, there is a growing awareness among clinicians that at early stage, particular 
note should be given to the importance of dysphagia7 and excessive drooling contributing 
substantially to the burden of a child with CP and his or her family.48 Ideally, the management 
of patients with swallowing problems requires the coordinated expertise of a number of 
health care professionals. Regular reassessment is necessary to gauge the response to 
oral motor training, nutrition, and drooling interventions. Tables 2 and 3 summarize our 
recommendations for evaluation and treatment of dysfunctional swallowing and drooling 
in children with CP.
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Abstract
Purpose: To assess the interrater reliability, construct validity and usability of the Eating 
and Drinking Ability Classification System (EDACS) among Dutch children with Cerebral 
Palsy (CP) when used by speech and language therapists (SLTs) familiar and unfamiliar 
with the child’s eating and drinking performance and parents.
Methods: Translation was undertaken using the method of Eremenco. Agreement 
between SLTs and parents when using EDACS was determined by intraclass correlation 
coefficient (ICC) and linear weighted Kappa (W). Associations with other functional 
classification systems including the Dysphagia Management Staging Scale (DMSS) were 
investigated to determine construct validity by Kendall’s tau-b.
Results: Thirty-one SLTs classified 149 children (67 girls; mean 10 y, SD 4 y, range 3–21 y) 
with EDACS. Pairs of SLTs showed good agreement ([ICC] = 0.84; 95% confidence interval 
[CI] 0.79–0.88; [W] = 0.71). Eighty-one parents showed good agreement with SLTs (n = 
31) as well (ICC = 0.80; 95% CI 0.71–0.87; W = 0.61). There was a significant and strong 
positive correlation of EDACS with DMSS (Kendall’s tau-b 0.81) supporting its construct 
validity. Usability of EDACS was generally good.
Conclusion: The Dutch version of EDACS is reliable and valid, and can be used easily by 
(familiar and unfamiliar) SLTs and parents of children with CP. Parents and professionals 
showed a high level of consistency when classifying eating and drinking abilities. EDACS 
enables uniform and efficient communication about safety and efficiency of functional 
eating and drinking ability in clinical and research contexts.
65
Reliability, construct validity and usability of the Eating and Drinking Ability Classification System (EDACS) among Dutch children with Cerebral Palsy
Ch
ap
te
r 4
Introduction
Cerebral palsy (CP) is a common neurological development disorder with a worldwide 
prevalence of approximately 2–2.5 per 1,000 live births.1 People with CP suffer from a range 
of activity limitations arising from disorders of movement and accompanying disturbances 
of sensation, perception, cognition, communication and behaviour. Impairments of 
movement, sensation and posture can limit oral skills required for speech, eating, drinking 
and swallowing. Bulbar and oral movement difficulties, that may lead to problems with 
eating and drinking, are common in individuals with CP.2 International prevalence estimates 
range from 27–99%, depending on the study population and measures of eating and drinking 
ability adopted.3-5
It is often assumed that there is a significant correlation of oral motor dysfunction 
affecting speech, eating, drinking and swallowing with the severity of limitations to gross 
motor function and mobility.2,3,6-8 According to the Dysphagia Disorders Survey (DDS),9 Calis 
et al.5 found a 99% prevalence of dysphagia in a group of Dutch children with a GMFCS 
level IV or V and an IQ < 55. These children were evaluated using a standardized mealtime 
observation. However, Sullivan et al. reported that almost a third of their study population 
with mild gross motor deficits (unilateral signs, GMFCS I and II) were identified as having 
feeding problems.6 Oral motor difficulties may be linked to increased risk of choking, 
aspiration of food and liquids, and malnutrition affecting overall quality and the ability to 
fully participate in daily life.10 In some cases, the consequences of eating, drinking, and 
swallowing difficulties may be fatal.11 It is important that limitations to children’s eating, 
drinking and swallowing are recognized as early as possible and that this information is 
shared effectively between parents, health professionals and other stakeholders.
Valid and reliable systems are available to classify specific aspects of everyday 
function in people with CP on the basis of their self-initiated movement (Gross Motor 
Function Classification System, GMFCS),12 manual ability (Manual Ability Classification 
System, MACS),13 and communication ability (Communication Function Classification System, 
CFCS).14,15 All systems look at achievements rather than deficits and each classification 
system describes “performance” (people’s usual activity) in five ordinal levels, rather than 
“capacity” (what people can do at their best). None of these systems is a performance test 
or even a diagnostic tool. These systems enable clinicians to communicate with families and 
other professionals in a uniform way about the child’s functional abilities.15
In their systematic review, Sellers et al. identified 15 ordinal scales used to classify 
eating impairments in children with CP;16 however, none met agreed quality standards 
of health measurement scales.17,18 In response to this identified gap in knowledge, a new 
Eating and Drinking Ability Classification System (EDACS) was developed in the UK19 with 
input from all stakeholders including expert professionals, people with CP and parents. 
This system consists of an extensive manual and an algorithm, both necessary for sufficient 
comprehension of eating and drinking abilities. It was designed analogous to other 
66
Chapter 4
functional classification systems for people with CP (e.g. GMFCS, MACS and CFCS). EDACS 
can be used to classify how children and young people with CP eat and drink in everyday 
life using distinctions that are meaningful (Italics show the official wordings as stated in the 
manual itself).20 EDACS identifies key features of safety (choking and risk of aspiration), and 
efficiency (time taken and loss of food from the mouth) linked with limitations to eating and 
drinking ability. Five distinct levels of ability are described in an ordinal scale ranging from 
Level I “eats and drinks safely and efficiently” to Level V “unable to eat and drink safely” 
(Fig. 1, the summarized algorithm). Degree of assistance required to bring food	and	drink 
to the mouth is described in a separate three level ordinal scale: “Independent”, “Requires 
Assistance” and “Totally Dependent”. The interrater reliability of EDACS met recognized 
quality standards when used by pairs of Speech and Language Therapists (SLTs) (n = 19) who 
classified the eating and drinking abilities of children and young people with CP they knew well 
(n = 100) (absolute agreement 78%; kappa = 0.72; ICC = 0.93; 95% CI 0.90–0.95).17
Sellers et al. also investigated the interrater reliability between parents and SLTs in 
order to examine the relationship between their respective viewpoints. By inviting parents 
to classify their children’s abilities, it is possible that parents will feel empowered and that 
their opinions matter.21 Differences of opinion can form the basis of discussion about the 
most applicable EDACS level with the recognition that parents will have better knowledge 
Figure 1. Clinical algorithm EDACS.
Level IV
Eats and drinks with
signicant
limitations to safety.
Level III
Eats and drinks
with some
limitations to
safety; there maybe
limitations to
eciency.
Level II
Eats and drinks
safely but with
some limitations
to eciency.
Level I
Eats and drinks
safely and
eciently.
Is  the individual
able to eat a meal
in the same time
as peers?
Is  the individual
able to swallow
food and drink
without risk of
aspiration? Can risks of 
aspiration be 
managed to 
eliminate harm to 
the individual?
Is  the individual
able to bite and 
chew on hard lumps 
of food without a 
risk of choking?
Eating and Drinking Ability Classication System - Algorithm
Level V
Unable to eat or
drink safely - tube
feeding may be
considered to
provide nutrition.
No
No
No
No
Yes
Yes
Yes
Yes
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than professionals of their child’s eating and drinking abilities across a range of situations 
and environments. There is evidence that parents can be reliable partners in classifying their 
child’s functional status.15
The objectives of this study were (1) to translate the EDACS into Dutch by a validated 
translation method, (2) to examine the interrater reliability of the translated EDACS among 
SLTs for a cohort of Dutch children and young people with CP, (3) to investigate interrater 
reliability between SLTs and parents in the same cohort, (4) to assess the usability of the 
Dutch EDACS by SLTs and parents, and (5) to examine association between the EDACS and the 
Dysphagia Management Staging Scale (DMSS),9 the GMFCS, CFCS, and MACS to determine 
its construct validity. A strong association was hypothesized for the DMSS in contrast to a 
moderate association for the other classification systems. The DMSS is a five-level ordinal 
scale used to classify severity of feeding and swallowing problems based on management 
needs and health related outcomes. It is used in conjunction with the DDS as a screening 
and clinical assessment of swallowing and feeding function for eating and drinking in people 
with developmental disability.9
Methods
The development of the Dutch version of EDACS involved two distinct phases. The first 
phase consisted of translation of EDACS into Dutch. The second study phase consisted 
of investigating reliability, validity and usability of this Dutch version of EDACS. Written 
informed consent was obtained from the parents (or caregivers) and participating SLTs. This 
research was conducted in accordance with national and international ethics standards. The 
study was submitted to the Regional Hospital Human Ethics committee (registration number 
2013–530).
Phase 1: Translation of the English EDACS into Dutch
First, a literature search by PUBMED on methods used to translate medical classification 
systems was conducted. Translation was undertaken using the method of Eremenco et al.21 
because it was considered to be thorough, practical, affordable, and used by other research 
groups in children’s rehabilitation. The method was applied in the following steps: (1) two 
forward translations were undertaken by a qualified translator with medical background 
and one without medical background (whose native language was Dutch), (2) one version 
combining both translations was agreed on by both translators, (3) one backward translation 
was created by a qualified translator with native English, (4) three reviewers (PJ, DSn and KvH) 
with expert knowledge of limitations of eating and drinking associated with CP reviewed the 
translation process and made adjustments, (5) the English member of the research group 
(DSe) reviewed and made adjustments to the backward translation, and (6) final adjustments 
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Table 1: Demographics of participants included in the reliability study.
Characteristics of children and young people with cerebral palsy  
(n = 150)
n %
Sex
Boys
Girls
83
67
55.3
44.7
CP classification according to SCPE
Spastic
Dyskinetic
Ataxia
Worster Drought
Mixed
104
8
1
2
35
69.3
5.3
0.7
1.3
23.4
GMFCS
I
II
III
IV
V
Unknown
14
30
23
51
32
0
9.3
20.0
15.3
34.0
21.3
0
MACS
I
II
III
IV
V
Unknown
8
40
38
38
18
8
5.3
26.7
25.3
25.3
12.0
5.4
CFCS
I
II
III
IV
V
Unknown
20
29
27
62
11
1
13.3
19.3
18.0
41.3
7.3
0.7
Feeding technique
Tube feeding
Oral feeding
Tube and oral feeding
6
130
14
4.0
86.7
9.3
Age
Mean y
Median y
10 (4)a
10 (3–19)a
Characteristics of Speech and Language Therapists  
(n = 31)
n %
Experienceb
< 1 y
1–5 y
5–10 y
> 10 y
1
3
7
20
3.33
10
23.3
66.7
aData of age are presented as mean (SD) and median (range).
bExperience in working with children and young people with Cerebral Palsy. CP, Cerebral Palsy; SCPE, Surveillance 
of Cerebral Palsy in Europe; GMFCS, Gross Motor Function Classification System;
MACS, Manual Ability Classification System; CFCS, Communication Function Classification System, y = year.
were made by the Dutch members of the research group. The Dutch version of EDACS with a 
clinical algorithm can be downloaded from the website: www.EDACS.org.
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Phase 2: Reliability, validity and usability study
Participants
Only participants (SLTs) of the last five curricula of the Pediatric Neurorehabilitation Cerebral 
Palsy course in the Netherlands, still working with children with CP were selected and invited 
to take part in the study. All SLTs were recruited by email. As recommended by Palisano et 
al.,12 the SLTs were trained in using EDACS, by attending a single 3-hour training session. The 
training session was provided by KvH, DSn and CE. This meeting consisted of an introduction 
to EDACS, an explanation of the manual, and a practice session using EDACS to classify 
function from video recordings of four children and young people with CP whilst eating and 
drinking. Parents received the EDACS user manual and a separate glossary by post and were 
invited to participate and classify their children’s eating and drinking abilities using EDACS. 
SLTs were asked to recruit and classify three to five children who were attending special 
schools and rehabilitation centers. The following inclusion criteria were: age between 3 to 
21 years, diagnosis of CP, and no intercurrent illness (e.g. cold or flu) at the time of rating. 
Two “mealtimes” (lunch and snack) were observed at the same day to observe the child’s 
abilities.
To include a heterogeneous group of children, it was not necessary to have established 
eating and drinking difficulties. Demographic information was collected from the medical 
record, including age, sex, CP subtype, GMFCS level, MACS level, CFCS level, and source of 
nutrition (tube, oral or combination). Table 1 shows the characteristics of 150 children with 
CP and 31 SLTs participating in this study.
Procedure
The reliability study was designed to reflect typical practice within the Dutch healthcare 
system. Rehabilitation teams, in the Netherlands, usually have only one SLT engaged in the 
treatment of a child with CP. Typically the SLT has sole knowledge of the child’s eating and 
drinking abilities.
In this study, we evaluate the differences in scoring between pairs of two SLTs. 
For the interrater study the SLTs (n = 31) had two distinct functions: they classified both 
the eating and drinking abilities of three to five children they knew well (primary as 
SLT-1) as well as three to five children they had not met before and with whom they were 
‘unfamiliar’ (secondary as SLT-2). In this way, each child was classified by a familiar SLT 
and an unfamiliar SLT. Furthermore, we evaluated the differences between SLT-1 and the 
parent(s). Parent rating was completed by one parent of each child.
All participating SLTs and parents independently classified the usual eating and 
drinking performance of the children with CP on EDACS. They also determined the degree of 
assistance required. SLTs-2 visited the children in the rehabilitation setting or special needs 
school they were attending. Two mealtimes (morning snack, lunchtime) were observed on 
the same day and all SLTs obtained access to the children’s health histories. They observed 
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Table 2: Interrater reliability measures with use of EDACS by SLTs (n = 31). (a) Reliability of EDACS 
levels I-V, SLT-1 versus SLT-2. (b) Reliability of degree of assistance needed, SLT-1 versus SLT-2.
SLT-2 Total
I II III IV V
SLT-1 I 18 8 2 0 0 28
II 9 37 6 0 0 52
III 0 9 12 5 0 26
IV 0 2 9 20 1 32
V 0 0 1 1 9 11
Total 27 56 30 26 10 149
SLT-2 Total
Independent Requires assistance Totally dependent
SLT-1 Independent 59 3 0 62
Requires assistance 19 25 4 48
Totally dependent 1 2 35 8
Total 79 30 39 148
SLT-1, Speech and Language Therapist familiar with the child; SLT-2, Speech and Language Therapist unfamiliar 
with the child. (a) ICC 0.84, 95% CI 0.79–0.88. (b) ICC 0.85, 95% CI 0.80–0.89. The grey boxes represent absolute 
agreement.
Table 3: Interrater reliability measures with use of EDACS by SLTs (a) Reliability of EDACS 
levels I–V, SLT-1 (n = 31) versus parent (n = 81). (b) Reliability of degree of assistance needed, 
SLT-1 (n = 31) versus parent (n = 82).
Parent Total
I II III IV V
SLT-1 I 9 9 0 0 0 18
II 6 15 4 0 0 25
III 0 6 7 1 0 14
IV 0 1 9 8 0 18
V 0 0 1 2 3 6
Total 15 31 21 11 3 81
Parent Total
Independent Requires assistance Totally dependent
SLT-1 Independent 20 14 0 34
Requires assistance 4 20 6 30
Totally dependent 0 1 17 18
Total 24 35 23 82
EDACS, Eating and Drinking Ability Classification System; SLT-1, Speech and Language Therapist familiar with 
the child. (a) ICC 0.80, 95% CI 0.71–0.87. (b) ICC 0.77, 95% CI 0.66–0.84. The grey boxes represent absolute 
agreement.
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the eating and drinking abilities ‘live’ (n = 105) or watched video clips of children engaged in 
usual eating and drinking routines at school (n = 43).
SLTs’ and parents’ opinions about the usability of EDACS were assessed by four 
questions. Both SLTs and parents were asked to rate the clarity of level descriptions and of 
level distinctions using a four-point scale: ‘outstanding’, ‘good’, ‘moderate’, or ‘bad’. Also, 
they were asked to rate how easy it was to use EDACS using a three-point scale: ‘easy’, 
‘neutral’, or ‘difficult’. Finally SLTs and parents were asked about the time needed to complete 
the EDACS (in minutes). All questionnaires were distributed and collected by a gatekeeper.
To determine the construct validity of EDACS, SLTs also classified children using one 
of the five levels of the DMSS. The DMSS consists of variables selected because they are 
sensitive indicators of the presence and functional adequacy of swallowing and feeding 
disorders in people with developmental disabilities. The level of the DMSS was determined 
by observation and on the basis of available medical information.9
Statistical analysis
Interrater reliability was analyzed using Intraclass Correlation Coefficient (ICC) with a two-
way random model for absolute agreement (single measure) and by linear weighted kappa 
kW. Weighted kappa was added as an indication of chance corrected agreement because 
it gives different weights to disagreements according to the magnitude of the discrepancy. 
For example, a rating difference of two levels is more serious than a difference of one level. 
Values for ICC and kW were interpreted following Cicchetti et al.: reliability is poor with 
an ICC < 0.40, fair between 0.40–0.59, good between 0.60–0.74, and excellent between 
0.75–1.00.22 Terwee et al. recommended ICC > 0.70 as a minimum standard for reliability 
in a sample size of at least 50 patients.17 A Wilcoxon signed-ranks test was performed to 
evaluate differences within paired scores of SLT-1 and a parent.
The associations of EDACS level with degree of assistance required, as well as 
with DMSS, GMFCS, CFCS, and MACS, were calculated using Kendall’s tau-b. Descriptive 
analysis was used to report the usability of the EDACS system. Missing values were 
considered as missing at random. For all statistical tests, the level of significance for 
two-tailed p-values was set at ≤ 0.05. Point estimates are presented with their 95% 
confidence intervals (CIs). Statistical analyses were carried out using SPSS 20.0 for Windows.
Results
Participants
An invitation to participate was sent by email to SLTs who met the inclusion criteria to 
participate in the initial meeting for the study (approximately 80 SLTs). Thirty-one of the 
38 SLTs who attended this initial meeting agreed to participate. In 16% of the cases, the 
familiar SLTs knew the child’s eating and drinking abilities through group therapy; in the 
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remaining cases, the familiar SLTs knew the child’s abilities from individual therapy in the 
past or present.
Reliability
The level of agreement between SLTs-1 and SLTs-2 was excellent. They agreed on EDACS 
level in 96 out of 149 children (ICC 0.84; 95% CI 0.79–0.88; Kw = 0.71); as reflected in Table 2. 
One child was scored only by SLT-1 and the parent. When pairs of SLTs scored the degree of 
assistance required, a good interrater reliability was achieved (ICC 0.85; 95% CI 0.80–0.89; 
Kw = 0.77). In five children, there was a twolevel difference between SLT-1 and SLT-2. When 
SLTs disagreed by more than 1 level, this seemed related to omission or misinterpretation of 
information concerning medical notes, respiratory function or changed food consistencies 
between the two observation moments influencing the scoring of EDACS level.
Eighty-one children (54%) were rated by their parents and SLTs for EDACS 
level, and 82 children (55%) were categorized on degree of assistance needed (see 
Table 3). The level of agreement was 0.80 (95% CI 0.71–0.87; kW = 0.61) versus 0.77 (95% 
CI 0.66–0.84; kW = 0.64) for the degree of assistance required. The Wilcoxon signed rank 
test indicated that the median SLT scores for EDACS level were statistically higher than the 
median parent scores (z = -1.94, p = 0.052), i.e. SLTs scaled the child as having more problems 
with eating and drinking than the parent of the child (Table 3). When comparing degree of 
assistance needed, SLTs scored the children as needing less help for eating and drinking than 
parents did (z = -3.00, p = 0.003).
Validity
There was a significant and positive correlation between EDACS level and degree of 
assistance required for eating and drinking (Kendall’s tau-b 0.69, p < 0.001). There was 
a strong association of EDACS level with DMSS level (Kendall’s tau-b 0.81, p < 0.001), 
whereas the other associations were only moderately positive (GMFCS: Kendall’s 
tau-b 0.60, p < 0.001; MACS: Kendall’s tau-b 0.48, p < 0.001; CFCS: Kendall’s tau 0.50, 
p < 0.001).
Usability
SLTs and parents were asked to judge the usability of EDACS. The questions assessing usability 
of EDACS showed that 23% of the EDACS classifications made by SLTs-1 and 2 (70/300) were 
categorized as ‘outstanding’ regarding the understanding of the user instructions, 73% 
(220/300) were categorized as ‘good’ and 3% (10/300) as ‘moderate’. Of the parents, 30% 
(24/81) understood the instructions ‘outstanding’, 65% (53/81) ‘good’, 3% (2/81) ‘moderate’, 
and 3% (2/81) ‘bad’. When the SLTs classified an unfamiliar child, in 34–39% of the cases, the 
SLTs considered choosing between levels to be ‘easy’, in 49–51% of the cases ‘neutral’, and 
in 10–14% of the cases ‘difficult’. In two cases, the SLTs did not answer this question. Similar 
to these results, 47% percent of the parents thought choosing between levels to be ‘easy’, 
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43% found it ‘neutral’, and 10% found it ‘difficult’. The mean time needed to classify a child 
on the EDACS was 13 minutes for SLTs-1 (SD 7.9 range 1–30), 15 minutes for SLTs-2 (SD 8.9 
range 2–60), and 16 minutes for parents (SD 8.1 range 1–35).
Discussion
The content of EDACS has been successfully translated into Dutch following a thorough, 
validated translation process. The key features of safety and efficiency of eating and drinking 
ability expressed in five distinct levels were considered meaningful and feasible by parents 
and SLTs working within the Dutch healthcare system. EDACS enables clear and efficient 
communication about a child’s eating and drinking skills between professionals and between 
professionals and parents.
There were only slight differences in interrater reliability outcomes among SLTs 
obtained in this study (ICC 0.84) compared to the original study by Sellers et al. (ICC 0.93). 
Both results are judged as statistically ‘excellent’ following the interpretation of Cicchetti.22 
Sellers et al.19 assessed reliability of EDACS when used by pairs of SLTs who were both 
familiar with the child’s usual eating and drinking performance. In this study, eating and 
drinking abilities were classified by one SLT familiar with the child’s current feeding abilities, 
and one SLT who was unfamiliar with the child’s feeding abilities. Videos, live observations, 
and medical records were used by the latter SLTs (SLTs-2) to classify eating and drinking 
ability. It is possible that in some cases the ‘unfamiliar’ SLTs (SLTs-2) did not have enough 
background information to be able to classify all aspects of eating and drinking. This might 
explain the slightly lower SLT interrater reliability in the present study compared to Sellers’ 
study. Another explanation may be found in the larger number of subjects used in our study 
and greater (between subjects) variability of their eating and drinking abilities. From these 
findings, it can be concluded that eating and drinking ability can be classified by SLTs who 
are ‘familiar’ or ‘unfamiliar’ with the child from direct observation or from video recording.
The ICC value of 0.8, when EDACS is used by SLTs as well as parents, shows that 
this instrument can be reliably used by an informed parent. This supports the idea that 
parents should be considered as serious discussion partners. There is a trend for parents 
to classify their child on a lower EDACS level, i.e. greater abilities with eating and drinking, 
when compared with the opinion of the SLT. Possible explanations for this finding are that 
parents may be less aware of risk factors for inefficient or unsafe eating and drinking, or that 
parents may be more tolerant of risks to support their child to function at the edge of his/
her abilities. SLTs may limit exposure to risks in a school or clinic setting for safety reasons. 
For the degree of assistance required during eating and drinking, parents reported their 
child to be in need of more help than the SLTs did. Parents may provide their child with more 
help when eating and drinking for practical reasons such as speeding up the time taken to 
finish a meal, whilst in a school setting when given enough time, a child may be able to eat 
and drink independently.
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The moderate positive association between EDACS and GMFCS highlights that 
measures of gross motor function will not be sufficient to predict a child’s eating and drinking 
ability. The moderate positive association between a child’s ability to use his/her hands 
(MACS) and level of assistance needed to bring food and liquids to the mouth also highlights 
that MACS as a measure of hand function is insufficient to predict levels of dependency at 
mealtimes. The strong correlation between EDACS and DMSS reflects the construct validity 
of EDACS. However, the DMSS (linked to DDS assessment) can be used only by qualified 
clinicians in people with developmental disabilities. It is a validated scale where the level 
of the swallowing and feeding disorder is determined rather than the eating and drinking 
ability of the child with CP.9 For scaling, the information from a parent questionnaire is used. 
It is not suitable for use by parents to convey their ideas about the child’s eating and drinking 
ability. Functional classification systems have arisen from models of healthcare based on 
family centered practice including collaborative teamwork with parents. The EDACS, along 
with the other functional classification systems for CP, enables parents, clinicians and 
researchers to communicate clearly with one another.23 In this respect, our findings support 
the complementary use of DMSS and EDACS in clinical practice.
Overall, this study shows that EDACS is reliable and valid when used by experienced 
SLTs, both ‘familiar’ and ‘unfamiliar’ with the child and also when used by parents. For other 
healthcare professionals, the concepts of EDACS should be known thoroughly for adequate 
use of this classification system in partnership with parents. The usability study showed 
fairly good results in differentiating between levels, and also shows room for improvement, 
considering that 10-14% of users of the EDACS (SLTs and parents) experienced difficulties 
differentiating between the various levels. An E-learning module is beneficial in this respect.
Limitations
Only SLTs experienced in working with children with CP participated in the present study. 
In daily practice, not all SLTs will meet this standard, which is a limitation of our study. In 
addition, SLTs only observed lunch and snack times at school and did not observe usual 
mealtimes at home. They were aware of, but did not observe, all the different food texture 
choices made at home to ensure mealtime safety and efficiency within the context of the 
child’s environment away from school. This emphasizes the need for discussing a child’s 
eating and drinking ability with parents in routine care, and the utility of EDACS to support 
this. It should be noted that selection bias may have influenced the observed interrater 
reliability and usability. For instance, parents whose native language was not Dutch were 
not included in our study.
EDACS can be used to describe limitations on someone’s overall eating and drinking 
ability arising from CP. The gross categorical distinctions between EDACS levels can be 
insensitive to subtle features of someone’s eating and drinking ability. For example, some 
children show greater limitations in eating and drinking ability than one may expect when 
only considering oral motor capacities because of behavioural issues or hypersensitivity of 
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the oral area. A child’s lack of experience or exposure to more challenging food textures or 
fluid consistencies may also suggest greater limitations to their eating and drinking ability. 
Future perspectives
EDACS has the potential to address questions concerning the prevalence of limitations in 
eating and drinking abilities of children with CP at the population level. Also, the association 
of eating and drinking ability with other areas of functional ability (including gross motor 
function, speech and hand function) can be addressed as well as weight/growth data and 
functional prognosis. EDACS provides professionals with a means to describe observations of 
safety and efficiency linked to eating and drinking. EDACS highlights and points to the need 
to explore the difference between the eating and drinking ‘performance’ (usual activity) and 
‘capacity’ (what a child can do at his/her best). As with the GMFCS, it is possible for eating 
and drinking difficulties to be identified and linked to different EDACS levels with the aim to 
support clinical management.
There is limited data concerning time related changes in eating and drinking abilities 
in people with CP. It is therefore uncertain how frequently children’s eating and drinking 
abilities should be reclassified using EDACS. Prospective longitudinal studies to examine the 
stability of EDACS levels over time are yet to be conducted. Longitudinal studies using the 
GMFCS and MACS demonstrate that individuals with CP usually remain stable over time and 
that, when there is change, it is no more than one level.24,25 Yet, uncertainties remain with 
regard to the natural course of eating and drinking difficulties in CP. Some clinicians expect 
that, over the years, a child may gradually be able to eat more challenging textures, use 
more types of utensils, and become more independent whilst eating and drinking.9 However, 
as children with CP reach puberty, risk of aspiration may increase; not only by changes in 
nutritional needs or increase in scoliosis, but also due to anatomical and physiological 
changes of the oropharynx.7 Consequently, oral motor growth and changes in posture might 
lead to a different EDACS level which would warrant repeated assessments. There is also 
clinical utility in investigating the correlation between nutritional status and EDACS level 
with the potential for EDACS to identify an increased risk of malnutrition due to limitations 
in eating and drinking abilities.
Conclusion
In conclusion, the Dutch EDACS is the first reliable, valid, and easily applicable tool to classify 
functional eating and drinking abilities in children with CP when used by experienced SLTs or 
parents. It will enhance the communication concerning eating and drinking abilities of these 
children among professionals and parents. It is analogous to other functional classification 
systems (GMFCS, MACS and CFCS). Use of EDACS may increase the awareness of safety and 
efficiency of eating and drinking ability in children with CP amongst different stakeholders. 
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It has the potential to form the basis for discussions with parents and other caregivers about 
the safety and efficiency of children’s eating and drinking abilities.
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Abstract 
Aim: The aims of this study were to examine whether objective measurements of the 
10-minute drooling quotient (DQ10) and the 5-minute drooling quotient (DQ5) are 
interchangeable; to assess agreement between the measurements and their accuracy 
in classifying drooling severity; and to develop a time-efficient clinical assessment.
Method: The study cohort included 162 children (61 females, 101males;mean age 11y 
6mo, SD 4y 5mo, range 3y 9mo–22y 1mo) suffering from moderate to profuse drooling. 
One hundred and twenty-four had cerebral palsy and 38 had other developmental 
disabilities. Seventy-four of the participants were ambulant and 88 non-ambulant. 
The original DQ10 was recalculated into a 5-minute score (DQ5). Assessments were 
undertaken while the participants were in a rest situation (DQR) and while they were 
active (DQA). Agreement in scores was quantified using intraclass correlations and Bland–
Altman plots. To classify drooling, area under the receiver operating characteristic curve 
analysis was used to compare accuracy of the DQ10 and DQ5 at rest and during activity.
Results: Agreement between DQ10A, and DQ5A, and between DQ10R and DQ5R was high 
(intraclass correlation coefficient > 0.90). Moderate agreement existed between DQA 
and DQR. DQA scores were more accurate in classifying children’s drooling behaviour. 
For DQ5A, a cut-off point of 18 or more (drooling episodes ⁄ observation time) might 
indicate ‘constant drooling’.
Interpretation: The DQ10 and DQ5 can be used interchangeably. DQA is most 
discriminative for drooling severity. For evaluating treatment efficiency the cut-off point 
can be used. For clinical and research purposes, the DQ5 is time efficient and cost saving 
while validity, and intrarater and interrater reliability are preserved.
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Drooling is defined as the unintentional loss of saliva from the mouth.1 In children with 
cerebral palsy or other developmental disabilities, drooling may persist after toddlerhood 
as a result of impaired muscle control of the tongue, lips, or throat; malocclusion; disturbed 
swallowing; inability to maintain an upright position of the trunk and head; or the incomplete 
development of an automatism to swallow saliva.2,3 The severity and impact of drooling 
are assessed by both subjective and objective measurements. Subjective scales such as the 
Drooling Rating Scale, the Drooling Frequency and Severity Scale, the Visual Analogue Scale 
(VAS), and the Drooling Impact Scale4,5 are completed by patients or their caregivers, who 
give their qualitative and quantitative impression of the severity and impact of drooling.
Although Blasco6 stated that the ‘ultimate test of whether treatment will be continued 
or not is whether it makes the caregiver’s life easier and their child’s life improved’, evidence 
for effective treatment cannot be derived from satisfaction scores alone. An additional 
objective measure may be supportive, both in effect evaluation and in decision-making for 
intervention. Objective measures related to drooling include salivary flow measures and 
direct observations of saliva loss (e.g. counts of saliva drops) from the mouth.4,7 In this 
study we focus on the objective measurement of drooling severity: the drooling quotient as 
originally proposed by Rapp8 and modified thereafter.4,9 The drooling quotient represents a 
semiquantitative, direct observational method that evaluates drooling by measuring leaked 
saliva from the mouth (so-called anterior drooling). In its original form, Rapp and Bowers10 
used a ‘teacher prompt device’ to obtain measurements of drooling in moment-by-moment 
sampling observations in the classroom. Forty randomly evoked bleeps over a 10-minute 
period ordered the teacher to score if the child drooled or not. Drooling was defined as 
a string of drool, either continuous or falling at the time of the cue. The authors found 
an interobserver agreement of 99%. Reddihough et al.11 redesigned the drooling quotient 
to a partial interval time sampling observation of drooling at 15-second intervals over a 
10-minute period. Drooling was defined as ‘new saliva present beyond the lip margin’, to 
avoid double counting. In a controlled clinical trial by Jongerius et al.,4 the drooling quotient 
was applied in a standardized setting during two observation sessions of 10 minutes. 
Drooling was scored positive if during a 15-second interval new saliva was present on the 
lip margin or dropping from the mouth or chin area. Because drooling severity may vary 
significantly depending on the level of activity or the ability to focus attention on the need 
to swallow, each child was observed both at rest (DQ10R) and during an activity (DQ10A) 
that demanded a higher level of concentration or physical effort.4,12
Although the 10-minute drooling quotient (DQ10) has been used to evaluate the 
effect of treatment for drooling, there are no validity and reliability data available for the 
DQ10. In addition, the procedure is rather costly and timeconsuming, taking two periods 
of 10 minutes (during activity as well as rest). From a clinical point of view, it would be 
valuable to reduce scoring time.
The aim of this study was to investigate whether the validity and reliability of 
drooling severity measurement would be preserved at a 5-minute scoring time. We 
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hypothesized that results from a 5-minute drooling quotient (DQ5) and DQ10 would be 
interchangeable for children with moderate to profuse drooling. In addition, we wanted to 
identify a clinically meaningful number of drooling episodes to support decisionmaking for 
intervention and measure response to these interventions.
METHOD
Participants
This study was part of a project in which the effectiveness of either botulinum toxin 
type A (BoNT-A) injections into the salivary glands or surgery to reduce salivary flow was 
evaluated.4,13,14 All participants attended the multidisciplinary outpatient drooling clinic at 
the Radboud university medical center, Nijmegen, the Netherlands, between 2003 and 2010. 
For this study, we included 162 children with moderate to profuse drooling (i.e. Teacher 
Drool Scale* scores 3 and higher15). Children were included if complete data for baseline 
drooling measurements and repeated drooling measurements 8 weeks after intervention 
were available.
Patient characteristics including some drooling measurement results are summarized 
in Table 1. One hundred and thirty-eight children received injections of BoNT-A to the salivary 
glands, 17 children had saliva control surgery, six children received behaviour therapy, and 
one child underwent an adenoidectomy. Sixty-one females and 101 males (age range 3y 
9mo–22y 1mo; mean age 11y 6mo, SD 4y 5mo) were enrolled. Among them, 74 children 
were ambulant and 88 children were wheelchair bound. Diagnosis comprised cerebral palsy 
(n=124) and developmental disability (n=38), mainly as part of a syndrome or unexplained 
developmental delay. 
Written and oral informed consent was obtained from either the children or their 
parents or caregivers. The research was conducted in accordance with national and 
international ethics standards. The Regional Committee on Research Involving Human 
Subjects approved the study. Exclusion criteria were enrolment in another medical study, 
use of drugs interfering with saliva secretion, and a previous surgical procedure for saliva 
control.
*Teacher Drool Scale: 1, no drooling; 2, infrequent drooling, small amount; 
3, occasional drooling, on and off all day; 4, frequent drooling, but not profuse; 
5, constant drooling, always wet.
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Measurement procedures
All children were assessed by two trained speech therapists (Karen van Hulst and Sandra 
de Groot) at baseline and follow-up. Follow-up was at 8 weeks after treatment when the 
children attended the outpatient clinic. If possible, the sessions were videotaped. From the 
completed assessment (162 children) we randomly selected baseline (n=86) and follow-up 
(n=76) data to create a study sample with a high degree of heterogeneity. All measurements 
took place under standardized conditions in the morning at least 1 hour after mealtime. 
During the drooling quotient ‘rest’ condition, the child was allowed to watch television, 
sitting upright in his or her own (wheel)chair and prohibited from talking. The kind of activity 
performed during the drooling quotient ‘activity’ condition was adapted to the child’s 
cognitive and movement abilities and interest: for example, some children built blocks for 
dual tasking while others used their electronic communication device.
In one morning session, the measurements occurred in the following order: (1) 
DQ10A, (2) salivary flow measure of the submandibular and parotid glands,12,16 (3) visual 
analogue scale scores of severity as perceived by the parents (0=no drooling, 100=excessive 
Table 1: Characteristics of the study group (n=162) and drooling measurement results.
Characteristics n %
Sex
Male
Female
101
61
62
38
Main diagnosis
Cerebral palsy
Other developmental disability
124
38
77
33
Mobility
Ambulant
Non-ambulant
Unknown
72
88
2
44
54
2
Intellectual impairment Developmental age
<4y
4–6y, IQ<70
4–6y, IQ>70
>6y
Missing
91
22
7
38
4
56
13
4
24
3
Intervention
Botulinum toxin A injections
Saliva control surgery
Behaviour therapy
Other
138
17
6
1
85
10
4
1
Drooling measurements Mean SD
VAS 66 23.94
Total salivary flow rates 0.62 0.56
DQ versions
DQ10A
DQ10R
DQ5A
DQ5R
20.07
14.04
20.28
14.54
16.77
13.51
18.12
15.00
Mean age of study cohort 11 years 6 months (SD 4y 5mo). VAS, Visual Analogue Scale; DQ, drooling quotient; 
DQ10A, 10-minute drooling quotient during activity; DQ10R, 10-minute drooling quotient at rest; DQ5A, 5-minute 
drooling quotient during activity; DQ5R, 5-minute drooling quotient at rest.
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drooling), (4) Drooling Severity and Frequency Scale scores, as judged by the parents or 
caregivers, and (5) DQ10R. Before starting the drooling quotient assessment, saliva was 
wiped off the chin, and any food that remained in the mouth was removed. Drooling was 
defined as a drip of new saliva present on the lip margin or a string of saliva dropping from 
the mouth or chin area. During 10 minutes, for every interval of 15 seconds, the presence or 
absence of drooling was determined. The drooling quotient was expressed as a percentage 
of observed drooling episodes and the total number of intervals.
Reliability of the assessments
An intrarater and interrater reliability design with four raters and 10 video clips of the DQ5R 
and DQ5A were used to assess reliability of the DQ5 version during rest and activity. The 
raters were selected on the basis of their broad experience in assessing the target group. 
All raters received a 3-hour training session and scored the video clips at two different time 
points separated by at least 3 weeks. A wide selection of available video clips was recorded 
with children in different mobility classes, at different developmental ages, with different 
diagnoses, and different measurement moments.
Statistical analysis
DQ10 measurements during rest and activity were recalculated into DQ5 by taking the first 
5 minutes of the scoring time; instead of 40 episodes of 15 seconds, the first 20 intervals 
of 15 seconds were judged. Agreement between the DQ10 and DQ5 during activity and at 
rest was quantified by the intraclass correlation coefficient (ICC), two-way random, single 
measure. For the evaluation of agreement, the classification of Landis and Koch17 was used. 
The magnitude of the DQ5 deviations from the DQ10 was examined by the Bland–Altman 
method and included the calculation of limits of agreement.18 Interrater reliability of the 
assessments from the video clips was evaluated using the ICC two-way random model for 
absolute agreement, single measure. Intrarater reliability was calculated by a two-way 
mixed model with the raters considered as a fixed effect, also single measure.
The criterion validity of the drooling quotient scores was evaluated by the relation 
with the parent’s evaluation of drooling frequency according to the four-point classification 
of drooling frequency by Thomas-Stonell and Greenberg,19 considering ‘frequently 
drools’ and ‘constantly drools’ as ‘constant drooling’ and ‘never drools’ and ‘occasionally 
drools’ as ‘on-and-off drooling’. The overall accuracy of all drooling quotient versions in 
correctly classifying children as ‘constant drooling’ was evaluated using receiver operating 
characteristic curve analysis. The area under the receiver operating characteristic curve 
(AUC) may range from 50% (meaning no accuracy of the drooling quotient score to classify 
correctly) to 100% (meaning excellent classifying accuracy). We considered an AUC of at 
least 0.7 as fair, 0.8 as good, and 0.9 as excellent.20
The optimal drooling quotient cut-off points were determined by applying the 
Youden method (% sensitivity + % specificity) -100),21 which minimizes the number of false-
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RESULTS
Figure 1 presents the ICC values and Bland–Altman plots for the agreement between the 
different drooling quotient versions. The ICCs for agreement between DQ10A and DQ5A 
and the agreement between the DQ10R and DQ5R were over 0.90, indicating a high level of 
agreement. The ICCs for agreement between the DQA versions and the DQR versions were 0.50 
and 0.53 respectively, representing a moderate agreement. The mean difference between 
Figure 1. Intraclass correlation coefficients (ICCs) and Bland–Altman plots for the agreement 
between different drooling quotient versions. (a) DQ10A–DQ5A (ICC 0.93; 95% confidence interval 
[CI] 0.90–0.96). (b) DQ10R–DQ5R (ICC 0.92; 95% CI 0.89–0.94). (c) DQ5A–DQ5R (ICC 0.53; 95% CI 0.42–0.64). 
(d) DQ10A–DQ10R (ICC 0.51; 95% CI 0.38–0.63).
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positive and false-negative misclassifications. We also calculated the Pearson’s 
correlation of the individual drooling quotient versions with the VAS for drooling severity. 
Furthermore, the correlation was calculated between all the drooling quotient versions and 
the scores of total salivary flow measured by the dental swab method.4
For all statistical tests, the level of significance for two-tailed p-values was set at 
≤ 0.05. Point estimates are presented with their 95% confidence intervals (CIs). All analyses 
were performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA).
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DQ10A and DQ5A scores -0.2; SD 6.39) indicates a small negligible systematic error. Six out 
of 162 deviation points (3.7%) were outside the 2SD limits of agreement. Two participants 
had much more saliva production and high DQ scores during the last 5 minutes of the DQ10 
and another four participants had more saliva dripping during the first 5 minutes, explaining 
most of the deviation outside the 2SDs. An almost similar number of outliers (6.8%) were 
registered from the Bland–Altman DQR plot. Here, again, the mean difference -0.5; SD 5.8) 
showed a small and negligible systematic error. The Bland–Altman plots for the DQA and 
DQR comparisons reflected the lower agreement. The systematic error for the DQ10A and 
DQ10R comparison was 6.03 (SD 14.7) and for the DQ5A and DQ5R comparison was 5.74 (SD 
16.5). The Bland–Altman plots for the DQ10A and DQ10R showed broad limits of agreement 
(between 34.8 and 122.8). Thus, the activity measurement may be 34.8 percentage points 
above or 22.8 percentage points below the rest situation.
The accuracy of the different drooling quotient versions to correctly classify children 
as ‘constant drooling’ is presented in Table 2. Thirty-two children (19.8%) were classified as 
drooling’ ‘on-and-off’ and 130 children (80.2%) were classified as drooling ‘constantly’. The 
accuracy of the DQ5R (AUC=0.69) and DQ10R (AUC=0.73) was lower than that of the DQ5A 
and DQ10A (both AUC=0.80).
Using the Youden method, the drooling quotient cut-off point with a minimum risk 
of false-positive or false-negative classifications was lower for DQ10 (DQA 11 points and 
DQR 14 points) than for DQ5 (DQA and DQR both 18 points). The correlations between the 
drooling quotient versions with the VAS scores and the salivary flows are summarized in 
Table 3. The Pearson’s correlations for the VAS ranged from 0.35 to 0.46. The correlations 
for the salivary flows ranged between 0.26 and 0.31. The correlations between the VAS and 
the activity versions of the drooling quotient, DQ10A and DQ5A, were higher than for the rest 
versions. The correlations with salivary flow were similar for the activity and rest versions of 
the drooling quotient.
The ICC for the interrater reliability of the DQ5 scores as obtained from the video 
assessments was 0.95 (95% CI 0.85–0.99). Intrarater ICCs for the four raters were 0.91 (95% 
CI 0.67–0.98), 0.86 (95%CI 0.55–0.96), 0.95 (95% CI 0.80–0.99) and 0.91 (95%CI 0.67–0.98), 
all representing good reliability.
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Table 2: Accuracy of the different drooling quotient activity and rest version.
DQ
version
AUC (95% CI) Youden
cut-off
Sensitivity Specificity
DQ5A 0.80 (0.73–0.88) 18 0.61 0.75
DQ5R 0.69 (0.60–0.78) 18 0.45 0.87
DQ10A 0.80 (0.72–0.88) 11 0.72 0.81
DQ10R 0.73 (0.63–0.82) 14 0.49 0.87
DQ, drooling quotient; AUC, area under the receiver operating characteristic curve; CI, confidence interval; 
DQ5A, 5-minute drooling quotient during activity; DQ5R, 5-minute drooling quotient at rest; DQ10A, 10-minute 
drooling quotient during activity; DQ10R, 10-minute drooling quotient at rest
Table 3: Correlation coefficients for drooling quotient versions with the Visual Analogue Scale (VAS) 
and total salivary flow rate.
Pearson’s r
(95% CI)
VASa
DQ5A
DQ5R
DQ10A
DQ10R
0.45 (0.32–0.58)
0.35 (0.21–0.49)
0.46 (0.33–0.59)
0.38 (0.24–0.52)
Total salivary flow rateb
DQ5A
DQ5R
DQ10A
DQ10R
0.26 (0.11–0.41)
0.28 (0.13–0.43)
0.27 (0.12–0.42)
0.31 (0.16–0.46)
aVAS (0=no drooling, 100=excessive drooling).
bFlow submandibular glands + flow parotid glandsmeasured during 5 minutes according to the swab method. 
CI, confidence interval.
DISCUSSION
The drooling quotient is a reliable and valid objective procedure to measure drooling 
severity. Our results show that, without loss of overall accuracy, the original DQ10 can 
be replaced by the DQ5 during the activity as well as rest observations. The agreement 
between the original drooling quotient and the shorter 5-minute version was almost 
perfect. The observed error was random and the number of outliers acceptable for the 
observation during activity as well as rest. The limits of agreement were all within 10%, 
which represents an acceptable random error. The interrater and intrarater reliability of 
the DQ5 in children with moderate to profuse drooling was excellent. In this respect, clear 
video clips and the work of well-trained raters may have been helpful. The Youden index 
of the cut-off score of 18 is a function of sensitivity and specificity and is a commonly used 
measure of classification of effectiveness of a cut-off point. This index is lower for the DQ5A 
(53 vs 36) than for DQ10A, indicating that a higher misclassification rate can be expected 
with the 5-minute version when using that cut-off. The overall accuracy (AUC) of the drooling 
quotients in the detection of children with ‘constant’ drooling behaviour was in both cases 
0.80 and therefore good. For reliable assessments with the DQ5, the assessments should be 
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carried out under standardized conditions. This is an important prerequisite: the results of 
the DQ5 will be reliable only if the natural variation in saliva flow rates across daily situations 
(for instance while eating, at rest, etc.) are minimized. For clinical practice, however, setting 
up a DQ5 assessment probably exceeds 5 minutes because of preparation time and data 
processing, but we still argue that 5 minutes less than using the DQ10 constitutes a notable 
reduction in assessment time.
Drooling quotient registrations during activity were more accurate than the rest 
versions in correctly classifying children’s drooling status. The DQ5A appears to be the measure 
of choice for use in clinical practice and research. Although the need to tailor the activity to 
the child’s cognitive and movement abilities introduces some variability in measuring the DQA, 
this individualized approach was assumed to be a valid way to represent drooling severity in 
daily life activities. Children in our study cohort drooled more frequently during strenuous 
activities demanding a high motor performance and cognitive level than during rest situations. 
This can be explained by insufficient attention given to swallowing during activities. The 
Pearson’s correlations, reflecting the association between the VAS (subjective assessment) 
for perceived drooling severity, were also higher for the DQA measurements than for the rest 
version. Although the DQA seemed more discriminative than the DQR, for clinical purposes the 
speech therapist might want to use both versions to direct the choice for intervention. For 
instance, in children drooling both at rest and during activities, the oral motor intervention 
should start during a rest situation; whereas for children who mainly drool during activities, 
intervention should start with promoting oral motor control during dual tasks.
Although the DQ10 can be replaced by the DQ5 in children with moderate to profuse 
drooling, we have to be cautious in generalizing this conclusion to drooling assessment in 
all children with slight to profuse drooling problems. Perhaps the frequency and occurrence 
of drooling episodes in children with minor drooling cannot be validly assessed during 
5-minute trials. For now, it remains unknown if the DQ5 is discriminative for children with 
infrequent and slight drooling.
With respect to saliva, the normal situation is not to drool, reflecting a drooling 
quotient of zero. All our patients drooled to some extent. The subjective measurements of 
parents with regard to their child’s drooling problem is important but should be supported 
by more objective measurements, especially in children with minor drooling problems. Clear 
cut-off points may be useful in clinical decision-making. In this study, the drooling quotient 
cut-off point was estimated based on the individually meaningful finding of ‘constant 
drooling’ or ‘on-and-off drooling’. The cut-off point reflects the best balance for classifying 
children according to their drooling status. For clinical decision-making, our results suggest 
the use of a DQ5 cut-off point of 18 or higher as ‘constant drooling’, irrespective of whether 
the child is active or at rest. The cut-off point of 18 means 3.6 out of 20 drooling episodes 
of 15 seconds x 100. A cutoff point could serve as a ‘rule of thumb’ for decisionmaking in 
drooling treatment. A drooling quotient of 18 or higher means that the drooling problem 
is at least frequent and ⁄ or has not been not satisfactorily resolved by previous treatment. 
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This cut-off point may be useful in deciding whether intervention is needed.
Children with a drooling quotient of less than 18 may be eligible for a more conservative 
intervention, such as oral motor training. In case of a higher score (drooling quotient > 18) 
other interventions, such as behaviour therapy, BoNT-A injections, or surgery, may be the 
therapy of choice. Analysing the data at group level, this cut-off point appears reasonable 
as the mean DQ5A at baseline was 26 points, decreasing to 14 points at follow-up. However, 
in clinical practice, the drooling quotient cut-off point should not be rigidly applied as the 
only variable. In addition to subjective and objective measurements, such as the drooling 
quotient, one should seriously consider the impact of drooling on the child and his or her 
environment, hour-to-hour and day-to-day variability in drooling, and the medical history of 
the child as well as the outcome of multidisciplinary decision-making. The individual patient 
may require a flexible approach and deviation of the chosen drooling quotient threshold 
value should be considered from case to case in a drooling team setting. Future research 
should reveal the applicability of the cut-off point.
Although drooling severity varies from day to day, and sometimes from hour to 
hour, and across daily life situations, there is a need to quantify the drooling frequency and 
severity, and its impact on the quality of life of children with drooling and their carers.14,22 The 
subjective opinion of parents on drooling severity and its impact, as measured by the VAS, 
the frequency and severity scale according to Thomas-Stonell and Greenberg,19 the Drooling 
Impact Scale, and parent questionnaires,5,22 is considered to be of utmost importance in 
evaluating treatment outcome. The DQ5 is measured over a brief period and gives a reliable 
outcome of the drooling severity. Following good clinical practice, it is particularly important 
to pair these measurements with the results of subjective tools that assess the impact of 
drooling on patient and caregiver daily life.
In recent research, little attention has been given to objective measurement 
methods for drooling. In addition, Parr et al.23 found that very few paediatricians in the UK 
use standardized methods of measuring the effectiveness of medications, or their adverse 
effects, as part of their management of drooling in children. Several methods of quantifying 
salivary flow or the amount of saliva loss are available, such as using collection units,24,25 
weighing bibs,5,22 or using cotton dental rolls to measure saliva flow.4 The development 
of valid and reliable direct measurement tools for anterior drooling is still a challenge 
in research and clinical practice. The results of the Pearson’s correlation of the drooling 
quotient versions with the VAS and the total salivary flow rate show a weak relationship, 
suggesting that drooling quotient cannot be replaced by the subjective VAS or an objective 
saliva flow measurement.
We argue that the drooling quotient is a valuable, additional, objective, 
semiquantitative observation tool that provides a representative measure of anterior 
drooling. The DQ5A modification is time saving and might reduce costs without affecting the 
accuracy of objective drooling measurements. To our knowledge, this is the first study on the 
subject of drooling which suggests the use of a cut-off point to guide clinical decision-making.
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Abstract 
Drooling, or sialorrhea, is a common problem among both children and adults with 
cerebral palsy (CP), with an approximate prevalence rate of 40%. There are numerous 
complications related to anterior and posterior drooling ranging from psychosocial 
impact to significant morbidity from chronic aspiration. Multiple interventions aimed 
at reducing or eliminating drooling have been described, however there has been no 
clear consensus on which are most effective. The objective of this narrative review is to 
summarize the published data and provide a comprehensive evidence-based overview 
of drooling management in children and youth with CP, from birth to age 25. While 
the emphasis in this paper is on individuals with CP, we have highlighted inclusion of 
other neurodisabilities when necessary to provide evidence of a particular treatment 
modality. A review of the literature review included all levels of evidence to best 
contextualize and guide the full range of potential clinical treatment interventions, 
including: oral motor and behavioral interventions, oral appliances, pharmacologic 
interventions, chemodenervation with botulinum toxin, and surgical options. A total of 
339 articles were identified and 132 articles met the classification criteria for inclusion. 
Articles were graded according to American Academy of Neurology guidelines. Highest 
level evidence was found for pharmacologic interventions, particularly glycopyrrolate 
and scopolamine, and salivary botulinum toxin.
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Introduction
Drooling, or sialorrhea, is a common problem among children and young adults with 
cerebral palsy (CP). Drooling occurs when an individual’s ability to control and swallow oral 
secretions is limited. Its prevalence is thought to be around 40% with a slightly increased 
occurrence among individuals with more severe forms of CP, where poor gross motor 
function can be associated with decreased head control and dysphagia.1 Individuals may 
experience anterior drooling, posterior drooling, or both. Anterior drooling, which manifests 
as saliva spilling out of the front of the mouth, can have significant psychosocial implications 
and may affect health related quality of life.2 Posterior drooling is often not visible but can 
be associated with pooling of saliva in the posterior oropharynx leading to serious medical 
consequences such as chronic aspiration, recurrent respiratory infections and progressive 
lung disease. Respiratory related illness is a leading cause of death in children with CP, thus 
any interventions that lower the risk of pulmonary deterioration are important to consider.3 
Prior to determining a treatment decision, clinical evaluation of the child with 
sialorrhea should be conducted via a multidisciplinary approach, either in real time or 
in series, with good communication between members of the child’s health care team. 
Intervention should only be considered after all conditions that exacerbate drooling 
have been optimized, including oral health, trunk and head positioning, lip occlusion, 
airway obstruction, drug effects, allergy, gastroesophageal reflux and excessive mouthing. 
Figure 1, extracted from the American Academy of Cerebral Palsy and Developmental 
Medicine (AACPDM) Sialorrhea Care Pathway algorithm, outlines the important assessment 
steps as well as the objective and subjective assessment tools used for evaluating the extent 
and frequency of drooling and the impact it has on the child and family.4   
Multiple interventions aimed at reducing or eliminating drooling have been described, 
however, there is no clear consensus on which are most effective. In 2012, a systematic 
Cochrane review analysed randomized and controlled clinical trials of drooling in individuals 
with cerebral palsy.5  This helped to inform the Sialorrhea Care Pathway supported through 
the AACPDM.4 However, there are a number of interventions that are used clinically in 
sialorrhea management for which there is limited or low level evidence about effectiveness 
and side effects. Due to Cochrane criteria, these were not included in their review. This 
paper outlines the full spectrum of interventions that have been reported for children with 
CP, including all levels of evidence, in order to inform the practicing clinician of the options 
available and the robustness of the literature behind those interventions. 
Methods
A computer assisted literature search for relevant articles published from January 1978 to 
December 2018 was performed in PubMed with an additional manual search. The keywords 
and Mesh terms used in the search were “sialorrhea”, “drooling”, “hypersalivation”, 
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“saliva loss” in various combination with “cerebral palsy”, “spastic diplegia” and “spastic 
quadriplegia”. Intentionally, no outcome was defined in the search strategy to prevent 
limitations in the search results. Inclusion criteria for the articles were English-language 
studies and those including individuals aged birth to 25 years. Initially the search was 
limited to studies including only participants with CP, however, in an effort to represent 
the full spectrum or clinically available interventions, the search strategy was broadened 
to include “neurodevelopmental disorders”, “developmental disabilities”, “motor skills 
disorders” or “intellectual disability”. The methodological quality of each study was 
evaluated independently by two readers according to the American Academy of Neurology 
(AAN) Clinical Practice Guideline Process Manual, which defines four hierarchical classes of 
Figure 1. Flow Diagram for Evidence-informed Clinical Practice guideline for assessment of sialorrhea in Children/
Youth with CP with subjective scales (the Teacher Drooling Scale (TDS)41, the Drooling Severity and Frequency Scale 
(DSFS)42, the Visual Analogue Scale (VAS)43, and the Drooling Impact Scale (Drl scale)18); and the Drooling Quotient 
(DQ)44 as an objective scale. The Pediatric Posterior Drooling Scale45 is piloted as a new screening tool for posterior 
drooling.
Medical assessment
• Medical History
• Neurologic assessment
• Respiratory status
• Gastroesophageal reﬂux (GER)
• Allergies
• Dental Examination
• Orofacial examination
Aspiration may be present with the following:
• Repeated episodes of pneumonia
• Repeated courses of antibiotics
• Wet breath sounds
• Need for frequent sucking
• Obvious pooling of secretions in the posterior oropharynx
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Social Evaluation
• Intrinsic motivation
• Child’s self-management skills
• Impact of sialorrhea
• Importance of saliva controle 
 to family
Oromotor Assessment
• Head Control
• Positioning
• Mouth Closure
• Occlusion
• Lip seal
• Sensorimotor examination
• Swallow examination
• Swallow on demand
Identify Risk for Aspiration
Visible spillage of saliva from the mouth
Consider quantitative assessment:
Droolong severity (subjective scales):
• Teacher Drool Scale (TDS)
• Drooling Severity and Frequency Scale (DSFS)
• Visual Analogue Scale (VAS)
• Number of bibs
Drooling Frequency (obkective scale):
• Drooliong Quotient (DQ)
Impact on Child and Family:
• Drooling Impact Scale (DIS)
Ánterior Drooling
Generally no quantitative assessment is available,
consider:
• Salivagram
• Flexible Endoscopic Evaluation of Swallowing
 (FEES)
• Pediatric Posterior Drooling Scale
Posterior Drooling
and / or
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therapeutic evidence (Table 1).6 Consensus for grading discrepancies was achieved through 
discussion. 
The full range of interventions for sialorrhea in individuals with CP is reported, with 
discussion of the level of evidence supporting each. This includes oral motor interventions, 
behavioral intervention, oral appliances, pharmacologic interventions, chemodenervation 
with botulinum toxin, and surgical options. The evidence is then considered in relationship 
to the treatment of children and young people with CP.  Evidence not restricted to a diagnosis 
of CP is noted.
Table 1: American Academy of Neurology Clinical Practice Guidelines 6 (appendix II).
CLASSES CRITERIA RECOMMENDATIONS CRITERIA
Class I - Randomized controlled clinical trial or crossover 
trial in a representative population
- Triple masked studies 
• period and carryover effects  
• statistical adjustments 
AND addition criteria a-e (see appendix II AAN)
High confidence  
(highly likely)
Requires at least two 
consistent class I studies
Class II - RCT that lacks one or two Class I criteria a-e
- Cohort studies employing methods that 
successfully match treatment groups on relevant 
baseline characteristics 
- Randomized crossover trial missing one of the 
following two criteria:
a. Period and carryover effects described
b. Baseline characteristics of treatment order groups 
presented 
- All relevant baseline characteristics are presented 
and substantially equivalent across treatment 
groups, or there is appropriate statistical 
adjustment for differences
- Masked and objective outcome assessment*
Moderate confidence  
(likely)
Requires at least one class 
I study 
OR
At least two consistent class 
II studies
Class III - Controlled studies 
- Crossover trial missing both of the following two 
criteria:
a. Period and carryover effects
b. Presentation of baseline characteristics
- A description of major confounding differences 
between treatment groups that could affect 
outcome
- Outcome assessment performed by someone 
who is not a member of the treatment team
Low confidence  
(possibly)
Required at least one class 
II study 
OR
At least two consistent class 
III studies
Class IV Studies not meeting criteria for Class I-III Very low confidence 
(insufficient)
When studies did not meet 
class I to III requirements 
OR
Included studies that were 
conflicting
* Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer’s (patient, 
treating physician, investigator) expectation.
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RESULTS
A total of 339 articles were identified (figure 2) and 132 articles met criteria for inclusion. 
The following section outlines available treatment options, depicted in figure 3, for both 
anterior and posterior drooling in the context of the published literature supporting the use 
of each intervention.
 
Treatment of anterior drooling
Oral motor intervention
Oral (sensory) motor therapy may be used as a first step in treating anterior drooling. 
The aim of oral motor therapy is: (1) to reduce the anterior loss of saliva; (2) to increase 
oral awareness and swallow frequency; (3) to improve lip and jaw closure; (4) to increase 
tongue control, reduce tongue thrust; and (5) to improve oromotor tone and facial and oral 
sensation.5 In general there are three main categories of oral-motor exercises (OME): active 
exercises, passive exercises, and sensory applications.3 
Searches revealed 18 studies on the effects of oral motor interventions on drooling 
in mixed populations of children with neurodisabilities, including, but not restricted to, CP. 
One was excluded because it was a review, eight were excluded based on content and one 
was not available in full text. The remaining eight studies were classified as Class IV because 
of the lack of objective or masked outcome measures. In general, oral motor training for 
drooling had positive results. However, in Inal et al.’s randomized controlled trial the severity 
of drooling decreased after home based chewing training in the experimental group, but 
drooling frequency did not.7 High level evidence supporting oral motor intervention is 
limited.  
Behavioral Intervention
Behavioral interventions are aimed at changing the frequency or type of a target behavior. 
Antecedents (behaviors or events that precede the target behavior) and consequents 
(behaviors or events that follow it) are systematically manipulated or controlled to alter 
the target behavior. In young people with anterior drooling, the frequency of swallowing 
or wiping of the mouth and chin are examples of targets for behavioral intervention. 
Instructions, prompts and automatic cueing (e.g. beeps or vibrations from an electronic 
device or smart phone) are antecedent control techniques. Positive feedback, automatic 
reinforcement (e.g. music), and decelerative procedures (i.e. some kind of correction) are 
consequent techniques. These techniques are often used in combination. If changes in target 
behavior are achieved, withdrawal of the (external) support of therapists, parents and/or 
devices may result in increased drooling. Additional self-management techniques may help 
children with sufficient learning abilities to control target behaviors themselves and become 
independent from help and cues from their social or physical environment. Limited clinical 
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evidence from case-studies and two case-series on self-management techniques indicate 
that they may be an effective treatment for anterior drooling in this subgroup.8, 9 
There is only low level evidence available for behavioral intervention for anterior 
drooling. Searches revealed 15 studies relevant to behavioral interventions. Two were 
excluded based on content and three were reviews. The remaining ten studies were all Class 
IV, mostly of single case experimental design, and included both children with CP and other 
neurodevelopmental disabilities. Based on references of three reviews from this search, 
an additional (manual) search for higher level evidence revealed no further studies. All 
10 studies report improvement in drooling, but because of different dependent variables 
and/or modes of measurement it is not possible to comment on a consistent response 
rate. A recent systematic review by McInerney et al.10 revealed low level evidence for the 
effectiveness of behavioral interventions to treat drooling, consistent with our findings but 
with slightly higher levels of evidence given a different grading metric.
Oral Appliances
Various oral appliances have been developed to modify and improve oral motor function 
and, in turn, saliva control. Use of the appliances is typically limited to children over six 
years of chronologic age. A multidisciplinary approach is essential as these appliances 
are prescribed by dentists, with input from speech pathologists and physicians needed to 
determine whether these are the correct approach, and to provide training, and monitoring. 
The most commonly described appliances are the palatal training appliance, the Castillo 
Morales appliance (CMA)11, 12 and the Innsbruck Sensorimotor Activator and Regulator 
(ISMAR).13 These appliances require daily use over an extended period. Compliance is a 
major limitation, both with palatal training devices14 and with the ISMAR.13 Oral appliances 
can pose risks during active seizures; individuals who use the ISMAR appliance must be able 
to breathe through their noses.    
The literature search identified 17 articles possibly related to oral appliance use 
in young people with CP and related neurodevelopmental disabilities. Five articles were 
excluded due to unrelated content, two were descriptive and one was a review with a 
broader scope. Only nine met inclusion criteria, and all reflected Class IV evidence consisting 
of either anecdotal, single case studies or retrospective group studies without control 
groups. All these studies with small numbers of participants reported improvement in 
drooling, however, due to different methodologies, and outcome tools it is not possible to 
comment broadly on degree of improvement.
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Treatment of anterior and posterior drooling
Pharmacologic Interventions 
Anticholinergic pharmacological interventions are commonly prescribed for sialorrhea. 
These medications work by inhibiting stimulation of the salivary glands, thereby reducing the 
volume of saliva produced. The literature review revealed glycopyrrolate (glycopyrronium), 
scopolamine (hyoscine hydrobromide/scopolamine hydrobromide), benztropine, atropine, 
and trihexyphenidyl (benzhexol) to be studied in sialorrhea management in individuals with 
CP. Thirty-four articles were identified, ten of which were excluded because they either 
did not meet inclusion criteria (n=3), were reviews (n=6) or full text was unavailable (n=1). 
There were six Class III studies, two of which related predominantly to children with CP; 
the remainder included children with CP as well as a spectrum of neurodevelopmental 
Figure 3. Interventions for sialorrhea from least to most invasive.
ANTERIOR DROOLING POSTERIOR DROOLING
Optimize conditions
Patient evaluation
• Oral motor interventions
• Behavioral interventions
• Oral appliances
• Pharmacological interventions
• Botulinum Toxin injections
• Surgical interventions:
 * Submandibular gland excision and/or parotid 2 duct ligation
 * Submandibular 2, 3 or 4 duct ligation
 * Submandibular duct relocation with sublingual gland excision (ONLY for ANTERIOR)
and / or
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disabilities. Several studies supported the efficacy of glycopyrrolate and/or scopolamine. 
It should be noted that two of the studies would have been Class II except for the AAN 
requirement that objective outcome measures should be used.  All other studies were 
Class IV (n=18), and most included children with both CP and other neurodevelopmental 
disorders. 
Various systematic reviews and several randomized controlled trials studying the 
outcomes of pharmacologic intervention for drooling in children with CP and neurodevelopmental 
disorders have been completed.5,15 The effectiveness of glycopyrrolate,21 scopolamine, 45 and 
benztropine4   have independently been studied with RCTs and cohort studies of mixed evidence 
class, which have demonstrated drooling reduction in children and young people with CP. Side 
effects, however, are common and may include xerostomia, constipation, headache, thickened 
mucus, dehydration, urinary retention, urinary tract infections, fever, dizziness, drowsiness, skin 
rash, dilated pupils, blurred vision, and epilepsy.3
One of the strongest studies was the single blind randomized controlled drooling 
reduction intervention trial16 comparing the effectiveness and side effect profile of 
scopolamine patches with orally administered glycopyrrolate in 90 children with CP and 
other neurodevelopmental disabilities. Findings suggested that both medications were 
equally effective in reducing drooling; however, glycopyrrolate was better tolerated by 
young people and parents. Following 12 weeks of treatment, 82% of those randomized to 
glycopyrrolate continued its use, compared to just 55% of those randomized to scoplamine. 
While scoplamine had fewer sides effects overall, when they occurred they were more likely 
to lead to treatment cessation. Unacceptable skin reactions to the patches were common 
and non-predictable side effects such as hyperactivity were seen.17 As a result of these 
findings, the study authors recommended glycopyrrolate as the first line anticholinergic 
medication; however, the authors note that for some young people and parents scoplamine 
is well tolerated and convenient. There is not long-term safety data for either medication.
Sublingual atropine, trihexyphenidyl and inhaled ipratropium are three additional 
anticholinergic medications that are used clinically in some settings for drooling treatment. 
Our literature search did not reveal any studies of ipratropium in individuals with CP or 
neurodevelopmental disorders of childhood. Literature supporting the use of sublingual 
atropine and trihexyphenidyl is limited, but does show both to have few short-term side 
effects and to be effective in some individuals. The Drooling Impact Scale (Drl Scale) is a 
simple 10 item tool to assess the impact of drooling on a child.18 A report comparing DrI 
Scale results pre- and post-treatment with sublingual atropine in 25 children with CP found 
a statistically significant decrease in drooling.19 Sublingual atropine was well tolerated with 
just 12% of participants reporting side effects (flushing and fever; irritability; flushing and 
irritability; flushing and angioedema).19 One class IV chart review of 101 children with CP 
reviewed outcomes with trihexyphenidyl and found a reduction in sialorrhea.20
In conclusion, there is evidence that glycopyrrolate and scopolamine are effective 
pharmacologic interventions for drooling reduction in children and young people with CP 
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but due to the strict criteria of AAN guidelines regarding objective outcome measures it 
was necessary to downgrade study scoring. The tradeoff between effectiveness and side 
effects may dictate which medication is used long term. Studies on benztropine also suggest 
effectiveness in treating sialorrhea. There is low level evidence that trihexyphenidyl and 
sublingual atropine demonstrate efficacy. 
Botulinum Toxin
Injections of botulinum toxin into the salivary glands have a local anticholinergic 
effect to decrease saliva production. Botulinum toxin is frequently administered under 
general anesthesia, with ultrasound guidance for identification of the salivary glands. 
The maximum effect is typically seen after 2-8 weeks; improvement lasts an average of 
four to six months.21 Due to its temporary effect, repeated botulinum toxin injections are 
typically required.
The literature search identified 60 articles related to botulinum toxin use for sialorrhea 
management, with 37 articles meeting inclusion criteria for this review. While the majority 
of the articles were graded as Class IV, there were two Class II and two Class III articles. The 
majority of articles focused on patients with CP (> 65% of study population), however one 
article included a mixed sample with just 29% of individuals carrying a CP diagnosis.
Injections may be performed to the submandibular glands (SMG), parotid glands 
(PG), or to a combination of both the SMG and PG. A prospective cohort study from 2010 
in 131 children undergoing botulinum toxin injections to the submandibular glands alone 
found an objective and subjective response rate of 50%, with improvement for a median of 
22 weeks.22 In a controlled clinical trial, Jongerius et al. compared a single-dose botulinum 
toxin injection to the SMG with scopolamine treatment.21 Results showed a significant 
decrease in drooling, with greatest reductions achieved 2 to 8 weeks post-injection. The side 
effect profile of botulinum toxin was preferable to that of scopolamine with 82% of patients 
reporting side effects from scopolamine. Restlessness was the most common reason to 
discontinue the medication. Following botulinum toxin injections, only mild incidental side 
effects were reported (5.1% transient flu-like symptoms; 7.7% mild swallowing difficulty).19 
The efficacy of PG injections alone is similar to that of SMG injections. Most retrospective 
reviews report a moderate or good response with PG injections alone, ranging from 53-
55%.23, 24 Results of combined PG/SMG gland injections were reviewed in a randomized 
controlled trial of 24 children. Following injections, caregivers reported a satisfactory 
response rate in approximately 68% of individuals.25 
Botulinum toxin injections have an overall favorable safety profile, however adverse 
side effects can occur. A cohort study of 209 children reported transient adverse events 
related to oral motor function in 33% of patients, 80% of which were characterized as mild. 
Onset was most commonly within one week (78.3%) and typically resolved by four weeks 
(53.6%).26 Oral motor side effects seemed to occur most commonly, while pain, hematoma, 
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infection, rash, dry mouth, or thickened saliva were seen with less frequency.24,27 Patients 
receiving higher doses of botulinum toxin were at a greater risk of side effects.27
Surgical Management 
Surgical interventions are considered in patients with profuse, consistent anterior drooling, 
patients with persistent sialorrhea despite conservative measurements, and patients with 
a high risk of morbidity associated with lower respiratory tract infections due to posterior 
drooling. All procedures require patients to be under general anesthesia. Goals of surgical 
management include 1) redirecting salivary flow through rerouting or 2) eliminating salivary 
flow through ligation of salivary ducts or elimination of salivary glands.  
The literature review identified 52 articles on surgical management of sialorrhea; 
44 articles met inclusion criteria. All articles were graded as Class IV evidence. The review 
included outcomes for patient with CP and other neurodisabilities. The most commonly 
cited procedures included duct ligation (2, 3, or 4 duct), bilateral submandibular gland 
excision with or without bilateral parotid duct ligation, and relocation of the submandibular 
duct (SMDR) with or without sublingual gland excision (SLGE). When considering surgical 
interventions, providers must rule-out aspiration in patients prior to SMDR due to the risk of 
redirecting saliva to the base of tongue in a patient with a dysfunctional swallow.
Outcomes following SMDR demonstrate a significant reduction in sialorrhea.28-30 
Kok et al. also demonstrated a decrease in daily cares and economic consequences and an 
increase in socialization.31 A comparison of outcomes of botulinum toxin and SMDR showed 
larger decrease in visual analogue scale (VAS) scores (a measure of subjective drooling 
severity over 2 weeks31) following SMDR than botulinum toxin injections, with 87.5% of 
patients reporting a statistically significant reduction.32 SLGE is frequently performed with 
SMDR to prevent the complication of a ranula (blocked sublingual gland). The literature has 
shown that this decreases complications, but does not improve drooling outcomes.33 
Bilateral submandibular gland excision may be performed in isolation or with parotid 
duct ligation. Performed in isolation, Delsing et al. reported an overall response rate of 
63%, defined as a 50% reduction in drooling quotient (DQ: measures mean number of new 
drooling episodes every 15 seconds over 5 or 10 minutes).34 This improvement persisted to 
32 weeks. Noonan et al.35 and Dundas and Peterson36 reviewed outcomes following bilateral 
SMGE with parotid duct ligation. The response rate in their respective groups was favorable 
with Noonan et al tracking significantly fewer lower respiratory tract infections and Dundas 
and Peterson reporting a good to excellent response in 85% of individuals. Two retrospective 
reviews reported outcomes following duct ligations have been variable, ranging from 50% to 
80% improvement.37, 38
Complications following all surgical interventions are varied, but include sialadenitis 
(salivary gland inflammation) following duct ligation, lingual nerve injury with SMD rerouting 
+/- SLG excision, and lingual nerve injury or marginal mandibular nerve injury following 
SMGE. 
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DISCUSSION
In our review of sialorrhea management for individuals with CP, as in the previous Cochrane 
review, there was a paucity of randomized and controlled clinical trials. In an effort to address 
clinician interest as well as geographic variability regarding choice and access to various 
treatment options, we have presented the full range of interventions for sialorrhea with 
the evidence base for effectiveness and associated side effects. Based on the results of 
this literature review, there is inadequate research to determine the effectiveness of oral 
motor therapy, behavioral therapy, oral appliances, and surgical interventions for sialorrhea 
management. The highest levels of evidence supported use of pharmacologic interventions, 
specifically glycopyrrolate, scopolamine and benztropine, and botulinum toxin injections into 
the salivary glands. Due to the strict criteria of the AAN guidelines, specifically the 
requirement for objective outcome measures, the grading for the interventions was largely 
limited to Class III and Class IV studies. The majority of the assessment tools used to measure 
drooling severity are subjective, which required downgrading of the research studies along 
these criteria. However, it is important to identify that perfectly objective criteria may never 
be possible to achieve in the context of sialorrhea outcomes.  Meaningful outcomes may 
instead be measured by perceived quantity of drooling, ease of care, and quality of life 
outcomes which are captured with existing tools.39 If this caveat is accepted, then the 
evidence supporting certain interventions is indeed upgraded, as noted below.
The literature on oral motor therapy is lacking with no agreement on effectiveness. 
The low level evidence and clinical experience of the speech and language therapist, 
however, suggest that active, functional and potentially passive exercises and sensory 
applications may be safely implemented in children with mild to moderate oral dysfunction, 
good cognitive skills, and who are highly motivated to address their drooling.40 There is low 
level evidence regarding the efficacy of behavioral interventions and some indication that 
the use of behavioral techniques tailored to the individual’s learning potential may help to 
reduce drooling in certain subpopulations. Similarly, there is low level evidence indicating 
positive impact of oral appliances on drooling. 
Literature discussing surgical management of sialorrhea is limited by patient 
heterogeneity, small samples sizes, and the Class IV evidence. Regardless, it is our clinical 
expert opinion that when other interventions have failed and the expectation exists that 
children are not able to learn more oral motor control, surgical procedures for drooling 
management should be considered. There is regional variation with respect to the earliest 
age at which surgery is offered. None of the evidence supports a specific age range, however 
clinicians need to consider risks from general anesthesia as well as individual risk factors, 
such as the presence of aspiration and chronic lung disease at a young age. Specifically 
SMDR has shown improved outcomes over botulinum toxin injections, however the risk 
of aspiration following duct relocation requires consideration.32 Based on the variability in 
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patient outcomes, 2, 3, and 4 duct ligation in isolation is typically not offered as the first line 
surgical intervention. 
Recommendations for oral motor intervention, behavioral interventions, oral 
appliances, and surgical interventions are based on clinical expert opinion, rather than clinical 
research evidence. This was likely impacted by the stringent AAN guidelines mentioned 
previously. Surgical interventions appear to have great promise and the emerging literature 
indicates likelihood of efficacy. However, high quality research and objective outcome 
measures are needed to evaluate effectiveness and side effects of these approaches, the 
limitations for children with intellectual disability, and contraindications for children with 
certain diagnoses.
The highest levels of evidence were for several pharmacologic interventions and 
botulinum toxin injections. Based on the Drooling Reduction Intervention trial, glycopyrrolate 
is recommended prior to scopolamine as the first line pharmacologic agent for sialorrhea. 
Both drugs had documented effectiveness in reducing drooling; however, side effects from 
scopolamine were more likely to lead to treatment cessation. Nonetheless, the authors 
note scopolamine remains well tolerated and convenient for some young people and 
families. Benztropine is also probably effective. Trihexyphenidyl and sublingual atropine 
have encouraging low level evidence supporting their use in the treatment of sialorrhea in 
individuals with CP but further research is required.
Based on the literature review and expert opinion, botulinum toxin injections for 
sialorrhea management are considered to be likely effective. Limitations of the injections 
include the need for general anesthesia and their temporary effect, with a median 
improvement for 22 weeks.22 Because of the risks of transient post-operative dysphagia, it is 
recommended that providers understand a patient’s swallowing function prior to botulinum 
toxin injections. 
There are a range of treatment options for sialorrhea management, with definitive 
recommendations limited by a lack of high-level evidence. This review does not delineate a 
specific order of interventions, but highlights the full range of treatment options as well as 
the published evidence for each intervention.  A strength of this review is the international 
team of authors which provided information about the geographic trends and biases in 
treating sialorrhea. Additionally, discrepancies in grading of the articles by two independent 
reviewers were addressed via discussion and the use of a third unbiased reviewer. Limitations 
of the review include the limited research evidence; this meant it was not possible to create 
a clear step-wise path for treatment based on effectiveness data. There was a lack of long-
term safety data and safety in treating very young patients with all interventions. More 
evidence to address these points is required for all interventions. Lastly, articles with a mixed 
sample of individuals with multiple diagnoses were included, with the results extrapolated 
to individuals with CP in areas we have highlighted. An international consensus defining 
best practices to evaluate treatment outcomes in sialorrhea management trials would be 
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helpful moving forward as we continue to determine which interventions are most valuable 
in treating sialorrhea in young people with cerebral palsy. 
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Abstract
Drooling is a common problem in children with progressive dystonia. The authors noted 
a 58% incidence of drooling in 22/38 children with MEGDEL, a rare neurodegenerative 
cause of dystonia and report on the clinical course of four patients. Drooling of 
varying severity and subsequent respiratory problems were treated at the authors’ 
multidisciplinary saliva-control outpatient clinic. One patient improved on antireflux 
medication, the second after medication with drooling as side effect was changed. Two 
other patients underwent salivary gland surgery, one of whom significantly improved; 
the other died shortly after surgery. The heterogeneity of the cases presented shows 
the need for stepwise and personalized treatment. The authors recommend the 
following: (1) optimize the treatment of the underlying neurological condition and 
replace medication that stimulates saliva secretion; (2) treat constipation, scoliosis, and 
gastroesophageal reflux if there is still a risk of chronic aspiration of saliva; (3) perform 
more intense/invasive treatment (botulinum toxin, salivary gland surgery).
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Dystonia is a movement disorder in which sustained muscle contractions cause twisting 
and repetitive movements or abnormal postures. It is classified on the basis of its clinical 
characteristics (age at onset, body distribution, temporal pattern, and associated features) 
and etiology, which includes nervous system pathology and inheritance.1 MEGDEL syndrome 
(MIM # 614739, SERAC1) has recently been described as a new deafness-dystonia syndrome 
and the number of affected patients is rapidly increasing (the author’s database has 60 
patients).2,3 MEGDEL syndrome is characterized by 3-MEthylGlutaconic aciduria, dystonia, 
Deafness, Encephalopathy, and neuroradiological features of Leigh-like disease. The dystonia 
becomes apparent in infancy, is multifocal or generalized progressive, and persistent, and 
is accompanied by other neurological features such as axial hypotonia and progressive limb 
spasticity.
Children with neurological disorders often experience swallowing and feeding 
problems, which can lead to excessive pooling of saliva in the anterior oral cavity, resulting 
in drooling.4 Drooling can be divided into anterior drooling and posterior drooling.5 
Anterior drooling is the unintentional loss of saliva from the lips, which leads to perioral 
infections, rejection by peers, and, when excessive, dehydration and damage of electronic 
devices in daily life. Posterior drooling refers to the spilling and pooling of saliva posteriorly 
into the oropharynx and hypopharynx. In children with severe pharyngeal dysphagia, 
the chronic aspiration of saliva can lead to cough, choking incidents, recurrent lower 
airway infections, or lung injury.5-7 Intestinal dysmotility is also common in children with 
neurological disorders and is caused by dysfunction of the brain-gut axis that controls the 
function of the entire gut, via the vagal nerve. Disturbances of the axis lead to gut motility 
disorders, gastroesophageal reflux disease, and constipation.5,8,9 The mechanisms by which 
these disorders give rise to drooling are not completely understood, but it is known that 
constipation aggravates gastroesophageal reflux disease, and that gastroesophageal reflux 
disease can increase sialorrhea via the esophago-salivary reflex.10-12 Therefore, treatment 
of gastroesophageal reflux disease and constipation may indirectly have a positive effect 
on drooling.
Little is known about the treatment of drooling in children with progressive dystonia. 
On the basis of a case series of 4 patients with MEGDEL syndrome, the authors propose a 
stepwise approach to the treatment and aftercare of drooling in children with progressive 
dystonia.
Methods
The author’s (SBW) database consists of 60 patients with genetically proven MEGDEL 
syndrome, four of whom are being treated at the Multidisciplinary Saliva-Control 
Outpatient Clinic, Radboudumc, Nijmegen, the Netherlands. A questionnaire about the 
clinical course, including questions about drooling, was sent to the physicians caring 
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for the other 56 patients. The data about the clinical course will be published in a 
separate article.
A multidisciplinary specialist team consisting of a pediatric neurologist, 
otorhinolaryngologist, rehabilitation physician, and speech language therapist assessed the 
patients. The assessment took 2 to 3 hours. It started with review of the patient’s medical 
and socialemotional history, including evaluation of the patient’s (or carer’s) motivation and 
ability to participate in possible treatment. Special attention was paid to oral hygiene, eating 
and drinking habits and abilities, nutritional state, the presence of allergies, as well as signs 
and symptoms suggestive of gastroesophageal reflux disease, constipation, or respiratory 
and neurological problems.5,13
The physical and neurological examinations focused on positioning, muscle tone, 
and movement disorder; ear, nose, and throat condition; dental status; oral functions; 
and speech and swallowing skills. The combined Drooling Severity and Frequency 
Scale was used to assess the quality and quantity of drooling.14 The severity of drooling 
was scored from 1 to 5 (1 = dry, never drools; 2 = mild, wet lips; 3 = moderate, wet lips 
and chin; 4 = severe, damp clothes; 5 = profuse, wet hands/clothes/objects) and the 
frequency of drooling was scored from 1 to 4 (1 = never, 2 = occasionally, 3 = frequently, 
4 = constantly drools). Depending on the assessment outcome and patient characteristics 
(age, diagnosis, cause of drooling, and the safety of swallowing), the team drew up 
a multistage proposal for treatment (speech and language therapy, physical therapy, 
behavioral, pharmacological, and surgical therapy) and communicated this to the patient and 
his or her carers. Follow-up measurements were standardized after treatment (outpatient 
clinic visit or telephone consulting).
Results
Data on drooling were available for 44 of the 60 patients in the authors’ database. Drooling 
was reported in 22 patients, giving an incidence of drooling in MEGDEL syndrome of 58% 
(22/38).
All four patients with genetically proven MEGDEL syndrome treated at Radboud 
UMC showed a characteristic clinical course. Their development was normal or delayed 
until about 2 years of age, when there was rapid deterioration with progressive bilateral 
spasticity and dystonia. All patients exhibited hearing loss, severe intellectual disability, 
and lack (or loss) of speech development. All were wheelchair bound. Feeding problems 
led to failure to thrive and necessitated gastrostomy tube feeding; all four patients had 
gastroesophageal reflux disease. The disorder was slowly progressive and all four patients 
developed progressive drooling for which they were referred to the Multidisciplinary Saliva-
Control Outpatient Clinic. The findings are summarized in Table 1.
Patient A, a girl, was first evaluated when she was 15 years old (155 cm tall [P2-16]; 
weight 35 kg [P2]). She had severe encephalopathy with persistent, generalized dystonia. 
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Her parents said that she had thick, mucous sputum and that she daily had several attacks of 
coughing, retching, choking, and dyspnea. The frequency of attacks had increased with time 
and attacks were worse at night. She suffered from recurrent pneumonia. She was being 
treated with omeprazole, polyethylene glycol, baclofen, and prophylactic co-trimoxazole.
On examination, severe and frequent anterior drooling was noted, together with 
intermittent torticollis (based on a pathological asymmetric tonic neck reflex combined with 
dystonia) with a strong tonic bite reflex, which caused her to bite her cheeks and lips. She 
tended to gurgle and choked on her saliva; her cough was insufficient to clear the larynx. 
Bilateral submandibular gland excision and bilateral parotid duct ligation were performed, 
without complications, to reduce the amount of saliva produced. Six months after surgery, 
her drooling had improved substantially—the severity of anterior drooling had decreased 
from severe (Drooling Severity and Frequency Scale score 4) to dry (Drooling Severity and 
Frequency Scale score 1) and its frequency diminished from frequently (Drooling Severity 
and Frequency Scale score 3) to never (Drooling Severity and Frequency Scale score 1). 
The patient had gained 8 kg (P50, weight for height) and no longer had recurrent airway 
infections (she was still taking antibiotics). She is now 19 years old and her condition is 
stable with no recurrence of drooling (Drooling Severity and Frequency Scale score 1 for 
severity and 1 for frequency).
Patient B, a girl, visited the Multidisciplinary Saliva-Control Outpatient Clinic 
when she was 15 years old. She suffered from continuous anterior drooling and posterior 
drooling with gurgling and sporadic episodes of aspiration and vomiting without efficient 
cough. The latter had become more frequent in the last few weeks. Her parents tried to 
remove mucus, using mechanical tracheal suctioning, several times a day but her brisk tonic 
bite reflex and trismus made this virtually impossible. Her parents reported that at night 
she breathed irregularly with long periods of apnea. She had been treated for recurrent 
aspiration pneumonia several times in the last few years and had severe restrictive lung 
disease. Despite treatment with omeprazole, polyethylene glycol, baclofen, pipamperone, 
melatonin, and prophylactic co-trimoxazole, her respiratory condition was deteriorating 
rapidly.
On physical examination, the patient exhibited spasticity of the arms, dystonia of 
the fingers, and no functional motor control of the lower extremities. She experienced less 
trouble when she sat in a supported sitting position than when she was lying down. Bilateral 
submandibular gland excision and bilateral parotid duct ligation was performed without 
complications, to improve her pulmonary condition; however, her respiratory status and 
overall condition continued to deteriorate and she was ventilator dependent. Treatment 
was stopped on the third postoperative day and the patient died immediately thereafter.
Patient C, a girl, was seen when she was 21 months old. She suffered from severe 
agitation, insomnia, spasticity of the extremities, and continuous tongue protrusion; 
the latter had become progressive in the last few months and was worse when she was 
tired, resulting in increased saliva production. This caused attacks of anxiety, choking, and 
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dyspnea and exacerbated her agitation. Her cough was weak and she recently had aspiration 
pneumonia twice. The development of frequent partial complex seizures made it almost 
impossible for her parents to care for her (e.g. changing clothes). She was being treated 
with ranitidine, polyethylene glycol, ondansetron, levetiracetam, diazepam, risperidone, 
levomepromazine, and prophylactic co-trimoxazole.
On physical examination, the infant was found to have encephalopathy with truncal 
hypotonia, frequent dystonic movements, ataxia, and myoclonus made independent 
sitting impossible. She showed mild anterior drooling. When the authors tried to initiate 
swallowing by placing a droplet of water on her tongue, it took her some time to interrupt 
the tongue protrusion to swallow. During swallowing, the droplet was moved dorsally and 
weak swallowing was heard upon cervical auscultation. The continuous tongue protrusion 
Table 1: Oral Motor Findings of Patients A, B, C, and D Before and After Treatment.
A B C D
Feeding
Oral feeding/tube feeding –/+ –/+ –/+ –/+
Gastroesophageal reflux
Reflux disease/medication +/+ +/+ +/+ +/-
Constipation + + - +
Respiratory status
Gurgly voice
Weak cough
Dyspnea/chronic cyanosis
Obstructive respiratory problems
Recurrent lower airway infections or pneumonia
Prophylactic antibiotics
+
+
+
+
+
+
+
+
+
+
+
+
+/-
+
+
+
+
+
+/-
-
-
-
+
-
Oral motor skills
Voluntary movements
Pathological oral reflexes (tonic bite, gagging)
Hyperkinetic oral movements
Trismus
Tongue protrusion
-
+
-
-
-
-
+
+
+
-
-
+
+
-
++
+/-
+
-
-
+
Oral swallow phase
Disturbed + + +/- +/-
Pharyngeal swallow phase
Delayed initiation
Residue after swallow
Saliva pooling
Choking
Aspiration
+
+
+
+
+
+
+
+
+
+
+
-
+/-
+/-
+/-
+/-
-
+/-
+/-
+/-
Drooling
Anterior
Posterior
+
++
+
++
++
+
+/-
+/-
Anterior drooling severity scale baselinea
Anterior drooling frequency scale baselinea
Intervention
4
3
Bilateral 
submandibular
gland excision and
parotid duct ligation
N/A
N/A
Bilateral 
submandibular
gland excision and
parotid duct ligation
3-4
4
Advice to interrupt 
tongue protrusion, 
adenotonsillectomy
4-5
4
Feeding advice, 
antireflux 
medication
Anterior drooling severity after treatmenta 1 (8 m)
1 (4 y)
N/A
N/A
N/A
N/A
3 (8 m)
4/5 (1 y)
Anterior drooling frequency after treatmenta 1 (8 m)
1 (4 y)
N/A
N/A
N/A
N/A
3 (8 m)
4 (1 y)
M, months; y, years; –, absent; +, present; +/–, occasionally present; ++, evident; N/A, not applicable.
aDrooling Severity and Frequency Scale.14
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led to increased saliva production and prevented the initiation of swallowing. Her parents 
were shown how to interrupt the tongue protrusion by stabilizing the jaw, to trigger 
a swallow and prevent pooling of saliva in the mouth. It was suggested that risperidone 
and levomepromazine should be tapered off (to reduce potential extrapyramidal side 
effects) and trihexiphenidyl should be started (to improve dystonia and use anticholinergic 
side effects). However, the parents were unable to accept any treatment suggestions. 
Adenotonsillectomy was performed elsewhere, which had a modest effect on the frequency 
of infections and the general quality of life (evaluated by the referring physician and the 
parents). Unfortunately, the parents refused further follow-up or treatment.
Patient D, a girl, was seen when she was 4 years old. Oral feeding was supplemented 
by tube feeding. Her parents reported tongue thrusting and gagging during eating and that 
she sometimes aspirated and then coughed. The child had developed aspiration pneumonia 
once after vomiting during gastroscopy. Several times a year she was admitted to the local 
hospital for infections of the airway, and she regularly vomited her food and thick sputum. 
She was being treated with baclofen, polyethylene glycol, alimemazine, erythromycin, and 
ibuprofen.
On physical examination, dystonia with ‘‘sensory tricks’’ (right fist under chin, 
a ‘‘geste antagoniste’’ which may serve to temporary interrupt dystonia symptoms) and 
severe tongue protrusion were evident. Pathological biting and gagging reflexes were 
present, and her mouth was constantly wide open. Minimal oral voluntary movements were 
possible. Anterior drooling was continuous and was profuse during activities, depending on 
her posture. Her pharyngeal swallow function seemed sufficient and there was no residue 
after feeding; however, some saliva pooling (posterior drooling) was observed at rest.
Antireflux medication was started and her parents were advised to feed her with her 
positioned with an extended neck and not to give oral feeding when she was tired. No further 
respiratory infections occurred during the 6-month follow-up and the drooling improved. 
However, the drooling subsequently worsened and the child experienced severe choking 
and vomiting. Because of the deterioration in the girl’s overall condition, her parents were 
reluctant to let her undergo narcosis for invasive antidrooling treatment and also refused 
anticholinergic medicines to reduce the drooling because of their potential side effects.
Discussion
These patients with MEGDEL syndrome illustrate the different aspects of diagnosing and 
treating anterior drooling/posterior drooling in children with progressive dystonia. The 
authors are well aware that this study has some limitations. The sample size is small and 
MEGDEL syndrome is a rare disorder. However, it allows us to illustrate the heterogeneity 
in severity of drooling, interventions performed and outcome in a group of patients with 
a homogenous course of disease. Although all four children had anterior drooling, neither 
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the parents nor the Multidisciplinary Saliva-Control Outpatient Clinic team considered it the 
main problem, possibly because the children had severe intellectual and physical disabilities 
and lack or loss of speech, problems that already severely limited the children socially in 
daily life, making anterior drooling less relevant. Posterior drooling is often more difficult to 
recognize and can lead to aspiration pneumonia, a life-threatening condition that was the 
reason for referral of the four children to the Multidisciplinary Saliva-Control Outpatient 
Clinic. Treatment should be personalized based on knowledge of the complex and interacting 
factors that influence saliva secretion and which involve the whole brain-gut axis (especially 
gastroesophageal reflux disease and constipation). Contributing factors should be evaluated 
and treated if necessary, starting with the least invasive intervention (figure 1).
In the authors’ proposed management strategy, the first step is to optimize, in terms 
of minimizing drooling as a side effect, drug therapy for the underlying neurological disorder. 
In patients A, B, and D there was no need and/or possibility to alter their medication. In 
patient C, the authors advised that drugs that affect saliva secretion, such as neuroleptic 
drugs or benzodiazepines, should be tapered off or replaced by drugs with fewer side 
effects. However, the parents did not accept the authors’ advice.
The second step is to improve supportive treatment for problems associated with 
the brain-gut axis, such as constipation, enteric dysmotility, and gastroesophageal reflux 
disease.6,8,9 This intervention had satisfactory results in patients A to C. A proton pump 
inhibitor was started in patient D, which had a beneficial effect on drooling but was of limited 
duration (Table 1). The authors always advise parents about oral hygiene, and a speech-
language therapist shows parents and carers how to feed the child safely (see patient D).15 
The child needs to be seated upright, which often necessitates use of a special chair or 
adapted corset.8 It should be remembered that scoliosis may aggravate gastroesophageal 
reflux disease.8 In general, children with complex neurological disorders often have many 
problems with swallowing, as seen in the authors’ patients, and their general condition 
and ability to swallow may fluctuate, depending on a number of factors, such as fatigue, 
distraction, positioning, and so on. For this reason, the authors usually recommend giving 
food and fluid via a gastrostomy feeding tube, with supplementary food being given 
orally on ‘‘good days.’’ An otorhinolaryngologist should evaluate whether tonsillectomy 
could facilitate swallowing by reducing pain, obstruction, and recurrent infections.16 The 
parents and doctor of patient D considered that tonsillectomy improved the situation, but 
unfortunately the parents refused further follow-up, and so the authors cannot comment 
on the indication and effect of this treatment.
If despite conservative measures posterior drooling persists, more aggressive 
treatment such as anticholinergic drugs, botulinum toxin type A injections, or surgery, is 
necessary (third step). A systematic review found some evidence that anticholinergic drugs 
are effective in the treatment of drooling in children with multiple handicaps.15 However, the 
side effects of these drugs (psychiatric symptoms, constipation, urinary retention) should be 
taken into account, because they may exacerbate the symptoms of MEGDEL syndrome.
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Figure 1. First, treatment of the neurological condition has to be optimized, if possible. Second, supportive 
treatment should be improved. Third, when a risk for chronic salivary aspiration remains, more invasive treatment 
follows.
Local ultrasound-guided injection of botulinum toxin type A into the submandibular 
and/or parotid salivary glands under anesthesia decreases drooling.13 However, changes in 
the viscosity of saliva (saliva becomes thicker) can exacerbate swallowing problems as a 
side effect.17 Existing swallowing problems are a strong predictor of increased swallowing 
problems after botulinum toxin type A (unpublished data), and therefore it is essential to 
investigate oral motor function before treatment. Because patients A, B, and C had weak 
oral motor control, the authors did not advise botulinum toxin type A injections. Patient 
D had sufficient oral motor function, making botulinum toxin type A injections a potential 
treatment option in the future. However, it should be realized that botulinum toxin type 
A is not a permanent therapy, which makes it less suitable for children with inherited and 
progressive neurological disorders such as MEGDEL syndrome.4,17 
There are several surgical options to treat drooling with more long-lasting effects. 
One successful procedure is submandibular duct relocation. This approach is, however, 
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contraindicated in children with MEGDEL syndrome because the ducts are moved from 
the anterior oral cavity to the base of the tongue, so that saliva passes directly into the 
oropharynx. In children with a weak oral motor function, the procedure increases the 
pooling of saliva in the oropharynx and consequently increases the risk of posterior drooling 
and aspiration pneumonia.18 Duct ligation is another surgical technique to improve drooling 
and has been found to reduce anterior drooling and possibly posterior drooling.19 Both 
procedures require skilled ear, nose, and throat surgeons. Salivary gland removal, which 
is often performed during otorhinolaryngological procedures, results in a long-lasting 
decrease in drooling.20,21 It is important to monitor dental health after a surgical procedure 
or botulinum toxin type A injections, because of an increased the risk of dental caries 
because of the reduced protective role of saliva.22,23
Currently, there is no evidence to support one surgical option over another. The 
authors opt for comprehensive surgery in children older than 10 years if their medical 
condition is life-threatening (due to severe chronic pulmonary aspiration) and the child’s 
health is too weak for repeated anesthesia. Bilateral removal of the submandibular gland 
and bilateral ligation of the parotid duct improved the general clinical condition of patient A, 
although prophylactic antibiotics are still required, which is not uncommon in children with 
severe multiorgan disease even without drooling. Unfortunately, the respiratory status and 
overall condition of patient B were too fragile to wean her off ventilation after surgery and 
she subsequently died. This underlines the need for early referral to a specialized center to 
save lives.
In conclusion, drooling is a common serious problem in children with MEGDEL 
syndrome. Although this study was limited by the small number of patients included and 
the short follow up period of maximally 4 years, the authors suggest a stepwise with 
multidisciplinary aftercare to diminish drooling in these and other patients with progressive 
dystonia. Tailored recommendations can improve respiratory health and symptom-free 
survival.
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Abstract
Aim: The aims of this study were: (1) to determine the incidence and nature of adverse 
effects on oral motor function after first injections of botulinum neurotoxin A (BoNT-A) 
in submandibular glands for excessive drooling in children with central nervous system 
disorders; and (2) to identify independent predictors of these adverse effects.
Method: A cohort study involved 209 children (123 males, 86 females, aged 4–27y, 
median 8y 4mo), who received submandibular BoNT-A injections for drooling. Adverse 
effects were categorized into swallowing, eating, drinking, articulation, and other 
problems. Univariable logistic regression was used to study differences in patients with 
and without adverse effects. Possible predictors were identified using multivariable 
logistic regression.
Results: Transient adverse effects occurred in 33% of the 209 BoNT-A treatments. Almost 
80% of these were mild, versus 8.7% severe. Approximately 54% of the adverse effects 
spontaneously resolved within 4 weeks; 3% still existed after 32 weeks. A diagnosis of 
cerebral palsy, higher range of BoNT-A dosage, and a pre-treatment drooling quotient 
< 18% were found to be independent predictors of adverse effects.
Interpretation: Before using submandibular BoNT-A injections for drooling, potential 
adverse effects should be discussed. Oral motor function needs to be monitored, 
because existing dysphagia may be worsened. The identified clinical predictors could be 
helpful to optimize patient selection.
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Treatment with botulinum neurotoxin (BoNT) in the salivary glands is a widely accepted 
effective intervention for drooling in children with central nervous system (CNS) disorders. 
When injected into the salivary glands, BoNT inhibits the acetylcholine release at the 
terminal nerve endings, decreasing the secretion of saliva and diminishes drooling in the 
majority of patients.1
The main group of children with neurological impairments treated with BoNT 
injections are children with cerebral palsy (CP), a vulnerable group with a spectrum of 
oral motor problems (estimated 40% drooling prevalence).2-4 Drooling has a serious 
impact on the children’s social interaction, self-esteem, and health.5 The effectiveness 
of salivary gland BoNT has been studied extensively, although the debate about which 
glands should be injected is still going on. Several studies demonstrated that, after 
BoNT, drooling is significantly reduced. In Scheffer’s study a clinically notable response 
was found in 46.6% of children.6 The duration of this effect was approximately 2 to 6 months 
(median 22wks).6-8 In most of these studies, botulinum neurotoxin A (BoNT-A) was used.9
Considering the increasing use of BoNT for drooling, studies to identify possible risk 
factors for adverse effects on oral motor functions before treatment are urgently needed.10 
Post-intervention assessments showed that adverse effects on oral motor functions 
with a potential negative effect on swallowing occurred from 0%11-13 up to 17.8%6 of the 
cases after submandibular gland injections, and up to 33%14 of the cases after combined 
submandibular/ parotid gland injections. To date no major complications were identified 
after submandibular injections.
Knowledge of the incidence, nature, and risk factors of adverse effects will help to 
predict which children with CNS disorders will positively qualify for BoNT to ameliorate 
excessive drooling.
The objectives of this study were: (1) to determine what adverse effects on oral 
motor function occur up to 8 months after the first BoNT-A injections in the submandibular 
glands; (2) to describe the incidence and course of these adverse effects; and (3) to identify 
independent predictors for adverse effects on oral motor function.
Method
 
Design and patient selection
In this cohort study, 209 children (123 males, 86 females; median age at inclusion 8y 4mo, 
aged 4–27y) participated. Inclusion criteria were: (1) first treatment with BoNT-A injections 
in the submandibular glands in the period between January 2002 and May 2013; (2) 
moderate to severe drooling with a score of three or higher on the Teacher Drooling Scale 
(occasional drooling, intermittent, all day); (3) minimum age of 4 years; (4) a minimum of 
two measurements representing baseline and at least one follow up; and (5) no previous 
surgical procedure for saliva control. 
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Informed consent for BoNT-A treatment was obtained from the child’s legal representative(s). 
Parents or caregivers were informed about the consequences and the expectations of the 
treatment before the injections. All injections were administered as part of regular care.
Patient characteristics
All children were assessed before treatment by members of the multidisciplinary saliva 
control team of the Radboud university medical center. A medical assessment was 
performed by the pediatric neurologist and the ear, nose, and throat (ENT) specialist. Two 
specifically trained speech and language therapists (SLTs) carried out a social evaluation 
and an oromotor assessment. The quantity of drooling and the impact of the intervention 
on the severity of drooling were measured with objective and subjective scales at three 
different moments: before (t1), 8 weeks (t2), and 32 weeks after the injections (t3). The 
severity of drooling was quantified with the modified drooling quotient.15 A caretaker visual 
analogue scale score (range 0–10) reflected the severity of drooling, with 0 indicating ‘no 
drooling’ and 10 indicating very severe drooling.5 Based on direct SLT observations and 
parental reports, the viscosity of saliva was judged before and after BoNT-A (more serous/
more mucus/unchanged).
Treatment characteristics
Intraglandular injections of BoNT-A (Botox; Allergan, Nieuwegein, the Netherlands) were 
performed by the team’s pediatric rehabilitation specialist under ultrasound guidance and 
general anesthesia. Treatment consisted of bilateral injections in the submandibular glands. 
Botox was diluted in saline 0.9% (25U/mL). Using a Spinocan needle, 1ml was divided over 
two or three sites throughout the gland. Occasionally, slightly more BoNT-A was injected 
to attain optimal spread, up to a maximum of 30U Botox per gland. For every child the 
applied dosage of BoNT-A per gland was noted in the medical records. The clinically relevant 
response at t2 to BoNT-A treatment was defined as ≥ 50% reduction in drooling quotient 
and/or a reduction of 2 standard deviations from the baseline visual analogue score to 
obtain a combined objective and subjective outcome.6
Adverse effects
If the caregivers noticed any post-treatment change in oral motor function during the first 
8 weeks, they were encouraged to contact the SLT for advice and, if needed, they were 
invited for an additional visit at the outpatient clinic. Adverse effects were elicited as a part 
of our usual care during each follow up moment at 8 weeks and 32 weeks through a semi-
structured interview. During the SLT measurements at t2 and t3, we specifically asked for 
any probable adverse effect or change in health condition. Negative oral motor problems 
were recorded and categorized according to the International Classification of Functioning, 
Disability and Heath, Children and Youth version (ICF-CY). Five subdomains remained: (1) 
saliva swallowing=reported changes in saliva viscosity, increased choking on saliva, and/
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or reported discomfort during swallowing saliva; (2) eating=reported discomfort during 
eating (coughing, gagging), deteriorated feeding pattern; (3) drinking=reported discomfort 
during drinking (coughing, choking, dyspnoea); (4) articulation=reported deteriorated 
speech; (5) other problem=reported other discomfort, as sore throat, dry mouth/lips, and 
teeth grinding. Adverse effects were subdivided into three categories: mild, moderate, 
and severe (definitions in Table 2). The predefined outcome definition was dichotomous: 
adverse effects occurrence ‘yes’ versus ‘no’.
Statistics
Descriptive statistics were used to determine general characteristics of the children and 
allocated treatments, and the incidence and occurrence of the adverse effects. Medians 
and minimal/maximal values were calculated for continuous variables. The association 
between post BoNT-A saliva viscosity (more concentrated mucus saliva) and the appearance 
of adverse effects was calculated by a chi-squared test, as well as the relationship between 
the occurrence of adverse effects and the response to BoNT-A injections. Univariable logistic 
regression was used to study associations between patient characteristics, the BoNT-A 
dosage, and the occurrence of adverse effects. The adverse effects prevalence (n) and the 
crude odds ratio (OR) with 95% confidence intervals (CI) are presented. Potential predictors 
of adverse effects incorporated in the model were based on biological plausibility and a 
previous publication of the drooling quotient.15 Model selection was done using backward 
stepwise elimination with p = 0.100 levels of removal. Results with two-tailed p-values 
<0.050 were considered significant. The adjusted ORs with 95% CI of the final model were 
calculated. The area under the curve (AUC) of the receiver operating characteristic (ROC) 
curve was used as a measure of predictive discrimination. Missing descriptive values were 
considered as missing completely at random (MCAR). To calculate treatment responses, 
missing values of drooling quotient and visual analogue scores were imputed according 
to the worst-case scenario: missing data were replaced with the last previous observation 
or replaced by baseline values. Statistical analyses were carried out using SPSS 20.0 for 
Windows (IBM Corp., Armonk, NY, USA).
Results
Patient and treatment characteristics
Our data set of 209 children contained 130 children with CP (62.2%), whereas 78 children 
(37.3%) were classified as non-CP (e.g. epileptic encephalopathy or neurogenetic syndromes) 
(Table 1). The disease course was complicated by intractable seizures in 18 children (8.6%). 
All children had received bilateral submandibular BoNT-A injections, 182 (87.1%) with a 
dosage of 25U, 16 (7.7%) had received <25U per gland, and 8 (3.8%) had received more 
than 25U per gland. Most children (n=136; 65%) were classified as responders, whereas 73 
(35%) were considered to be non-responders at t2.
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Table 1: Characteristics of study population at baseline (t1) (n=209).
Patient characteristics n (%)
Sex
Male
Female
123 (58.9)
86 (41.1)
Age at inclusion
Median
8.4 (4.1–27.8)a
Diagnosis
CP
Non-CPb
Unknown
130 (62.2)
78 (37.3)
1 (0.5)
Disease coursec
Complicated
Non-complicated
Unknown
18 (8.6)
190 (90.9)
1 (0.5)
Mental ability
Developmental age <4y
Developmental age >4y
131 (62.7)
78 (37.3)
Degree of mobility
Ambulant
Non-ambulant
104 (49.8)
105 (50.2)
Cause of drooling
Low cognitive awareness
Impaired oral phase of swallowing
Impaired oropharyngeal phase of swallowing
25 (12)
126 (60.2)
58 (27.8)
Nutrition intake
Tube/tube and oral
Oral
34 (16.3)
175 (83.7)
Choking on saliva
Yes
No 
Unknown
59 (28.2)
145 (69.4)
5 (2.4)
Choking on food
Yes
No 
Unknown
96 (45.9)
109 (46.8)
4 (1.9)
Choking on drinks
Yes
No 
Unknown
107 (51.2)
99 (47.4)
3 (1.4)
DQ
Median
Unknown
27.5 (0–100)a
2 (1)
VAS
Median
Unknown
8 (3.4–10)
2 (1)
Treatment characteristics:
Dosage of BoNT-A per gland, n (%)
Dosage<25U
Dosage=25U
Dosage>25U
Unknown
16 (7.7)
182 (87.1)
8 (3.8)
3 (1.4)
Saliva viscosity at t2, n (%)
More serous
More mucus
Unchanged
Unknown
17 (8.1)
76 (36.4)
76 (36.4)
40 (19.1)
Treatment response,d n (%)
Responder
Non-responder
136 (65.1)
73 (34.9)
a  Data of age, DQ and VAS are presented as median (min/max).
b  Non CP: children with developmental disability mainly as part of a syndrome, genetic, metabolic or neurodegenerative   
 disorder.
c  Complicated: in case of a progressive disease or if something unexpected happened (e.g. uncontrolled epilepsy), 
 Non-complicated: when the course did not deviate from expected. 
d  Treatment response: treatment with BoNT-A was defined as effective and clinically useful if ≥50% reduction in DQ was 
 found and/or if a reduction of ≥3.86 (2SD) of the VAS score (0–10) occurred at t2 compared to t1. CP, cerebral palsy; y, year; 
 BoNT-A, Botulinum neurotoxin A; t1, baseline; U, unit; DQ, drooling quotient; VAS, visual analogue scale.
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Adverse effects
The incidence and characteristics of the adverse effects are listed in Table 2 together 
with the advices and interventions given post treatment. Adverse effects were recorded 
in 69 (33%) of the children. Of the 69 children with adverse effects, 22 children (31.9%) 
experienced saliva swallowing, 51 (73.9%) eating, 22 (31.9%) drinking, 4 (5.8%) articulation, 
and 15 (21.7%) other problems. In 37 children (53.6%) with any type of adverse effects, an 
isolated oral motor problem occurred. Simultaneous problems co-occurred in two domains 
in 23 (33.3%), in three domains in 5 (7.2%), and in four domains in four children (5.8%). 
Severe adverse effects appeared to be related to the occurrence of multiple problems in 
one individual at the same time. Of the six children with severe adverse effects, only one 
child reported one problem, whereas one child experienced two problems, two children 
three problems, and two children four problems at the same time. In 54 (78.3%) the onset of 
the adverse effects occurred within 1 week after treatment, while complete disappearance 
occurred in 37 children (53.6%) before the end of the fourth week post treatment. Two 
children experienced adverse effects longer than 8 months. The severity of the adverse 
effects was mild in 55 (79.7%) and no post-treatment intervention was needed in 50 of these 
children (72.5%). Of the children who experienced severe adverse effects, 4 (5.8%) needed 
hospital admission or required a substantial change in feeding or a nasogastric tube feed 
for a few weeks (2.9%). Concerning the phone calls by SLTs and additional outpatient visits, 
advice involved medication, the adaptation of the food consistency, supportive care, and 
explanation of the problem (21.7% of the cases). In 76 of the 209 cases (36.4%) saliva became 
more mucus at t2. Increased viscosity of saliva was positively related to the occurrence of an 
adverse effect (X² [1, n=209]=11.5, p=0.001). No relation was found between the occurrence 
of adverse effects and being a responder or non-responder to BoNT-A injections at t2 (X² [1, 
n=209]=0.42, p=0.521).
Prediction model
In Table 3, crude ORs and adjusted ORs are given for the biologically plausible risk factors for 
any adverse effect. The ordinal category with the suspected lowest adverse effect chance 
was chosen as a reference. Statistically significant predictors of adverse effects were having 
a diagnosis of CP, higher dosage of BoNT-A, and a pre-treatment drooling quotient below 
18%. When all other variables remained stable, children with CP were 3 times more likely to 
experience an adverse effect (OR: 3.08; 95% CI: 1.53–6.19) than other children. Compared 
to children injected with <25U Botox, treatment with a dosage of 25U Botox increased 
the odds of experiencing an adverse effect by a factor 5 (OR: 5.06; 95% CI: 1.07–23.84), 
whereas children injected with more than 25U Botox were eight times more likely to have 
an adverse effect (OR: 8.13; 95% CI: 1.02–64.96). Lastly, a pre-treatment drooling quotient 
<18% increased the odds (OR: 2.40; 95% CI: 1.18–4.88) of developing adverse effects 
compared with a pre-treatment drooling quotient ≥18%. The AUC of the ROC curve for the 
multivariable regression analysis was 67% (95% CI: 60–75%).
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Discussion
To our knowledge this series represents the largest cohort of children (n=209) who 
received BoNT-A injections exclusively in the submandibular glands. Moreover, our 
registration of adverse effects was based on a standardized face-to-face contact 8 weeks 
and 32 weeks post injections. From this study it can be concluded that adverse effects 
on oral motor functions occur in 33% of the children but, at the same time, that almost 
Table 2: Incidence and characteristics of adverse effects of first botulinum neurotoxin A (BoNT-A) 
injections in the submandibular glands as well as advices/interventions given post treatment (n=209).
n (%)
A. Incidence of adverse effects 
 Adverse effects
Yes
No
69 (33.0)
140 (67.0)
B. Characteristics of adverse effects (n=69) 
 Severity of problema
Mild
Moderate
Severe
Not specified
55 (79.7)
7 (10.1)
6 (8.7)
1 (1.5)
 Oral motor problemb
Saliva swallowing problems
Eating problems
Drinking problems
Articulation problems
Other
22 (31.9)
51 (73.9)
22 (31.9)
4 (5.8)
15 (21.7)
 Number of co-occurring oral motor problems
1
2
3
4
37 (53.6)
23 (11.0)
5 (2.4)
4 (1.9)
Time of problem onset
<1wk
1–8wks
Unknown
54 (78.3)
5 (7.2)
10 (14.5)
Duration of problem
<1wk
1–4wks
4–8wks
8–32wks
>32wks
Unknown
12 (17.4)
25 (36.2)
6 (8.7)
7 (10.2)
2 (2.9)
17 (24.6)
C. Post treatment advices/interventions 
 Interventions
None
Phone consultancy
Additional outpatient visit
Hospital admission
Otherc
50 (72.5)
11 (15.9)
3 (4.3)
4 (5.8)
1 (1.5)
 Advices
Start (or increase) of tube feeding
Adapt feeding/consistency
Medication
Other
None
Unknown
2 (2.9)
9 (13.0
1 (1.5)
5 (7.2)
50 (72.5)
2 (2.9)
a Mild: short transient changes in saliva swallowing, eating, drinking, or articulation, not leading to changes in lifestyle or 
 doctor visits. Moderate: transient changes in oral motor functions or losing weight, nearly always requiring consultation by a 
 general practitioner. Severe: change in oral motor function requiring one or more days of hospitalization or substantial 
 changes in feeding (e.g. tube feeding). 
b Multiple problems per child are possible.
c Other: combination of advice or interventions.
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80% of the adverse effects were ‘mild’ and 54% disappeared within 4 weeks after the 
injections. By categorizing the oral motor problems after BoNT-A in different domains, 
we found that eating problems were reported the most, followed by (saliva) swallowing 
and drinking problems. Only the group of children with moderate and severe adverse 
effects (n=13) needed advice and supervision of the SLT or physician. Considering 
the pharmacology of BoNT-A, two individuals exhibited unexplained adverse effects 
lasting longer than 32 weeks, as the normal (median) duration of BoNT efficacy for drooling 
is 22 weeks.6
In previous studies, the incidence of mild or moderate complications of submandibular 
BoNT injections in children ranged from 0% to 17.8%.6, 11-13 In the present study we found 
such complications in 29.7% of the cases, whereas severe adverse effects occurred in 2.9%. 
Because protocols differed between studies with respect to intervention and follow-up, 
we estimated the percentages of patients with complications per treatment. Most studies 
reported complications after combined BoNT injections into the parotid and submandibular 
glands, or after repeated salivary gland injections in the same individual.14,16–18 Chan et 
al.19 found 15.8% complications after combined injections with major complications in 4% 
of the cases. In a study by Khan et al., 15 of the 45 patients (33.3%) experienced at least 
one problem after combined injections. Major problems requiring intensive therapy and 
prolonged hospitalization occurred in 11.1% of the cases.14 The adverse effect definition 
and strict follow-up protocol in our study may be the reason for the relatively high adverse 
effect percentages. However, it should be noted that some adverse effects in Chan et al.’s 19 
study may not have been recognized because of possible recall bias (telephone survey 
response rate 51%). In conclusion we see fewer severe adverse effects (2.9%) after the two-
gland method with isolated submandibular injections than after the four-gland method with 
combined parotid and submandibular gland injections (4–11.1% complications); this, as also 
indicated by Gok et al.,13 would be the first choice in saliva control treatment when BoNT-A 
injections are considered in children.
Children with CNS disorders who are treated for drooling are vulnerable with regard 
to their oral motor abilities. In present study, 28.2 to 51.2% already showed dysphagia at 
baseline. After BoNT-A, the oral motor problems increased in 69 children (33%). As expected, 
a higher frequency of adverse effects occurred in children with oral feeding skills (87%). 
Our findings underline the recommendation by Reddihough et al.1 to regularly contact the 
patient’s caregivers in the weeks after BoNT injections to evaluate oral motor problems.
Authors mentioned two main causes for the deterioration of swallowing and/or 
speech. Higher salivary viscosity after BoNT-A injections may result in problems with intraoral 
processing of (solid) food.20,21 Indeed, we found a significant association between increased 
salivary viscosity and the occurrence of adverse effects. Concerning oral motor function, 
the second potential cause of BoNTrelated problems is the diffusion of the toxin outside the 
salivary gland leading to muscle weakness.6, 20 The submental muscle group (SMG) plays an 
important part in normal swallowing.22,23 After submandibular BoNT, diffusion into the SMG 
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most likely results in muscle weakness and, as a consequence, the child may not properly 
control the swallowing process leading to oral dysfunction. 
Up to now, it has been unknown which children with CNS disorders will experience 
adverse effects after BoNT treatment. We tried to discover potential risk factors and identified 
three clinically significant predictors of the occurrence of adverse effects: diagnosis of CP, 
higher BoNT-A dosage, and pre-treatment drooling quotient of < 18%.
Children with CP were three times more likely to experience an adverse effect than 
other children. This finding may be attributed to the fact that, in children with CP, drooling 
is generally caused by an impaired oropharyngeal swallowing caused by poor oral muscle 
Table 3: Number of patients with and without adverse effects (AE+/-) and ORs and adjusted ORs 
with 95% confidence interval based on univariable and multivariable logistic regression analysis 
with AUCa respectively.
Number of patients
Characteristics AE-
(n=140)
AE+
(n=69)
OR 
(95% CI)
Adjusted OR 
(95% CI)
Sex
Male
Female
81 (57.9)
59 (42.1)
42 (60.9)
27 (39.1)
1.00 (reference)
0.88 (0.49–1.59)
-
-
Developmental age
<4y
≥4y
91 (65.0)
49 (35.0)
40 (58.0)
29 (42.0)
1.35 (0.75–2.43)
1.00 (reference)
-
-
Diagnosis
Non CP
CP
Unknown
61 (43.9)
78 (56.1)
1
17 (24.6)
52 (75.4)
1.00 (reference)
2.39 (1.26–4.54)
1.00 (reference)
3.08 (1.53–6.19)b
Degree of mobility
Ambulant
Non-ambulant
75 (53.6)
65 (46.4)
29 (42.0)
40 (58.0)
1.00 (reference)
1.59 (0.89–2.85)
-
-
Injected dosage BoNT per gland
<25U
25U
>25U
Unknown
14 (10.2)
119 (86.9)
4 (2.9)
3
2 (2.9)
63 (91.3)
4 (5.8)
1.00 (reference)
3.71 (0.82–16.82)
7.00 (0.92–53.23)
1.00 (reference)
5.06 (1.07–23.84)b
8.13 (1.02–64.96)b
Nutrition intake
Tube/tube and oral
Oral
25 (17.9)
115 (82.1)
9 (13.0)
60 (87.0)
1.00 (reference)
1.45 (0.64–3.30)
-
-
Choking on saliva (t1)
No
Yes
Unknown
98 (70.5)
41 (29.5)
1
47 (72.3)
18 (27.7)
1.00 (reference)
0.92 (0.48–1.76)
4
-
-
Choking on food (t1)
No
Yes
Unknown
77 (55.8)
61 (44.2)
2
32 (47.8)
35 (52.2)
1.00 (reference)
1.38 (0.77–2.48)
2
-
-
Choking on drinks (t1)
No
Yes
Unknown
67 (48.6)
71 (51.4)
2
32 (47.1)
36 (52.9)
1.00 (reference)
1.06 (0.59–1.90)
1
-
-
DQ (t1)
DQ<18
DQ≥18
Unknown
87
52
1
52
16
1
1.94 (1.01–3.75)
1.00 (reference)
2.40 (1.18–4.88)b
1.00 (reference)
a The area under the ROC curve for multivariable logistic regression analysis was 67% (95% CI: 60–75%). 
b Significant predictors of adverse effects based on multivariable logistic regression analysis. AE+, patients with adverse effects; 
AE-, patients without adverse effects; OR, odds ratio; –, variables not selected in the multivariable logistic regression analysis.
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control.3,16 In other children with CNS disorders drooling is usually less associated with motor 
control, but more commonly caused by less awareness and inability to recognize salivary 
spill.17 We hypothesize that, in some children with CP, changes in the viscoelastic properties 
and the decreased salivary amount, or induced muscle weakness, cannot adequately be 
compensated by the oral motor system.
In the present study we had the opportunity to compare different dosages of BoNT 
per submandibular gland. Children treated with 25U and > 25U Botox per gland were more 
at risk of an adverse effect (5 and 8 times higher risk respectively). Recently, Moller et al.9 
found no relationship between adverse effects and the administered dose or injection 
method of BoNT-A. Some authors have speculated whether a high volume of liquid or a 
slower speed of delivery may affect the likelihood of dispersal into surrounding tissues.18 
Currently, the most effective dilution of BoNT and the number of injection sites within the 
gland are still under debate. Normally, the amount of fluid injected raises the intraglandular 
pressure and, theoretically, leakage of the drug might occur. Tighe et al.24 also recently 
reported dysphagia after BoNT-A extravasation from the glandular puncture site, possibly 
depending on the injected volume.
At baseline, children who had a drooling quotient < 18 (i.e. mild drooling) were 2.4 
times more likely to develop an adverse effect. The drooling quotient is a reliable objective 
measure of unintentional loss of saliva from the mouth. In a previous study by our team, we 
concluded that children with a drooling quotient < 18 may be eligible for a more conservative 
intervention, such as oral sensorimotor training. In cases when those children receive BoNT, 
because of a failure of the oral motor training and the high impact of the drooling, the 
mouth could possibly become dry, interfering with mastication. On the other hand, the 
drooling quotient is a measurement for anterior (visible) drooling and children with a low 
drooling quotient might be sensitive to posterior drooling, making them more vulnerable 
to adverse effects – i.e. those children lack the strength to process the thickened saliva 
making them prone to saliva swallowing problems. We argue that this cut-off threshold 
should not be applied as the only variable to indicate an invasive treatment. The use of 
subjective measurements of the severity and impact of drooling on the child and parents 
should also be encouraged.15 
Interestingly, we could not find a relation between the occurrence of an adverse 
effect and being a responder or not. Thus, we are convinced that it is justified to treat 
children with CNS disorders for chronic drooling because the majority of the adverse effects 
are mild and will improve within a few weeks in most of the cases.
A limitation of our study is that we focused on a limited set of factors that might 
influence the occurrence of adverse effects. There may be other risk factors of importance 
such as the use and/or change of oral medication during/after BoNT treatment. In addition, 
we did not document any concurrent BoNT injections into the skeletal muscles to treat 
spasticity. Indeed, disturbances of swallowing and speech have been reported after 
multilevel intramuscular injections,25,26 because the total amount of BoNT in the body is 
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substantially increased after combined intraglandular and intramuscular injections. Thus, 
clinicians should be aware of the increased risk of oral motor dysfunction if they treat both.
In conclusion, BoNT-A injections can reduce saliva production and constitute one of 
the treatment options for children with CNS disorders and excessive drooling. However, in 
one-third of the treatments, mild and transient oral motor problems can be expected. A 
diagnosis of CP, higher BoNT-A dosage, and mild visible drooling at baseline are associated 
with an increased risk of oral motor problems. However, more scientific research at both 
the neurophysiological level (i.e. determinants of the entire pharyngeal swallowing process) 
and the pharmaceutical level (dose and concentration-finding) is needed. Moreover, such 
treatment and subsequent follow-up should preferably take place under the responsibility 
of a multidisciplinary saliva control team that is capable of anticipation and immediate 
management of adverse effects.
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Abstract 
Aim: To examine changes in objective and subjective drooling severity measures and 
explore their relationship after submandibular Botulinum Toxin-A injections in children 
with neurodevelopmental disabilities. To evaluate if clinically relevant response relates 
to change in impact of drooling.
Method: This longitudinal, observational cohort study involved 160 children (92 males, 
3-17 years), treated between 2000-2012 at the Radboud university medical center. 
Repeated-measures ANOVA was used to compare Drooling Quotient 5 minutes version 
(DQ5) and Visual Analogue Scale for drooling severity (VAS-
DS
) pre- and post-treatment, 
and Pearson’s rho to assess their association. A parent questionnaire was used to assess 
the drooling impact in responders (defined as ≥50% reduction of DQ5 and/or ≥2SD 
reduction of VAS-
DS
 8 weeks post intervention) and non-responders.
Results: 112 children (70%) were responders. Their mean VAS-
DS
 and DQ5 scores were 
still significantly lower 32 weeks post intervention compared to baseline. At baseline, 
the VAS-ds /DQ5-relationship was ‘weak’ (rs=0.15, p 0.060 ), whereas it was ‘fair’ at 8 
(rs=0.43, p 0.000) and 32 (rs=0.30, p 0.000) weeks. For responders, a significant change 
was found in the impact of drooling on daily care and social interaction at 8 weeks after 
intervention with maintenance of most of these effects at 32 weeks.
Interpretation: A clinically relevant response based on a combination of objective 
and subjective measures of drooling severity was accompanied by positive changes in 
drooling impact.
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Botulinum toxin type A (BoNT-A) injections in the salivary glands represent an accepted 
treatment option for drooling in children with cerebral palsy (CP) and other neuro-
developmental disabilities. After initial case studies,1,2 the reduction of salivary flow and 
its effect on drooling frequency and severity have been documented in cohort studies as 
well as controlled studies including randomized controlled trials (RCTs).3-8 In a systematic 
review, Rodwell et al.9 concluded that BoNT-A is a temporary effective treatment. Outcomes 
in these studies included both objective and subjective measures such as flow rate, the 
Drooling Quotient (DQ),10,11 Visual Analogue Scales (VAS),12 the Drooling Frequency and 
Severity Scale,13 and the Teacher Drool Scale.14
Only a few studies have evaluated changes in the impact of drooling on children 
and their families. In an RCT, Reid et al.5 evaluated the effect of BoNT-A injections into the 
submandibular and parotid glands in 61 children with developmental disabilities. They found 
a highly significant difference in the mean scores on the Drooling Impact Scale (DrI) between 
the treatment and control group at one-month follow-up.5,15 The most significant changes 
were found in items addressing the severity and frequency of drooling and the number of 
bibs and clothing changed during a day. They defined non-response to BoNT-A treatment as 
a reduction of < 10 points on the DrI (100-point scale). In a controlled clinical trial (n=45), 
comparing bilateral submandibular BoNT-A injections to scopolamine treatment, parents 
reported changes in the impact of drooling up to 24 weeks.16 Clinically notable responses 
were found in the frequency that parents wiped the children's chins and changed their bibs, 
making daily care less demanding. After intervention, the number of parents that reported 
damage to electronic devices and computers decreased. In addition, social contacts with 
peers increased. Parents also indicated that the perceived impact of drooling on the 
child's satisfaction concerning physical appearance, relations within the family and life in 
general, improved. Since there were only a few parents in this study who observed an overt 
emotional reaction by the child concerning the impact of drooling, no significant changes in 
self-esteem could be established in the follow-up period.
Studies on the effect of BoNT-A treatment for drooling in larger groups of children 
with neurodevelopmental disabilities have become available.7,17 Unfortunately, alterations 
in drooling and the possible impact on the daily lives of the children and their parents are 
mostly not reported.18
The saliva control clinic at the Radboud university medical center Nijmegen the 
Netherlands, has systematically collected objective and subjective measurement outcomes 
at baseline and after 8 and 32 weeks to evaluate the effectiveness of medical interventions 
for drooling.
With this study we aim: (1) to examine changes in both objective (Drooling Quotient 5 
minutes version (DQ5)) and subjective (VAS drooling severity (VAS-
DS
)) measures of drooling 
severity and to explore the relationship between these measures up to 32 weeks after first 
bilateral submandibular BoNT-A injections in children with CP or other neurodevelopmental 
disabilities, and (2) to evaluate if a clinically relevant response to treatment (in accordance 
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with our response definition) is related to parental report of changes in the impact of 
drooling on daily life.
Method
Inclusion
The flowchart in Figure 1 shows the enrolment and inclusion of participants in this 
observational study. After standardized assessment of swallowing, children eligible for 
participation underwent a standardized first-time BoNT-A submandibular treatment (n=160) 
in the years 2000-2012. Informed consent for BoNT-A treatment was obtained from the 
child’s legal representative(s). The study was conducted in accordance with national and 
international ethics standards and was approved by the local medical ethical committee 
(CMO: 2018-4954).
Figure 1. Flowchart of enrolment of participants with Cerebral Palsy (CP) or other neurodevelopmental
disabilities.
Assessed for eligibility database saliva control team 
Nijmegen (2000-2012)
n=373 children
Included 246 children for first subm. BoNT injection
Mild to severe drooling (Score >3 TDS)
Age 3-17.11 Years
First BoNT A injections submandibular
No previous surgical procedure for saliva control
Informed Consent
Enrolment 
160 children
Excluded 86 children
5 children: Age ≥18 Years
58 children: missing lists baseline or two FU
22 children:  progressive disease
1 child: surgery before BoNT
Drooling measurements
Baseline
FU 8 weeks after BoNT
FU 32 weeks after BonT
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BoNT-A procedure
Bilateral injections in the submandibular glands with BoNT-A (Botox®; Allergan, the 
Netherlands) were performed by the same physician (PJ) using ultrasound guidance and 
general anesthesia. Botox® was diluted in saline 0.9% (25U/ml) and 1 ml was divided over 
two or three sites throughout the gland using a Spinocan© needle.
Outcome measures
During outpatient visits before injection (baseline) and 8 and 32 weeks after intervention, 
drooling severity was assessed with the DQ5 and a VAS. The DQ5 was determined by speech 
language therapists (SLT) of the team and carried out under standardized conditions during 
an individualized seated activity.11 During this 5 minute observation, the presence or absence 
of new saliva was determined at 15 seconds intervals. The DQ5 is expressed as a percentage 
of observed drooling episodes (intervals with new saliva) and the total number of intervals 
(0=no new saliva, 100 =100% of the intervals new saliva).
During the three time points, parents also filled in a VAS regarding drooling severity 
(VAS-
DS
) (0=no drooling, 100=excessive drooling) and a parent questionnaire (appendix A) 
on the impact of drooling.12,19 This questionnaire evaluates the impact of drooling on daily 
life and care, social interaction and self-esteem.16 It was developed by our saliva control 
team20 and shortened to enhance applicability.19 Earlier studies have demonstrated that this 
questionnaire demonstrates the changes in impact after intervention.12,16,19
A clinical response was defined as a ≥ 50% reduction of the DQ5 and/or a reduction 
of ≥ 2 standard deviations of the VAS-DS 8 weeks post intervention compared to baseline.17
Data analysis
To evaluate the effects of BoNT-A intervention on drooling severity over time, a repeated-
measures ANOVA was used to analyze DQ5 and VAS-
DS
 scores. Baseline DQ5, and baseline 
VAS-
DS
 scores were compared at 8 and 32 weeks, and a comparison was made between 8 
and 32 weeks. If the assumption of sphericity had been violated according to Mauchly’s test, 
the Greenhouse-Geisser correction was used. Post-hoc tests were performed to interpret 
changes that were significant using Bonferroni correction (i.e., p	= 0.05/number of tests). 
The Friedman test was used for nominal and ordinal variables (questions 6-10) to evaluate 
the effects over time. Also changes in daily care (parent questionnaire: questions 3-4-5) 
were analyzed by the repeated-measures ANOVA (interval data) for the responder group 
(RG) and non-responder group (NRG).
To study the correlation between outcomes of the objective (DQ5) and subjective 
(VAS-
DS
) measures at baseline and 8 and 32 weeks after intervention, the Pearson’s rho was 
used (0.0-0.25 weak or no relationship; 0.25-0.5 fair relationship; 0.5-0.75 moderate to 
good relationship; > 0.75 excellent relationship).21
To explore different options in evaluating change after BoNT-A treatment, we critically 
reflected on our response definition and presented the data of the parent questionnaire for 
two groups.
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To describe and analyze data about the impact of drooling on self-esteem (questions 
11-14, Appendix A), VAS scores (0= very dissatisfied, 100= very satisfied) concerning 
satisfaction with respectively 1) ‘social contact’, 2) ‘physical appearance’, 3) ‘relations within 
the family’ and 4) ‘life in general’ were re-coded in three categories: 0-32 (dissatisfied), 
33-66 (neutral) and 67-100 (satisfied), according to Kok et al.19 VAS scores for the ‘extent to 
which drooling contributes to the level of satisfaction’ (0= not at all, 100= very important) on 
these four elements were also recoded in three categories: 0-32 (low contribution), 33-66 
(neutral) and 67-100 (high contribution). For each question in this section on self-esteem we 
determined the number of participants that combined dissatisfaction (VAS 0-32) with a high 
contribution (VAS 67-100) of drooling.
A pooled multiple imputation method (5 iterations) was used to deal with missing 
values at baseline. To avoid bias in favor of positive outcomes, missing values at 8 or 32 
weeks were imputed following a worst-case-scenario: a missing value during follow-up was 
replaced by the baseline value of the participant. If both baseline and follow-up items were 
missing, no imputation was performed and the participant was omitted from the analysis 
for that item. Statistical analyses were performed using SPSS 21.0 for Windows (IBM Corp., 
Armonk, NY, USA).
Results
Participants (see also Table 2 in the appendix)
Of the 160 participants, 92 were male. Chronological age at the injection date varied from 
3-17 years (M 9y1mo, SD 3y 6mo). All children had neurodevelopmental disabilities, and 
123 children (76.9%) were diagnosed with CP (Gross Motor Function Classification System 
(GMFCS)22 level: I (n=2); II (n=18); III (n=27); IV (n=33); V (n=43)). Of the non-CP children 
31 were ambulant and 6 non-ambulant. Eighty-two children were diagnosed with epilepsy 
of which 18 had uncontrolled epilepsy. The developmental age (DA) of the children was 
determined based on prior information from their schools, day centers and/or parents. 
For 87 children (54.4%) the DA was below 4 years, for 39 children (24%) DA was between 
4 and 6 years, and for 28 children (17.5%) DA was above 6 years. Data from 5 children 
were missing (3.1%). From standardized assessment of swallowing by specialized SLTs, 109 
children (69.0%) had oral dysphagia and 49 (31.0%) had oropharyngeal dysphagia. Twelve 
children (7.5%) were partially dependent on tube feeding, 8 were fully tube-fed and had no 
oral intake (5.0%), 138 had only oral feeding (86.3%) and for 2 children data about feeding 
were missing (1.3%). All baseline measures were performed prior to the BoNT-A injections 
(M 2.88mo, SD 2.45mo). At baseline, the mean VAS-
DS
 score was 78.09 (SD 17.74) and the 
mean DQ5 score was 32.43 (SD 22.15).
Almost all demographic data in the RG and NRG were comparable. We only found a 
significant difference in the diagnosis (p 0.013). In the RG (n=112), 80 (71.43%) children were 
diagnosed with CP, whereas 32 (28.57%) had a different non-progressive neurodevelopmental 
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disability for example a syndrome or genetic disorder. The NRG (n=48) consisted of 43 children 
(89.58%) with CP and 5 children (10.42%) with different neurodevelopmental disabilities.
In total, there were 16.6% missing values on the parent questionnaire due to 
incomplete or incorrect questionnaires. Consequently, there was a difference in the number 
of children analyzed for different items in the questionnaire. There were no missing values 
in the DQ5 and VAS-
DS
 measurements.
Clinical response
At 8 weeks after BoNT-A injections, 94 children (58.8%) showed a ≥50% reduction in DQ5, 
while 58 children (36.3%) showed a reduction of 2 SD in VAS-
DS
 from baseline drooling 
severity. Forty children met both criteria. Applying our clinical response definition, 112 
children (70%) experienced a 50% reduction in DQ5 and/or a reduction of 2 SD (2SD=35.48) 
in VAS-
DS
 at 8 weeks after injections. They were considered responders.
Drooling severity: relation between objective and subjective measures
Figure 2a shows the reduction of drooling severity, depicted as both the mean VAS-
DS
 and 
the mean DQ5-scores for the entire group of participants (n=160) over time. Repeated-
measures ANOVA revealed that mean VAS-
DS
 and DQ5 scores differed significantly between 
time points (VAS-
DS
: F(1.927, 306.382)=48.96, p 0.000), DQ5: F(1.856, 295.136)=54.64, 
p .000)). Post-hoc tests revealed a significant decrease in both mean VAS-
DS
 (p 0.000) and 
DQ5 (p 0.000) scores between baseline and 8 weeks follow-up. Between 8 and 32 weeks 
there was a significant increase in drooling severity for the mean VAS-
DS
 (p 0.000) and DQ5 
(p 0.027), although both mean scores at 32 weeks indicated that drooling severity remained 
significantly below baseline level. Time effects between baseline and 32 weeks were still 
significant for both measurements: VAS-
DS
 (p 0.000) and DQ5 (p 0.000).
In terms of correlation, there was a ‘weak’ relationship between VAS-
DS
 and DQ5 at 
baseline (rs=0.15, p 0.060). However, at 8 (rs=0.43, p 0.000) and 32 weeks (rs=0.30, p 0.000) 
the relationship was ‘fair’.
Figure 2b and 2c outline the changes in drooling severity for the RG and the NRG 
until 32 weeks. As expected, the RG showed significant differences between the three time 
points for both VAS-
DS
 (F(2,222)=66.54, p 0.000) and DQ5 (F(1.863,206.743)=92.36, p 0.000). 
In the NRG, changes between all time points for both VAS-
DS
 (F(1.729,81.242)=0.58, p 0.539) 
and DQ5 (F(2,94)=1.49, p 0.232) were not significant.
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Figure 2. Mean drooling severity based on Visual Analogue Scale (VAS-DS) and Drooling Quotient (DQ5) at baseline 
(Bsl), and 8 and 32 weeks after submandibular BoNT-A injections in the total group (figure 2a), in the responder 
group (RG) (figure 2B), and in the non-responder group (NRG) (figure 2C).
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Changes in impact of drooling based on the parent questionnaire.
Part 2. Impact of drooling on daily care and economic consequences.
Figure 3 shows the changes in daily care at three points (frequency of mouth wiping 
(Figure 3a), verbal prompts to swallow (Figure 3b), and bib replacements (Figure 3c)) for the 
RG and NRG, respectively.
Repeated-measures ANOVA indicated that the frequency of wiping the mouth and chin 
by parents of responders (n=101) decreased significantly across time (F(1.417, 141.706)=20.43, 
p 0.000). Post-hoc tests revealed a significant decrease in mouth wiping between baseline 
and 8 weeks, baseline and 32 weeks, and 8 and 32 weeks follow-up. In the NRG (n=42), no 
significant changes over time were found regarding the frequency of mouth wiping.
The frequency of verbally prompting the child to swallow in the RG (n=108) decreased 
significantly from baseline to 32 weeks follow-up (F(1.819, 194.609)=8.07, p 0.001). Post-
hoc tests revealed a significant decrease between baseline and 8 weeks after injection, but 
the scores returned almost to baseline level between 8 and 32 weeks. In the NRG (n=44) no 
significant changes over time were found for prompting the children to swallow after the 
intervention.
From baseline to 32 weeks after BoNT-A, a significant decrease in the frequency of 
replacing the bibs was found in the RG (F(1.443, 160.204)=10.86, p 0.000) and in the NRG 
(F(1.587,69.822)= 5.39, p 0.011). In the RG (n=112) a significant decrease in replacing the 
bibs was found between baseline and 8 weeks and baseline and 32 weeks, whereas the 
change between 8 and 32 weeks was not significant. In the NRG (n=45) only the change 
between baseline and 8 weeks was significant.
Friedman’s test indicated no significant changes in the number of parents in the RG 
(n=112) that reported damage to computers or other devices during the study(χ2(2)=5.786, 
p 0.055). However, in the NRG (n=48) the changes in time were significant (χ2(2)=9.692, p 
0.008) meaning that the number of parents reporting damage to computers or other devices 
decreased from 15 at baseline, to 6 at 8 weeks and increased to 9 at 32 weeks. In the RG, 
the number of parents that reported damage to floors and furniture increased significantly 
(χ2(2)=11.706, p 0.003; 35 at baseline, 20 at 8 weeks and 22 at 32 weeks), whereas in the 
NRG these change were not significant (χ2(2)=3.647, p 0.161).
Part 3. Impact of drooling on social interaction.
Table 1a, illustrates the changes in social consequences for both the RG and the NRG as 
reported by parents. In the RG there was a significant decrease in the number of parents 
that reported (a) their child to be avoided by peers because of drooling (χ2(2)=25.409, 
p	0.000), (b) being avoided by adults because of drooling (χ2(2)=7.548, p 0.023), and (c) 
that the mental ability of their child was underestimated because of drooling (χ2(2)=12.742, 
p 0.0002). In the NRG decreases were not significant for all 3 items (a) (χ2(2)=1.733, p .420), 
(b) (χ2(2)=0.667, p 0.717) and (c)(χ2(2)=4.429, p 0.109).
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Figure 3. Change in impact of drooling on daily care in Non-responders group (NRG) and Responders Group (RG).
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Figure 3a. Mean mouth wiping  
NRG (n=42)  
no signiﬁcant change before and 
after BoNT-A (F(2,82)=2.332, p 
0.104).  
RG  (n=101) 
Bsl-8 wks (M=6.11, p 0.000,  
95%CI 3.33 – 8.89);  
Bsl-32 wks (M=2.78, p 0.000, 
95%CI 1.36 – 4.20);  
8-32 wks (M=-3.33, p 0.006,  
95%CI -5.88 - -.77) 
 
Figure 3b. Mean swallow cues 
 
NRG (n=44) 
no signiﬁcant change before and 
after BoNT-A (F(1.630, 
70.086)=0.12, p 0.845) 
RG (n=108)  
Bsl-8 wks (M= 2.20, p 0.002,  
95%CI .69 – 3.72);  
Bsl-32 wks (M=1.14, p 0.054, 
95%CI -0.14 – 2.29);  
8-32 wks (M=-1.06,  p 0.152,  
95%CI 2.37 .25)
Figure 3c. Mean bib replacement 
NRG (n=45) 
Bsl-8 wks (M=3.51, p  0.02,  
95%CI .44-6.58),  
Bsl-32 wks (M=.62, p  1.00,  
95%CI -1.38-2.63);  
8-32 wks (M=-2.89, p  0.10,  
95%CI -6.17-.39) 
RG (n=112) 
Bsl-8 wks (M=2.44, p 0.000,  
95% CI 1.57-3.31);  
Bsl-32 wks (M=2.24, p 0.004, 
95%CI .60-3.89);  
8-32 wks (M=-.20, p 1.00,  
95%CI -1.78-1.39)
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Part 4. Impact of drooling on emotional development (self-esteem).
Parent impression.
Across the study, only a few parents in both groups reported that their child felt dissatisfied 
during the past four weeks about social contacts with other children, his/her physical 
appearance, relations within the family, or his/her life in general because of drooling. Table 
1b, shows the numbers and valid percentages for each item. Because of the small numbers 
of children for whom this was reported, no statistical analysis could be performed. Visual 
analysis shows a decline in all items in the RG.
Emotional reactions of the child.
Only a small number of children were able to articulate (verbally or with augmentative 
communication) positive or negative feelings about their appearance and social acceptance 
by adults or by peers (Table 1c). At 8 weeks, the number of parents in this subgroup that 
reported negative feelings related to drooling expressed by their child, decreased in both the 
RG and the NRG. At 32 weeks, the number of parents who reported emotional reactions of 
their child increased in comparison with 8 weeks. No statistical analysis could be performed 
because of the small sample size.
Discussion
This study in a group of 160 children with neurodevelopmental disabilities strengthens the 
findings of previous studies that submandibular BoNT-A injections reduce the severity of 
drooling. We found a clinical response in 70% of the children at 8 weeks post injection based 
on our definition. Remarkably, merely a ‘fair’ correlation was found between the objective 
and subjective outcome measures at 8 weeks post treatment. Almost 60% of the children 
showed a reduction of ≥50% of the DQ5. A change of ≥ 2 SD reduction of the parental VAS-
DS
 
was found in 36% of the children 8 weeks after BoNT-A injection. Apparently, the subjective 
opinion of parents with regard to the reduction of drooling severity in daily life did not 
correspond well with the objective assessment of drooling. This discrepancy between 
objective and subjective assessments is a striking result of the present study and suggests 
that both types of assessments do not reflect the same response dimension. Therefore, 
the DQ5 cannot simply be replaced by the VAS-DS. This conclusion is in contrast with the 
study of Rashnoo et al.,23 who found a strong correlation between the objective DQ and a 
subjective tool, the Drooling Severity and Frequency Scale (DSFS). They suggested that the 
DSFS and DQ were interchangeable to guide the clinical management of drooling. The results 
of the current study, however, indicate that a response definition based on a combination of 
objective and subjective measurements is preferable.
The second aim of this study was to evaluate if a clinically relevant response to BoNT-A 
treatment was related to the parents’ perspectives of meaningful change in the impact 
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of drooling on daily care, economic consequences, and social and emotional aspects.12,16 
It appeared that BoNT-A injections can make daily care for parents less demanding, as 
significant decrements in wiping children’s mouths and chins, cueing the child to swallow, 
and bib replacements were demonstrated. The observed group differences in the changes 
of impact of drooling on daily life between the RG and the NRG seem to support our clinical 
response definition. Indeed, the decrease in reported frequencies of mouth wiping and 
prompting the child to swallow was significant for the RG, but not for the NRG. Although 
the mean amount of bib use was not equally divided between groups at baseline, the mean 
bib replacement was significantly lower at 32 weeks in the RG, whereas in the NRG it was 
lower only at 8 weeks post BoNT-A injections. It should be recognized, however, that the 
frequency of bib changing may not be a sensitive marker of treatment effect, as indicated by 
Rashnoo et al.23 who found a rather weak association between the DQ and the number of 
bib changes. They argued that bib replacement is not sensitive for measuring clinical change 
after drooling treatment, because parents may change the bib out of habit (e.g., after every 
meal) rather than to clear dampness. In our opinion, parent behavior regarding bib change 
will be more related to the severity of drooling as reflected in their VAS-score and not to the 
DQ-score.
As expected, the results for the social consequences of drooling showed differences 
between the RG and the NRG: only the parents of the RG group reported that children were 
less likely to be avoided by other children or adults and to be underestimated with regard to 
mental capacity. For the emotional consequences of drooling, no substantial changes after 
BoNT injections could be established in both groups so only tentative conclusions may be 
drawn.
This may be due to the small number of children who were able to reflect on this 
important subject: only 28 participants had an estimated developmental age above 6 years.
Not all results were in line with our definition of a good clinical response. For 
example, in the RG no significant change was found in the number of parents who reported 
damage to computers or other devices before and after treatment. Surprisingly in the NRG, 
a significant decrease on this item was found after treatment. No clear explanation could be 
given for this finding, further research is necessary.
A strength of this observational study is the systematic way in which data were 
collected in a sample of 160 children. To our knowledge, this study represents the largest 
cohort of children in which submandibular BoNT injections for drooling is evaluated. All 
children were systematically selected from a tertiary outpatient clinic and received a first-
ever bilateral submandibular BoNT-A injection for drooling, while treatment effect was 
objectively monitored and parents were asked to fill in questionnaires at baseline, and 8 and 
32 weeks after intervention. Our study has several limitations as well. First, SLTs were not 
blinded during DQ5 observations. Second, the parent questionnaire has not yet been tested 
on all aspects of reliability and validity, has been shown to be sensitive to change in previous 
research as well as in the current study.12,16,19 A favorable aspect of the questionnaire is that 
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analysis can be done per item, which gives a balanced opinion about (changes in) the impact 
of drooling on various aspects in daily life. Third, no guarantee could be obtained whether 
the same parent completed the baseline questionnaire and follow-up questionnaires, 
which might have affected the response consistency across time. Another limitation is the 
low developmental age of the children. In our group of participants, 56% of the children 
had a DA below 4 years. It may have been difficult for parents to report on the social and 
emotional consequences of drooling for these children. Lastly, with regard to the definition 
of clinically meaningful change, we acknowledge the limitation of using a dichotomous 
model of ‘responders’ versus ‘non-responders’.
With reference to the title of this paper, the question was raised: “how to define 
a meaningful change”? Change basically represents a complicated concept to define as it 
involves clinical as well as statistical considerations.24 Change relates closely to the concept 
of difference that is based on difference scores of measurable entities and in most instances 
related to a time span. It can be argued that ‘change' should primarily be measured on 
a subjective individual level while making sure that the measurement is objective and 
accurate. In our response definition, we combined objective (DQ5) and parent-reported 
subjective (VAS) outcomes for drooling severity. By relating this to parent-reported changes 
in impact of drooling after BoNT-A injections, we tried to substantiate this definition as 
reflecting a meaningful change. If we only had used the DQ5 change, there was a risk that 
relevant post-intervention changes in the home situation would not have been included in 
the effect evaluation. If we had only used the VAS as an outcome, the basic rules of science 
that conclusions must be based on objective measurements would have been ignored. 
Therefore we recommend to use the DQ5, VAS-
DS
 and a parent impact questionnaire in 
assessing all aspects of drooling. Parent experience of change in drooling severity and its 
impact after intervention is crucial for their willingness to undetake further treatment. As 
BoNT-A injection is a temporary effective treatment with a need for general anesthesia, this 
is an important issue.
The population of children with chronic drooling is very heterogeneous with regard 
to mental and motor capacities and in our country their social participation ranges from 
regular and special education to attendance at daycare centers and homes for youth with 
developmental disabilities. Consequently, the impact of drooling may be different for each 
individual and his/her relatives. Changes in impact may be valued differently depending 
on the social and cultural situation within this heterogeneous population. From this 
perspective, we make a plea for a more personalized approach to the evaluation of drooling, 
in which meaningfulness of treatment results is considered in the context of the individual’s 
characteristics, circumstances and opinions.
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Table 2. (appendix) Characteristics of participants at baseline (total and RG and NRG) and mean 
outcomes on DQ5 and VAS-DS 
RG= n=number, responder group, NRG= non-responder group, CP= cerebral palsy, Y= year. mo=months, DQ5= drooling 
quotient 5 minutes, VAS-SD=visual analogue scale drooling severity , SD= Standard deviation 
a Non CP= children with developmental disability mainly as part of a syndrome, genetic, metabolic or neurodegenerative 
disorder.  
b. Mobility: Ambulant: Children with CP with GMFCS I,II and III, and ambulant non-CP children. Non-ambulant: Children with 
CP with GMFCS IV and V, and wheelchair depended non-CP children. 
Patient characteristics                                                  n total (%) n RG (%) n NRG (%) 
Sex 
    Male 
    Female 
 
92  
68  
 
(57.5) 
(   (42.5) 
 
62 
50 
 
(55.4) 
(44.6) 
 
30 
18 
 
(62.5) 
(37.5) 
Diagnosis 
    CP 
    Non-CPa  
 
123 
37 
 
(76.9) 
(37.3) 
 
80 
32 
 
(71.4) 
(28.6) 
 
43 
5 
 
(89.6) 
(10.4) 
Epilepsy 
    Absent 
    Controlled 
    Uncontrolled 
    Unknown 
 
77 
64 
18 
1 
 
(48.1) 
(40.0) 
(11.3) 
(  0.6) 
 
58 
44 
9 
1 
 
(51.8) 
(39.3) 
(  8.0) 
(  0.9) 
 
19 
20 
9 
0 
 
(39.6) 
(41.7) 
(18.8) 
Mental ability 
    Developmental age <4 y 
    Developmental age 4-6y 
    Developmental age >6 y 
    Unknown 
 
87 
39 
28 
5 
 
(54.4) 
(24.0) 
(17.5) 
(  3.1) 
 
61 
29 
19 
3 
 
(54.5) 
(25.9) 
(17.0) 
(  2.7) 
 
26 
11 
9 
2 
 
(54.2) 
(22.9) 
(18.8) 
(  4.2) 
Degree of mobility 
    Ambulant  
    Non-ambulant  
 
82 
78 
 
(51.3) 
(48.7) 
 
57 
55 
 
(49.1) 
(50.9) 
 
23 
25 
 
(48) 
(52) 
Dysphagia 
    Oral dysphagia  
    Oropharyngeal dysphagia 
    Unknown 
 
109 
49 
2 
 
(68.1) 
(30.6) 
(  1.3) 
 
81 
29 
2 
 
(72.3) 
(25.9) 
(  1.8) 
 
28 
20 
0 
 
(58.3) 
(41.7) 
Nutrition intake 
    Tube and oral 
    Tube 
    Oral 
    Unknown 
 
12 
8 
138 
2 
 
(  7.5) 
(  5.0) 
(86.3) 
(  1.3) 
 
7 
6 
97 
2 
 
(  6.3) 
(  5.4) 
(86.6) 
(  1.8) 
 
5 
2 
41 
0 
 
(10.4) 
(  4.2) 
(85.4) 
Patient data Mean (SD) Mean (SD) Mean (SD) 
Age at inclusion (Y/mo) 9.1 (  3.6) 9.4 (  3.6) 8.7 (  3.4) 
DQ5 32.43 (22.15) 33.89 (22.6) 29.42 (20.52) 
VAS-DS 78.09 (17.74) 79.10 (17.1) 75.75 (19.10) 
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Summary
Healthy people are usually unaware of their adaptability in oral motor performance. Essential 
activities like eating, drinking and saliva control are executed without hesitation and in a 
smooth way. But for children with neurodevelopmental disabilities, especially for those with 
cerebral palsy (CP), it is often challenging to chew, drink and swallow in an efficient and safe 
way. The risk of malfunction in the oral and pharyngeal phase of swallowing as well as the 
incessant attention needed for oral motor activities have a great impact on the daily life of 
the child and its caretakers. Inadequate intake of food or serious aspiration of nutrients or 
saliva will have negative consequences for general health.
In chapter 1 a general introduction to oral motor performance in children with 
neurodevelopmental disabilities is presented. The primary goal of the assessment of 
dysphagia and drooling, and of all possible interventions in this area, is to improve health 
related quality of life of the children and their caregivers and to enhance meaningful 
participation. A team approach is recommended and the identified gaps in the assessment 
of oral motor performance and the management of dysphagia and drooling are described 
as the inspiration for the research presented in this thesis. In addition, the thesis’ outline is 
delineated in this chapter.
PART I: Towards refined assessment of oral motor performance
Chapter 2 describes saliva control in typically developing children between 0 and 4 years 
of age. Data was collected by means of a validated parent questionnaire (Drooling Infants 
and Preschoolers Scale; DRIPS) to quantify drooling frequency and severity. The DRIPS 
consists of 20 items and was developed to identify severity and frequency of drooling 
during meaningful daily activities. Sex-specific reference charts were constructed presenting 
percentile curves for drooling during activities, during feeding, during non nutritive sucking, 
and during sleep. To illustrate the development of saliva control, eight sex-specific reference 
curves were constructed to plot the scores of the DRIPS, ordered by age groups, at the 
15th, 50th, 85th, and 97th percentiles. About 3–15% of the preschoolers in our cohort did not 
acquire full saliva control at the age of 4 years.
In chapter 3 a review is presented concerning swallowing impairments in children with CP. 
CP is the most common cause of physical disability in childhood with a worldwide prevalence 
of approximately 2-2.5 per 1000 living births. Children with CP may experience reduced 
oral motor performance with consequences for swallowing, possibly resulting in severe 
drooling. Both ‘anterior’ drooling (visible drooling) and ‘posterior’ drooling (saliva pooling 
or saliva aspiration) may occur. A format for the approach to assess and treat swallowing 
problems in CP is provided.
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Chapter 4 summarizes the interrater reliability, construct validity, and usability of the Eating 
and Drinking Ability Classification System (EDACS) among 149 Dutch children with CP. An 
officially translated Dutch EDACS version was scored by different speech language therapists 
(SLTs). Parents also filled out the EDACS scoring forms following the algorithm outlined in 
figure 1. Usability of EDACS was generally good. Pairs of SLTs as well as parents and SLTs 
showed good agreement. A strong, significant correlation was found of EDACS with the 
Dysphagia Management Staging Scale (DMSS). Based on these results, it was concluded 
that the Dutch version of EDACS is reliable and valid, and can easily be used by SLTs who are 
either familiar or unfamiliar with the child. Parents of children with CP can also adequately 
score the Dutch version of the EDACS. Both parents and professionals showed a high level of 
consistency when classifying eating and drinking abilities. We expect that the use of EDACS 
can increase the awareness of the safety and efficiency of eating and drinking amongst 
different stakeholders.
Figure 1. Clinical algorithm EDACS.
Level IV
Eats and drinks with
signicant
limitations to safety.
Level III
Eats and drinks
with some
limitations to
safety; there maybe
limitations to
eciency.
Level II
Eats and drinks
safely but with
some limitations
to eciency.
Level I
Eats and drinks
safely and
eciently.
Is  the individual
able to eat a meal
in the same time
as peers?
Is  the individual
able to swallow
food and drink
without risk of
aspiration? Can risks of 
aspiration be 
managed to 
eliminate harm to 
the individual?
Is  the individual
able to bite and 
chew on hard lumps 
of food without a 
risk of choking?
Eating and Drinking Ability Classication System - Algorithm
Level V
Unable to eat or
drink safely - tube
feeding may be
considered to
provide nutrition.
No
No
No
No
Yes
Yes
Yes
Yes
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In Chapter 5 we reassessed the 10-minute Drooling Quotient (DQ10) and the 5-minute 
Drooling Quotient (DQ5) as objective measures of the severity of drooling to evaluate the 
effects of treatment. No validity or reliability data was available for the DQ10 while from 
a clinical point of view it would be valuable to reduce scoring time. It appeared that, for 
clinical and research purposes, the DQ5 is interchangeable with the DQ10 and, thus, time-
efficient and cost-saving, while validity, intrarater and interrater reliability are preserved. A 
cut-off point is suggested to support clinical decision making.
Part II: Towards a personalized approach to the treatment of drooling
The second part of this thesis is dedicated to evidence-informed and customized  approaches 
to treat drooling. Special attention is given to adverse effects on oral motor performance 
after submandibular botulinum toxin injections and to the clinical response definition of 
drooling intervention.
In chapter 6 an international, evidence-informed approach is presented based on the care 
pathway for sialorrhea of the American Academy for Cerebral Palsy and Developmental 
Medicine (AACPDM). A comprehensive overview of drooling management in children 
and youth with CP from birth to 25 years of age is described. This chapter includes 
all levels of evidence to contextualize and guide assessment and treatment regarding 
oromotor strategies, behavioral therapy, oral appliances, pharmacologic interventions, 
chemodenervation with botulinum toxin, and surgical treatments for drooling. Flowcharts 
for assessment and intervention are outlined. 
Chapter 7 delineates the personalized management of drooling in children with progressive 
dystonia (MEGDEL syndrome). The heterogeneity of the cases presented shows the need for 
stepwise and customized approach in the treatment of drooling.
In chapter 8 adverse effects on oral motor function after  submandibular injections with 
botulinum toxin for drooling are assessed in 209 children. Transient adverse effects 
occurred in 33% of the 209 treatments. Almost 80% of these were mild versus 8.7% severe. 
Approximately 54% of the adverse effects spontaneously resolved within 4 weeks, whereas 
3% persisted after 32 weeks. A diagnosis of CP, higher botulinum toxin dosage, and a pre-
treatment drooling quotient < 18% were found to be independent predictors of adverse 
effects. Before using submandibular botulinum toxin injections for drooling, potential 
adverse effects should be discussed. Oral motor function needs to be monitored, because 
existing dysphagia may be worsened. The identified clinical predictors could be helpful to 
optimize patient selection.
In chapter 9 changes in objective and subjective drooling severity measures are evaluated 
and their mutual relationship are explored after submandibular injections with botulinum 
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toxin in 160 children. A clinical response was defined as a ≥ 50% reduction of the (objective) 
DQ5 and/or a reduction of 2 standard deviations of the (subjective) VAS
-droolingseverity
 at 8 weeks 
post intervention compared to baseline. A parent questionnaire was used to assess the 
drooling impact in responders and non-responders. Results showed that 112 children (70%) 
were good responders. Their mean VAS
-droolingseverity
 and DQ5 scores were still significantly 
lower 32 weeks post intervention compared to baseline. Significant differences in change of 
drooling impact were present between responders and non-responders. It turned out that a 
clinically relevant response based on a combination of objective and subjective measures of 
drooling severity was accompanied by positive changes in drooling impact. 
General discussion
The studies in this thesis were intended to refine the assessment of oral motor performance 
in children with neurodevelopmental disabilities and to develop a personalized approach to 
the treatment of drooling. This ambition was based on the great challenges that swallow and 
saliva-control teams are faced with during the process of diagnosing and treating dysphagia 
and drooling. Over the past 20 years more than 1000 children have visited the academic 
swallow and saliva-control team of the Radboud university medical center. This experience, 
previous doctoral research, and the studies presented in this thesis have led to new insights 
regarding the measurements and treatment of oral motor performance. 
Team approach
Dysphagia in children with neurodevelopmental disabilities was the central theme of this 
thesis. Dysphagia covers difficulties in eating, drinking, and swallowing saliva and may 
have serious health complications as well as social and emotional consequences. Impaired 
swallowing is an important focus area for SLTs. SLTs play a central role in the assessment, 
diagnosis, and treatment of infants and children with swallowing and feeding disorders. 
As outlined in the national guideline for swallowing disorders,1 knowledge of and affinity 
with the patient with dysphagia is necessary for an appropriate process of diagnosing 
and treatment. Years of clinical practice have shown that clinical experience with adult 
swallowing disorders does not necessarily qualify an SLT to perform swallowing assessments 
and interventions in children. Additional knowledge and skills concerning the (developing) 
anatomy and physiology of swallowing in pediatric populations are needed. Therefore, SLTs 
who serve the pediatric population at large should be specifically educated and trained. On 
top of that, a team approach is necessary for correctly diagnosing and managing pediatric 
feeding and swallowing disorders, as the severity and complexity of these disorders vary 
widely in pediatric populations.2 The clinically trained SLT specialized in dysphagia plays a 
major (and sometimes leading) role in this professional care team.
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The pivoting role of the SLT
The SLT is the team member who particularly faces the consequences of a disturbed oral 
motor performance during eating and drinking and takes care of the daily management of 
saliva. SLTs have a crucial role in accurate mapping of dysphagia and drooling. From our 
clinical practice paper regarding swallowing problems in CP (chapter 3), we learned that at 
an early stage of development particular note should be given to the important impact of 
dysphagia and drooling. A number of clinical phenomena are closely related to dysphagia 
(e.g. choking, asphyxiation, motility disorders), which may lead to serious complications 
(e.g. respiratory tract infections) or long-term health threats such as malnutrition or even 
mortality. This cascade of consequences stresses the importance of a thorough assessment 
of all aspects of oral motor performance at an early stage. Existing international consensus 
states that drooling is a multifactorial problem. In addition, the management of children 
suffering from dysphagia and drooling requires the coordinated and tailored expertise of 
an interdisciplinary team.3, 4 In fact, professionals agree that a personalized approach to the 
assessment of each child, along with a stepwise approach to the available treatment options, 
should be pursued. Considering the mission of our swallow and saliva-control team, the 
ultimate goal is to follow a seamless, interdisciplinary approach to clinical management in 
which the parents (or legal representatives) and even the child itself are engaged in making 
clinical decisions. Such an approach must be tailored to the child’s needs and unconditionally 
starts with a thorough assessment by the SLT.
The toolkit of the SLT refined
The crucial role of parents in the assessment of dysphagia
Parents are essential team members who are considered experts of their child’s needs. 
Therefore, their observations form a valuable addition to the toolkit of the SLT. According to 
the mission of the Radboudumc, family-oriented care primarily concerns improving quality 
of life and should be centered around the child and its parents and family. Combining the 
expertise and involvement of the parents with the expertise of a diversity of clinicians leads 
to meaningful collaboration. Customized goals for assessment and for treatment should 
preferably be identified by the parents or their child in partnership with the clinical team. 
Nowadays, it is also widely accepted that parents are indispensably needed to recognize 
dysphagia. 
It is well known that swallow dysfunctions or dysphagia may occur in all phases of the 
swallowing process and that signs and symptoms may vary based on the phases affected, 
the child’s age, and its developmental level. Because there are a lot of underlying etiologies 
associated with pediatric feeding and swallowing disorders, clear history taking is important 
to convert the parental story into professional language, which is needed to communicate 
among team members. This process of clinical reasoning can be facilitated by the use of the 
Eating and Drinking Ability Classification System (EDACS). The EDACS can reliably be used 
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by parents and SLTs as outlined in chapter 4. At the outpatient clinic, the classification of 
EDACS level by both the SLT and the parents forms the basis for discussing the safety and 
efficiency of the child’s eating and drinking. Most parents of children with CP are familiar 
with the system of the Gross Motor Function Classification System (GMFCS) and know the 
GMFCS-level of mobility of their child. Given the fact that the EDACS and the GMFCS have 
only a moderate (positive) association, parents and professionals should be aware that 
these levels are not interchangeable. Considering that the EDACS exclusively describes 
the performance of eating and drinking, and not the capacity of the child, parents need to 
be closely involved in classifying the efficiency and safety during daily feeding situations. 
Discrepancies between the opinion of the SLT and parents should be discussed and are 
important for sufficient comprehension of the oral motor performance of the child during 
eating and drinking. The outcome of the discussion has implications for the therapeutic 
approach. In general, children with EDACS levels I and II present problems in the oral phase 
of swallowing. Children classified as EDACS level III typically have additional problems in the 
pharyngeal phase of swallowing, whereas children with EDACS levels IV and V have severe 
(oro)pharyngeal problems. The EDACS provides direction with regard to swallowing capacity 
and the possible existence of dysphagia.
The crucial role of parents in the assessment of drooling
Apart from the assessment of dysphagia, the existence and severity of (possible) drooling 
should be assessed. Next to the SLT’s judgment of drooling severity, it is important to ask 
parents about the impact and consequences of drooling in their own lives and the life of 
their child. With regard to treatment effect, no internationally accepted clinical response 
definition exists. Therefore, our swallow and saliva-control team has proposed a definition of 
clinical response combining an objective (quantitative) with a subjective (semi-quantitative) 
criterion (i.e., ≥ 50% reduction of the objective DQ5 and/or a reduction of 2 SD of the 
subjective VAS
-severity
 at 8 weeks after intervention). In addition, a parental questionnaire 
is used comprising questions regarding the severity of drooling in daily situations and the 
impact of drooling on daily care, costs, social interactions, self-esteem, and emotional 
reactions of the child. 
In chapter 9 we showed that there was a discrepancy in response between objective 
(measurement scales) and subjective (parental information) measurements of drooling 
severity after botulinum toxin injections in the submandibular glands. An explanation for 
this discrepancy may be that both types of assessments do not reflect the same response 
dimension. This ‘response disparity’ forces clinicians to approach the consequences and 
the impact of drooling in a more individual manner, tailored to the families of the drooling 
child. Even more, a balanced management of outcome expectations by the parents with 
respect to their cultural values has to be addressed at an early stage (pre-treatment) after 
first contact with the team. The question arises whether there can ever be a single approach 
that can be applied generically, taking into account the enormous variation in socio-cultural 
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backgrounds. To achieve this, an assessment is needed that reflects both the individual 
performance and the (parents’) satisfaction with drooling treatment. For this purpose, a new 
outcome measure, based on the Canadian Occupational Performance Measure (COPM),4 
has been developed and used by our team.5 This so called Measure of Performance and 
Satisfaction for Saliva Control (MPSsaliva control) requires parents to identify five daily activities 
that are important to their child in which saliva spill is most problematic. The outcomes 
allow to calculate difference scores with regard to both the performance of and satisfaction 
with these activities before and after treatment. The experiences with the introduction of 
the MPSsaliva control support our philosophy that parents are valuable team members and have 
strengthened our expectation that the MPSsaliva control is a promising addition to the existing 
instruments. However, further research is needed to determine the true value and position 
of the MPSsaliva control in the field of drooling interventions.
Assessment of the preschooler
From the neonatal period up to a certain age, drooling can be regarded as normal. Although 
there is discussion among professionals about the minimum age at which children should 
be referred to an interdisciplinary saliva-control team, the policy in our team is to examine 
the children from the age of four years. Nowadays, however, SLTs experience an increasing 
number of questions and concerns from parents of younger children. In general, parents 
become worried when the severity and frequency of drooling seems to be more than in 
peers. Indeed, the normal intensity of drooling in children under the age of four is repeatedly 
subject to debate. Therefore, we developed a parental questionnaire abbreviated as DRIPS 
(Drooling Infants and Preschoolers Scale), and validated this scale to fill this gap (chapter 
2). Although in the literature it is generally accepted that drooling ceases after the age of 
four years, our study provided evidence that a substantial part of the typically developing 
preschoolers (3-15%) are still drooling to a certain extent at four years of age. Hence, the 
question arises from what age drooling has to be considered as pathological. The answer 
to this question is crucial for saliva-control teams and formed the basis to develop an 
evidence-based algorithm for the treatment of drooling (this chapter). Based on the results 
of the DRIPS study, we suggest to use the 97th percentile on the DRIPS charts as the cut-off 
value for pathological drooling and to consider DRIPS scores above the 85th percentile as an 
indication of deviated saliva control. In both these instances, children should be referred to 
an SLT for oral motor therapy. 
The use of the DRIPS essentially changed the approach of our saliva control team 
and, more generally, the referral to SLTs for further treatment. When children below the age 
of four years are referred to our team, parents are advised to fill out the DRIPS. Based on 
the DRIPS scores and charts a personalized approach is taken. When the percentile score is 
below the 85th percentile no treatment will be started, but it is advised to the primary-care 
SLT to monitor the child by means of the DRIPS (parental questionnaire) every three months. 
When the percentile scores of one or more DRIPS factors is above 85, oral motor treatment 
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by specially trained SLTs is advised. In the Netherlands, recently developed workshops are 
available to instruct SLTs to assess and interpret the individual DRIPS profiles. In the age 
group under four years, only children that present with symptoms of posterior drooling (not 
visible dripping, saliva aspirations) are encouraged to consult our saliva-control outpatient 
clinic.
Assessment of dysphagia and drooling
After optimizing any neurological dysfunction (in particular dysfunctions of the brain-gut 
axis) (chapters 3 and 7), the SLT focuses on the clinical evaluation of swallowing, the impact 
of dysphagia on general health, and the impact of swallowing and feeding impairments on 
quality of life. One of the first steps in the clinical evaluation of oral motor performance is 
to determine what contributing conditions cause the child to drool and whether the child 
aspirates during feeding, aspirates saliva (posterior drooling), or spills saliva from the mouth 
(anterior drooling). The distinction between anterior and posterior drooling is important 
because both problems need their own approach as shown in figure 2 in this chapter.
In children with CP, a close connection can be expected between drooling and 
aspiration of saliva and food.6 Drooling often occurs simultaneously with eating and 
drinking problems, because all of these problems are related to dysfunctions in the oral and 
oropharyngeal phases of swallowing. Thus, a close relationship between eating and drinking 
ability, dysphagia, and drooling is likely, although the literature to support this relationship 
is still scarce. Based on a study by Tas et al.7, a significant difference of eating and drinking 
abilities was found between a group of CP children who drooled and a group who did not. 
They were able to establish that when head control improves, drooling severity diminishes. 
They also showed that drooling severity increased with decreasing body-mass index. This 
could be explained by the fact that children who experience saliva and food loss are at 
greater risk of malnutrition due to their disturbed oral motor performance. Generally, they 
determined that drooling affected nutrition and that drooling control was affected by head 
control. The notion that drooling affects nutrition is corroborated by the results of our study 
regarding the adverse effects of submandibular botulinum toxin injections for drooling 
(chapter 8). We found that existing swallowing problems (e.g. choking on drinks, food or 
saliva) increased in 88% of the children who experienced adverse effects after treatment 
(33%) which shows the vulnerability of the oral motor system. If the EDACS classification 
gives rise to doubts about the safety of swallowing, it is essential to investigate efficiency and 
safety of swallowing with an objective evaluation prior to drooling treatment. Instrumented 
evaluation by videofluoroscopy or fiberoptic endoscopy of swallowing (FEES) may be 
indicated for children with neurodisabilities if further information is needed to determine 
the nature of the swallowing disorder. Instrumented evaluation can also help to find out if 
swallow safety can be improved by modifying food texture, liquid consistency, volume and 
rate of feeding, or positioning. 
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Most of the quantitative scales for children with anterior drooling were not designed 
to measure posterior drooling. In patients with posterior drooling, practitioners are typically 
dependent on clinical information to assess drooling severity such as signs and symptoms 
of recurrent respiratory tract infections, number of episodes of respiratory infections and 
antibiotic use, history of chronic lung disease, and the need for frequent suctioning. Because 
posterior drooling is often suspected in children with severe oropharyngeal dysphagia, we 
developed and piloted the Pediatric Posterior Drooling Scale (PPDS).8 The PPDS is a new 
screening tool to score the presence and severity of posterior drooling with the use of 
cervical auscultation. The PPDS scores the quality of breathing and swallowing using a 5-point 
scale. Previous research has shown that cervical auscultation may be used to evaluate post-
swallow respiration.9-11 The PPDS can be scored reliably by experienced SLTs and may be 
an appropriate screening tool to score the presence and severity of posterior drooling in 
children with central neurological disorders. It can also be used to evaluate interventions 
for posterior drooling. However, further research has to be done to definitively establish 
the reliability and validity of the scale in a larger population. Until then, we use the PPDS 
as a screening instrument to measure the effect of a drooling intervention on saliva pooling 
before and after treatment. The diagnostic position of the PPDS is illustrated in figure 1 of 
chapter 6.
In contrast, the severity of anterior drooling can be assessed with a range of objective 
and subjective measures. Quantifying the severity and frequency of drooling is important, 
particularly because it allows for tracking of symptoms during consecutive interventions. 
The shortened version of the drooling quotient (DQ5) is proven to be reliable (chapter 5) 
and the DQ5 during daily activities appears to be the objective measure of choice for use in 
clinical practice and research. A cut-off point has been introduced that could serve as a ‘rule 
of thumb’ for decision-making in drooling treatment. A DQ ≥ 18% means that the drooling 
problem is frequent and/or has not been satisfactorily resolved by previous treatment. 
This cut-off point is useful in clinical decision making. Children with a DQ < 18% may be 
eligible for more conservative treatment, such as oral motor training or behavioral therapy. 
In children with a higher score (DQ ≥ 18%), invasive interventions such as botulinum toxin 
injections or surgery may be the therapy of choice, combined with oral motor treatment or 
behavioral therapy. In one of our studies on the adverse effects of submandibular botulinum 
toxin injections (chapter 8) we also found that the cut-off DQ point(< 18%) is one of the 
independent predictors of adverse effects. Children with a pre-treatment DQ < 18%  are more 
likely to experience adverse effects than children with a higher pre-treatment DQ. This could 
be explained in two ways: children with a DQ < 18% may experience too much dryness of the 
mouth after treatment, which interferes with mastication, or children with a DQ < 18% are 
more likely to suffer from posterior drooling. Overall, it is possible that children have more 
problems to process the reduced but thickened saliva after treatment,12 as their oral motor 
dysfunction makes them vulnerable to adverse effects. These results underline the need of 
a precise and accurate pre-treatment oral motor performance assessment. Obviously, our 
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team does not use this cut-off point as the only indicator of the need for invasive treatment, 
as we argue that a combination of objective and subjective measurements is preferable to 
decide if and what treatment is necessary and to evaluate treatment effects.  
Figure 2. A stepwise approach to the clinical management of drooling at the Amalia children’s hospital of the 
Radboud university medical center, Nijmegen, the Netherlands.
Legend: DRIPS= Drooling Infant and Preschoolers Scale, P= Percentile, BoNT = Botulinum Toxin -A
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A stepwise approach to the clinical management of drooling
The flowchart outlined in figure 2 is based on the results of this thesis as well as on previous 
research from our swallow and saliva-control team and starts with a solid assessment of oral 
motor performance to decide which treatment option is most appropriate for an individual 
child in a specific developmental stage. Several differences in treatment approaches became 
apparent when our team collaborated with an international peer group to construct a 
care pathway for sialorrhea (drooling) for the American Academy for Cerebral Palsy and 
Developmental Medicine (AACPDM)13 (chapter 6). The current literature did not allow the 
development of a uniform evidence-based worldwide guideline for the clinical management 
of drooling. Therefore, the review in chapter 6 does not delineate a specific order of 
interventions for drooling, but highlights the treatment options as well as the published 
evidence for each intervention. Global differences in approach were found regarding the 
age at which interventions should take place, the treatment sequence or treatment choice.
Global similarities and differences in drooling treatment
In most teams abroad, oral motor therapy is seen as the first mandatory step in the treatment 
of drooling. However, we argue that oral motor therapy should only be considered after 
identifying and optimizing risk factors which may exacerbate drooling (e.g. incomplete 
oral health, inadequate posture and positioning, head instability, malocclusion, airway 
obstruction, excessive mouthing). Our clinical experience suggests that oral motor therapy 
is most effective in children with mild to moderate oral dysfunction and good cognitive skills, 
who are highly motivated to improve their drooling.14 With the recently developed DRIPS, 
teams are able to monitor drooling in infants and preschoolers under the age of four years 
using the parental questionnaire and the charts. Based on this assessment, a customized 
advice to improve factors responsible for the lack of saliva control can be given. More 
research is necessary to develop an evidence-based oral motor treatment for older children. 
In the international literature, most studies on behavioral intervention apply 
techniques for external control of antecedents and consequents of drooling (i.e. instruction, 
cues and feedback from people or devices) with the risk of an increase of drooling after 
the intervention procedure is stopped. The development and implementation of a self-
management program for drooling was reported by our team and attracts worldwide 
interest.15, 16 This program aims to teach self-management skills (internal control) to the 
child with anterior drooling in order to improve the frequency of swallowing and/or wiping 
the mouth and chin and teach the child to monitor salvia control.15 The program is suited for 
children with a mental developmental age above 6 years and intrinsic motivation to remain 
dry. Children also must be able to swallow on request before the start of a self-management 
program. That is why oral motor therapy to teach active swallowing often is advised before 
the start of behavioral intervention.
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There is a large variation worldwide with respect to the earliest age at which treatment 
with botulinum toxin is offered. Since 2001, such injections were described by Jongerius et 
al. as a new treatment option for drooling in children with CP.17 At present, the minimum 
age for botulinum toxin treatment in the Netherlands is four years, with an exception for 
younger children who suffer from posterior drooling and who need urgent treatment to 
prevent saliva aspiration.18 The reason for applying a minimum age in our team is supported 
by the DRIPS study.19 Nowadays, we are able to monitor saliva control under the age of four 
years, so that we can treat preschoolers based on their specific drooling profile. Other teams 
sometimes inject children with anterior drooling around the age of two years.
Although there is an international consensus statement on the treatment of drooling 
with botulinum toxin injections,3 no consensus exists as to which salivary glands should 
be injected in first instance. The submandibular glands are responsible for the majority 
of salivary production at rest, whereas the parotid glands are mainly functional during 
mastication and digestion of food. Thus, when botulinum toxin injections are indicated, our 
team decided to start with injecting the submandibular glands only. It was expected that 
injections in the submandibular glands would sufficiently diminish salivary flow to reduce 
drooling, whilst preserving saliva excretion by the parotid glands during eating and drinking. 
This last aspect is particularly important for children with dysphagia. Although some authors 
share our policy, in many countries it is common to inject both the submandibular and parotid 
glands as the first step in the treatment of drooling with botulinum toxin. This approach 
may, however, imply overtreatment since previous studies18, 20 and the research reported in 
chapter 9 have shown that there is a large proportion of children that sufficiently respond to 
submandibular gland injections alone. Hence, we argue that submandibular gland injections 
are satisfactorily effective if patients are carefully selected and receive an adequate follow-
up. Due to their temporary effect, botulinum toxin injections need to be repeated if the child 
appears to be a responder at follow-up. When there is no (or an unsatisfying) response, the 
parotid glands may still be injected in second instance, along with the submandibular glands. 
Because the parotid glands are mainly active following tactile and gustatory stimulation, the 
SLT has to judge the food consistency and the swallow and chewing capacities of the child 
before treatment of these glands with botulinum toxin. In addition, parents should be given 
specific advice for the period following this intervention. 
Various surgical options exist for the treatment of drooling. Generally, our team 
offers surgery to children above the age of 10 years, as we want to await the development 
of oral motor skills and growth of the mouth area. Submandibular duct relocation combined 
with excision of the sublingual glands is considered to be the most effective intervention 
by all saliva-control teams. There is an attractive physiological principal underlying this 
type of surgery. It’s aim is not to diminish salivary flow, but to relocate the ducts of the 
submandibular glands towards the base of the tongue where saliva is triggering the swallow 
reflex. This treatment option is, however, only possible in children with a safe pharyngeal 
swallow function and without posterior drooling, which is why prior to intervention a 
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thorough oral motor assessment is needed. Our team has proven that submandibular duct 
relocation combined with excision of the sublingual glands appears to be safe and effective 
in diminishing visible drooling in children with neurological disorders, particularly in children 
aged 12 years or older with a safe pharyngeal swallow function and without a protracted 
head position.21 In contrast, bilateral submandibular gland excision is the procedure of 
choice in children with neurological disorders who drool due to severe dysphagia, in whom 
submandibular duct relocation is contraindicated. A previous study of our team showed 
that drooling intensity was significantly reduced compared to baseline following this type 
of surgery.22 
Recently, a randomized controlled trial has been conducted in which botulinum toxin 
treatment of the submandibular glands was compared with bilateral submandibular duct 
ligation (2-DL).23 This study suggested that 2-DL could be an effective follow- up therapy after 
botulinum toxin treatment, since 2-DL proved to be more effective for drooling reduction 
than the use of botulinum toxin. The exact position of 2-DL in the treatment of drooling has 
yet to be determined. 
Another difference in treatment approach between our team and other saliva-control 
teams worldwide is the use of anticholinergic medication. Currently, there is evidence 
that glycopyrrolate is recommended (before scopolamine) as a first-line pharmacological 
agent for anterior drooling in children with CP.24 However, in our team we are reluctant to 
prescribe anticholinergic drugs because of their side effects and because published safety 
data are not yet available beyond 24 weeks treatment duration. As stated by the European 
Medicine Agency (EMA), total treatment duration should be kept as short as possible, 
given the limited long-term safety data available and the uncertainties about the potential 
carcinogenicity of anticholinergic drugs. We believe that, only if no other treatment is 
effective and anesthesia brings about too great a risk, anticholinergic drugs may be used to 
treat drooling, provided that the side effects are carefully monitored. The most disturbing 
side effect of anticholinergic medication, just as of botulinum toxin, is thickening of saliva. 
This is the reason why, in the process of deciding how to reduce (the impact of) drooling, the 
adverse effects of these treatments on mastication and swallowing should be considered. 
Future research
Despite scientific developments, dysphagia and drooling remain extremely challenging 
clinical problems, particularly in (young) children with neurological disabilities. From 
this perspective, a strong case can be made for a mechanism-based and, at the same 
time, personalized treatment approach. Such an approach requires the unraveling of the 
pathophysiology of dysphagia and drooling in detail. For instance, there is still little insight 
in why one child with CP drools and the other child with exactly the same type and severity 
of CP does not. ‘Unawareness to swallow’ is often taken as an explanation. However, 
to improve and develop mechanism-based therapies for drooling, more knowledge is 
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essential. For instance, one can train ‘awareness of drooling’ only if there is adequate 
sensibility, whereas one must learn compensatory tricks (e.g. performing visual checks in 
the mirror) if there is lack of sensibility. In our clinical practice, we notice children with saliva 
loss who are unresponsive to the feeling of getting a wet chin. Because sensibility testing 
is challenging and maybe unreliable in this group of children, we intend to conduct a pilot 
study with short- and long-latency Somato Sensory Evoked Potentials (SSEP) to investigate 
the relationship between drooling and oral sensation. Another way to get insight in the 
mechanisms underlying dysphagia is the use of ultrasound to assess the quality of the 
muscles involved in the swallowing process, like van den Engel-Hoek et al. suggested.25, 26 
Moreover, it is necessary to improve the clinical usefulness and accuracy of the 
DRIPS and the EDACS. Cross-sectional data have been acquired in the DRIPS study, but a 
longitudinal study still needs to be conducted. Future research should preferably investigate 
long-term data on saliva control in typically developing children as well as in children with 
pathological saliva loss. Looking back critically at the process of developing the DRIPS, it 
would have been of value to widen the inclusion of participants up to six years of age, 
because it turned out that some of the typically developing children still lose saliva at four 
years of age. Furthermore, the relationship of the EDACS score with drooling has not yet been 
elucidated. We hypothesize that children with EDACS levels I, II or III are most likely to suffer 
from anterior drooling, whereas children classified as EDACS level IV or V are more likely 
to show posterior drooling. A related challenge is to investigate the relationship between 
EDACS level and nutritional status in order to improve health related feeding issues. This is 
something to look at in a natural history study.
The existing global differences in the use of botulinum toxin also emphasize the 
need for further clinical studies in this area. At the moment, our team advices bilateral 
injections into the submandibular glands as a first step, followed by combined injections 
into the four major salivary glands (bilateral submandibular and parotid glands) as a second 
step to manage drooling. To determine if the ‘foreign’ (combined) approach might be more 
effective, we  intend to conduct a comparative study and, at the same time, examine the 
characteristics of non-responders to improve treatment selection. 
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Nederlandse samenvatting
Gezonde mensen zijn zich meestal niet bewust hoe vanzelfsprekend en gemakkelijk zij eten, 
drinken en (speeksel) slikken. Op het moment dat de mondmotorische uitvoering ‘even’ 
moeizaam verloopt kunnen zij zich aanpassen door bijvoorbeeld de hap wat langer in de 
mond te houden, de hap beter te kauwen, een kleinere slok te nemen of desnoods het eten 
of speeksel uit te spugen. Dit aanpassingsvermogen hebben kinderen met neurologische 
ontwikkelingsproblemen niet. Dit geldt in het bijzonder voor kinderen met Cerebrale 
Parese (CP) of kinderen met ernstig meervoudige beperkingen (EMB). Voor hen is het een 
uitdaging om te kauwen, drinken en slikken op een efficiënte en veilige manier. Het risico op 
slikproblemen in de orale (mond) en/of faryngeale (keel) fase, en de constante aandacht die 
nodig is voor het veilig en efficiënt eten en drinken, hebben grote impact op het dagelijkse 
leven voor zowel het kind als de verzorgers. Onvoldoende intake van voedingsstoffen of 
ernstige aspiratie (verslikken) van voeding of speeksel kan negatieve consequenties hebben 
voor de algehele gezondheid van het kind.
Hoofdstuk 1 bevat een algemene introductie over ‘oral motor performance’ (de uitvoer van 
oraal motorische bewegingen voor bijvoorbeeld slikken en speekselcontrole) waarin wordt 
gerefereerd  aan de moeilijkheden die kinderen met neurologische ontwikkelingsproblemen 
zoals CP, kunnen hebben bij de uitvoering van mondmotorische vaardigheden in het dagelijks 
leven (eten, drinken, slikken en speekselcontrole). De eet-, drink- en slikproblemen hangen 
vaak samen met de gestoorde mondmotoriek, een abnormale neurologische rijping en 
aansturing en houdings- en bewegingsstoornissen. Gedegen diagnostische onderzoek naar 
slikstoornissen (dysfagie) en speekselverlies (drooling) is belangrijk voor de juiste interventie. 
Het primaire doel is dan ook om de gezondheidsgerelateerde kwaliteit van leven, voor zowel 
het kind als de verzorgers, te verbeteren zodat participatie in het dagelijks leven wordt 
vergemakkelijkt. In verband met de complexe problematiek van deze kinderen wordt een 
teambenadering aanbevolen voor het onderzoeken en behandelen van de kinderen. In de 
introductie wordt een beschrijving gegeven van bestaande diagnostische instrumenten en de 
geconstateerde hiaten in het onderzoek naar ‘oral motor performance’. De gevonden hiaten 
vormden de basis van de studies die worden gepresenteerd in deel I van dit proefschrift. De 
behandeling van speekselverlies heeft als doel om het zichtbare speekselverlies (anterior 
drooling) te doen afnemen maar ook om het verslikken in speeksel (posterior drooling) te 
verminderen, zodat het leven van het kind en de verzorgers aangenamer wordt. Sinds 2001 
hebben verschillende leden van het slik- en speekselcontroleteam hun PhD project afgerond 
en zijn er vele studies verricht naar dysfagie en de behandelaspecten van speekselverlies. 
Hoewel significante vooruitgang is geboekt in de behandeling van speekselverlies bij 
kinderen met neurologische ontwikkelingsstoornissen, zijn er nog steeds substantiële 
hiaten in onze kennis over de manier waarop het onderzoek en de behandeling op maat 
moet zijn voor ieder kind. Het tweede deel van dit proefschrift is dan ook gewijd aan het 
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ontwikkelen van een evidence informed (op bewijs gestoelde) en kindspecifieke benadering 
van de behandeling van speekselverlies. Er wordt met name aandacht besteed aan de 
nadelige effecten van Botuline Toxine A injecties in de speekselklieren op de ‘oral motor 
performance’. Tevens wordt de klinische responsdefinitie zoals gehanteerd binnen onze 
klinische en research praktijk geëvalueerd.
In hoofdstuk 2 wordt een beschrijving gegeven van de ontwikkeling van speekselcontrole 
bij normaal ontwikkelende kinderen tussen 0 en 4 jaar, gebaseerd op gegevens van 652 
vragenlijsten. Om de ernst en frequentie van het speekselverlies te kwantificeren werden 
gegevens verzameld door middel van een gevalideerde oudervragenlijst (Drooling Infants 
and Prescoolers Scale; DRIPS). De DRIPS bestaat uit 20 items en is ontwikkeld om de ernst 
en frequentie van het speekselverlies te identificeren gedurende dagelijkse activiteiten. 
Geslachtspecifieke referentiegrafieken zijn samengesteld met percentielcurves voor 
de mate van speekselverlies tijdens activiteiten, eten en drinken, niet voedend zuigen 
(speen of duim) en tijdens slaap. Om de ontwikkeling van speekselcontrole te illustreren 
worden er 8 specifieke referentiegrafieken gepresenteerd waar de scores van de DRIPS, 
per leeftijdsgroep, kunnen worden afgezet tegen de 15e, 50e, 85e en 96e percentiel lijnen. 
Tussen de 3-15% van de kleuters in het cohort had nog geen volledige speekselcontrole 
bereikt op de leeftijd van 4 jaar.
In hoofdstuk 3 wordt een overzicht (review) gepresenteerd betreffende slikstoornissen 
bij kinderen met cerebrale parese. CP is de meest voorkomende oorzaak van motorische 
beperkingen bij kinderen met een wereldwijde prevalentie van ongeveer 2 tot 2,5 per 
1000 levend geboren kinderen. Kinderen met CP hebben vaak een beperkte ‘oral motor 
performance’ met gevolgen voor het slikken, soms resulterend in (ernstig) speekselverlies. 
Zowel anterieur speekselverlies (zichtbaar speekselverlies uit de mond), als ook posterieur 
speekselverlies (speekselstase in de keel of speekselaspiratie) kunnen voorkomen. Een 
opzet voor de wijze waarop slikproblemen bij CP kunnen worden onderzocht of behandeld 
wordt voorgesteld.
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Hoofdstuk 4 beschrijft het onderzoek naar de interbeoordelaarsbetrouwbaarheid, de 
construct validiteit en de gebruiksvriendelijkheid van het Eating and Drinking Ability 
Classification System (EDACS) bij 149 Nederlandse kinderen met CP. Een volgens officiële 
weg vertaalde Nederlandse EDACS versie is gescoord door verschillende logopedisten 
(één bekend met het kind en één onbekend met het kind). Ouders hebben het EDACS ook 
geclassificeerd bij hun kind aan de hand van het klinische stroomdiagram in figuur 1.
Niveau IV
Eet en drinkt met 
aanzienlijke 
beperkingen 
t.a.v. veiligheid.
Niveau III
Eet en drinkt met 
aantal beperkingen 
t.a.v. de veiligheid; er 
kan sprake zijn van 
beperkingen t.a.v. de 
doelmatigheid.
Niveau II
Eet en drinkt veilig 
maar met een aantal 
beperkingen ten 
aanzien van de 
doelmatigheid.
Niveau I
Eet en drinkt veilig 
en doelmatig
Kan de persoon eten 
en drinken in 
hetzelfde tempo als 
leeftijdgenoten?
Kan de persoon  
voeding en vocht
doorslikken zonder
risico op aspiratie?
Kan aspiratie risico 
met maatregelen 
worden 
voorkomen?
Kan de persoon 
bijten en kauwen 
op harde structuren 
zonder risico op 
verstikking?
Eating and Drinking Ability Classication System - Algorithm
Niveau V
Niet in staat veilig te 
eten of drinken
sondevoeding kan 
worden overwogen.
Nee
Nee
Nee
Nee
Ja
Ja
Ja
Ja
Figuur 1. klinisch stroomdiagram EDACS.
De gebruiksvriendelijkheid van het EDACS was over het algemeen goed. Er was een 
goede overeenstemming in classificeren tussen de logopedist die het kind kent en de 
logopedist voor wie het kind onbekend was (n=31). Ook de 81 ouders bereikten een goede 
overeenstemming met de classificatie van logopedisten. Er was een significante, positieve 
correlatie tussen het EDACS en de Dysphagia Management Staging Scale (DMSS). Gebaseerd 
op deze resultaten kon geconcludeerd worden dat de Nederlandse versie van het EDACS 
betrouwbaar en valide is en gebruikt kan worden door zowel logopedisten die bekend zijn 
met het kind als onbekend met het kind. We verwachten dat door het gebruik van het EDACS 
de bewustwording ten aanzien van veiligheid en efficiëntie van eten en drinken toeneemt 
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bij de verschillende betrokkenen en dat zorgprofessionals en ouders vaker dezelfde taal 
zullen spreken.
In hoofdstuk 5 hebben we de Drooling Quotiënt 10 minuten (DQ10) versie en de Drooling 
Quotiënt 5 minuten (DQ5) versie onderzocht als objectief meetinstrument voor het 
evalueren van de ernst van speekselverlies voor en na behandelingen. Er waren geen data 
bekend over de validiteit en betrouwbaarheid van de DQ10 en vanuit klinisch oogpunt zou 
het waardevol zijn om de observatie/scoringtijd te reduceren. Uit onderzoek is gebleken 
dat de DQ10 onderling uitwisselbaar is met de DQ5. Daarmee is de DQ5 dus tijd-, en 
kostenbesparend, terwijl de validiteit en de interbeoordelaars-, en intrabeoordelaars-
betrouwbaarheid behouden blijven. Er wordt een afbreekpunt voorgesteld dat behulpzaam 
kan zijn voor klinische besluitvorming.
In hoofdstuk 6 (deel 2) wordt een internationale, op wetenschap gebaseerde benadering 
gepresenteerd die is voortgekomen uit het zorgpad voor speekselverlies (sialorrhea) van 
de American Academy for Cerebral Palsy and Developmental Medicine (AACPDM). Een 
uitgebreid overzicht van zowel het diagnostische als interventieproces voor speekselverlies 
bij kinderen en jongeren met CP tot de leeftijd van 25 jaar is beschreven. Dit review bevat 
de gevonden niveaus van evidentie voor het onderzoek en de behandelvormen van 
speekselverlies wat betreft oraal motorische interventies, gedragstherapie, orale applicaties, 
farmacologische behandeling, chemodenervatie bij Botuline Toxine en chirurgische 
interventies. Stroomdiagrammen voor onderzoek en behandeling worden weergegeven.
Hoofdstuk 7 beschrijft de gepersonaliseerde benadering van speekselverlies bij een 
specifieke groep kinderen met progressieve dystonie (MEGDEL syndroom). De heterogeniteit 
van de vier gepresenteerde casussen laat zien dat een stapsgewijze en op maat afgestemde 
benadering noodzakelijk is. 
In hoofdstuk 8 wordt het onderzoek beschreven dat verricht is naar nadelige effecten op de 
oraal motorische functies ná injecties met Botuline Toxine in de submandibulaire klieren. Dit 
onderzoek is verricht bij 209 kinderen met hinderlijk speekselverlies. Tijdelijke bijwerkingen 
traden op in 33% van de 209 behandelingen. Bijna 80% van de bijwerkingen werd als 
mild beschreven en bijna 9% als ernstig. Ongeveer 54% van de bijwerkingen verdween 
spontaan binnen 4 weken terwijl 3% persisteerde na 32 weken. Een diagnose CP, een hogere 
dosis Botuline Toxine en een DQ5 van < 18 in de voormeting, waren de onafhankelijke 
voorspellers voor bijwerkingen. Het is belangrijk dat vóór het gebruik van Botuline Toxine 
voor speekselverlies mogelijke bijwerkingen worden besproken. Het is tevens van belang 
om de oraal motorische functies goed te monitoren want een reeds bestaande dysfagie 
kan verergeren. De geïdentificeerde klinische voorspellers kunnen behulpzaam zijn bij het 
verbeteren van de patiëntselectie voor deze behandeling.
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In hoofdstuk 9 worden bij 160 kinderen, die Botuline Toxine in hun submandibulaire klieren 
kregen in verband met speekselverlies, de veranderingen in objectieve en subjectieve 
metingen van de speekselernst geëvalueerd. Tevens wordt de wederzijds relatie tussen de 
metingen onderzocht. Een klinische respons was gedefinieerd als ≥ 50% reductie van de 
(objectieve) DQ5 en/of een reductie van minimaal een afname van 2 standaard deviaties 
(SDs) van de (subjectieve) VAS-ernst bij 8 weken na injectie vergeleken met de voormeting. 
Een oudervragenlijst is gebruikt om de impact van speekselverlies bij responders (kinderen 
die voldeden aan de responsdefinitie) en bij non-responders te onderzoeken. Resultaten 
toonden dat er 112 kinderen (70%) responders waren. Hun gemiddelde VAS-ernst en  DQ5 
sores waren significant lager bij de 32-weekse nameting vergeleken met de baselinemeting. 
Verschillen in de veranderingen in impact van speekselverlies op de dagelijkse zorg, 
economische consequenties, de sociale interactie en het zelfbewustzijn zijn weergegeven 
bij responders en non responders. Het bleek dat een klinisch relevante respons, gebaseerd 
op een combinatie van objectieve en subjectieve maten van speekselverlies, gepaard ging 
met positieve veranderingen in de mate van impact.
Hoofdstuk 10 bevat de general discussion waar kritisch wordt terug gekeken op de studies in 
dit proefschrift en gereflecteerd wordt op de consequenties van deze studies. De studies in 
dit proefschrift waren bedoeld om de diagnostiek van ‘oral motor performance’ bij kinderen 
met neurologische beperkingen te verfijnen en om een gepersonaliseerde benadering van 
de behandeling van speekselverlies te ontwikkelen. Deze ambitie was gebaseerd op de grote 
uitdagingen waarmee slik- en speekselcontroleteams worden geconfronteerd tijdens het 
proces van diagnose en behandeling van dysfagie en speekselverlies. In de afgelopen 20 jaar 
hebben meer dan 1000 kinderen het academische slik- en speekselcontroleteam van het 
Radboud universitair medisch centrum bezocht. Deze ervaring, eerder promotieonderzoek 
en de studies die in dit proefschrift zijn gepresenteerd, hebben geleid tot nieuwe inzichten 
met betrekking tot de metingen en behandeling van de ‘oral motor performance’.
Suggesties voor toekomstig onderzoek:
Ondanks wetenschappelijke ontwikkelingen blijven dysfagie en speekselverlies 
uiterst uitdagende klinische problemen, vooral bij (jonge) kinderen met neurologische 
ontwikkelingsproblemen of beperkingen. Vanuit dit perspectief wordt gepleit voor een op 
mechanismen gebaseerde en tegelijkertijd gepersonaliseerde benadering. Een dergelijke 
benadering vereist het ontrafelen van de pathofysiologie van dysfagie en speekselverlies 
in detail. Er is bijvoorbeeld nog steeds weinig inzicht waarom het ene kind met CP kwijlt 
en het andere kind met precies hetzelfde type CP en dezelfde ernst niet. Nader onderzoek 
met behulp SSEP (somato sensory evoked potentials) zal ons wellicht helpen om de relatie 
tussen speekselverlies en orale sensaties te begrijpen.
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De klinische bruikbaarheid en nauwkeurigheid van zowel de DRIPS als het EDACS 
zullen verder moeten verder worden verbeterd.
Daar de Nederlandse speekselreducerende behandeling met Botuline Toxine afwijkt 
van de wereldwijde benadering is het belangrijk om vergelijkende studies te verrichten. 
Ook zullen we ons meer moeten gaan richten op de karakteristieken van notoire non-
responders om zo te begrijpen welke kinderen wel of niet kunnen profiteren van bepaalde 
behandelingen.
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Dankwoord
‘It	always	seems	impossible	until	it’s	done’ (Nelson Mandela)
Wat is het geweldig om een proefschrift te schrijven met zoveel mensen om je heen die 
het je gunnen, meewerken en meeleven. Heel bijzonder dat ik de ruimte heb gekregen om 
het op ‘mijn’ manier te doen. Iedere keer een stukje verder, nooit opgejaagd maar zelf ook 
verrast als er weer een artikel afgerond en gepubliceerd was. Prachtig dat ik deze kans heb 
gekregen en trots dat het gelukt is.
Bij een uitgebreid proefschrift, hoort een uitgebreid dankwoord. Graag zou ik dan ook de 
mensen die dit promotieproces mede hebben mogelijk gemaakt en een belangrijke rol 
hebben vervuld, willen bedanken.
Dank gaat in eerste instantie uit naar al die honderden kinderen met slik, eet- en 
drinkproblemen en hun ouders. Het is ongelofelijk hoe vaak jullie naar het ziekenhuis zijn 
gekomen. Zonder jullie zou er geen proefschrift zijn, zonder de vragen die vanuit de praktijk 
gegroeid zijn geen onderzoeken. Dank voor al jullie inspiratie, vragen en het stimuleren van 
mijn professionele nieuwsgierigheid.
Beginnend bij het begin, wil ik allereerst de mensen van het eerste uur bedanken die mijn 
carrière als logopedist hebben ondersteund en me de kans hebben gegeven om te groeien 
binnen het Radboudumc. Dank gaat uit naar mijn toenmalige docent Mevrouw Angela 
Bomers, die in 1985 vroeg of ik als haar collega in het Radboud wilde komen werken en 
zich nog altijd belangstellend toont voor mijn loopbaan. Dank aan Professor F. Gabreëls, 
het toenmalige hoofd van de kinderneurologie, die mij zelfs tot tweemaal toe heeft 
aangenomen. Hij heeft me gestimuleerd om mezelf uit te dagen als logopedist. Ook grote 
dank aan Professor Jan Rotteveel die vanaf 1986 hoofd was van het IKNC. Hij is diegene 
geweest die niet alleen mij, maar de hele afdeling logopedie gestimuleerd heeft zich verder 
te ontwikkelen en te specialiseren. Door mijn bijdrage aan de promotie van revalidatiearts 
Peter Jongerius groeide mijn nieuwsgierigheid naar wetenschappelijk onderzoek. Wat 
ben ik dankbaar voor de kansen die je dan hebt in academische setting met een hoofd 
logopedie, Dr. Bert de Swart, die overal mogelijkheden ziet, in je gelooft en ‘gewoon’ regelt 
wat nodig is binnen de afdeling kinderrevalidatie. Beste Bert, jij hebt het mede mogelijk 
gemaakt dat ik mijn master kon halen en dit promotietraject in kon gaan. Mede dankzij jouw 
hulp zijn we een sterk academisch team geworden gericht op patiëntenzorg, onderwijs en 
wetenschappelijk onderzoek.
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Professor Geurts, beste Sander, wat een voorrecht om jou als promotor te hebben. 
Belangstellend voor onze studies, kritisch, to-the-point, accuraat en zeer deskundig. Bij het 
nalezen van de artikelen of onderdelen van dit boek, doorzag je binnen no time de logica (of 
onlogica) van een stuk. Je hebt door jouw manier van analyseren en bevragen vele artikelen 
stukken beter gemaakt! Dank je wel voor je stimulerende hulp en steun. We mogen trots 
zijn op zo’n hoogleraar revalidatiegeneeskunde.
Dr. Erasmus, lieve Corrie, jij bent erg belangrijk geweest voor mij als copromotor maar ook 
als collega en vriendin. Met je nuchtere kijk, je snelle blik en de vakkundige wijze waarop 
je naar kinderen kijkt heb ik veel van je vakmanschap geleerd. Samen konden we eerst aan 
jouw promotie werken en tijdens mijn proces stond je, op jouw beurt, ook altijd klaar! Je 
hebt me niet gepusht maar ik voelde dat er altijd vertrouwen was dat het goed zou komen. 
Wat was het leerzaam om te zien hoe jij artikelen tot de kern terugbracht. Corrie, jij hebt 
vanuit je kinderneurologische achtergrond de ‘bulbaire neurologie’ omarmt. Samen met ons 
logopedieteam heb je een slik- en speekselcontrole team opgezet en uitgebouwd. Ik weet 
zeker dat we als afdeling logopedie nooit zo ver gekomen waren zonder jou als coördinator 
slik/droolingteam. Wat mij betreft gaan we door met het leven delen, zowel zakelijk als 
privé, we hebben het goed met elkaar en onze ‘Peters’!
Dr. Jongerius, lieve Peter, voor mij zo’n logische keus dat jij mijn copromotor zou worden. 
Heel stiekem begon mijn carrière als onderzoeker al in 1999 toen jij mijn kamer binnen 
stapte en vroeg of ik mee wilde doen aan je promotieonderzoek. Er moesten kinderen met 
Cerebrale Parese (CP) en hinderlijk speekselverlies worden onderzocht om te bezien of 
injecties met Botuline Toxine-A in de speekselklieren effect hadden op de ernst en mate van 
kwijlen. Natuurlijk had ik daar oren naar, de zorg rondom kinderen met CP, daar lag en ligt 
mijn hart. Het geworstel van deze kinderen met hun bewegingen, hun spraak, het slikken en 
het eten en drinken, daar wilde ik me voor inzetten.
In de loop der jaren ben ik je gaan waarderen als collega en vriend. Prachtig zoals jij denkt en 
nieuwe ideeën genereert. Je bent creatief en origineel en als begeleider ben je rustig maar 
altijd aanwezig. Als er maar iets is wat geregeld moet worden doe je het, klaarstaan voor de 
ander is jouw motto en of dat nu is om een artikel na te kijken en het in leesbaar Engels om 
te vormen of om wat extra financiën te regelen, je doet het! Dank je wel Peter dat je zoveel 
vertrouwen in me hebt en dat we dit tot een goed einde hebben gebracht. Ik hoop dat we, 
samen met Lina en ‘mijn’ Peter, nog veel leuke avonden met etentjes zullen hebben want 
inmiddels zijn onze levens verbonden.
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Veel dank gaat uit naar mijn dierbare, directe collega’s van ’ons team’ t.w. Lenie van den 
Engel-Hoek, Marjo van Gerven, Sandra de Groot, Leenke van Haaften en Marloes Lagarde. 
Wat is het heerlijk om te mogen werken in zo’n stimulerend team waar we plezier hebben, 
elkaar uitdagen, elkaar uit de wind houden, en indien nodig voor elkaar klaar staan. Mede 
door jullie is het mogelijk geweest dat ik mijn promotieproces kon afronden. Als kers op 
de taart hebben we zelfs samen het boek ‘eet- en drinkproblemen bij jonge kinderen’ 
herschreven en geven we cursussen en workshops! Ook collega Sanne Diepenveen, die 
via de koppelstructuur met de HAN, in deeltijd bij ons werkt wil ik bedanken voor de 
samenwerking. Sanne, door jouw komst blijven we op de hoogte van ontwikkelingen binnen 
het onderwijs. Succes met jouw promotie!
Lieve Lenie, als daily supervisor, mede auteur maar zeker ook als mijn collega, ben je 
van onschatbare waarde. Over vrijwel alle (wetenschappelijke en levens)vragen kun 
je meedenken en antwoord geven en met je deskundige kijk weet je mij altijd weer aan 
het denken te zetten of op weg te helpen. Zo bijzonder zoals we samen over het DRIPS 
onderzoek konden discussiëren en je me geleerd hebt hoe ik kon opschrijven wat ik moest 
opschrijven. Ook voor ons team ben jij de drijvende kracht voor nieuwe ontwikkelingen en 
zorg je ervoor dat we onszelf blijven uitdagen. Lenie dank je wel voor je zijn. Fijn dat we ook 
vriendschappelijk veel aan elkaar hebben en elkaar kunnen steunen.
Lieve Marjo, als collega van het eerste uur hebben we heel wat ontwikkelingen samen 
doorgemaakt. Van BOB tot logopedie kinderrevalidatie binnen Amalia, we houden elkaar 
vast. Marjo, door jou heb ik geleerd om naar mezelf te luisteren en mijn gevoel te volgen. 
Jij was het die me telkens voorhield dat het goed was zoals ik het deed, want oh wat is een 
promotieproces een periode met twijfels en onzekerheden. Jij zorgt er regelmatig voor dat 
we als team met twee benen op de grond blijven staan. Mede door jouw vragen en kritische 
blik blijft het wetenschappelijk onderzoek doelgericht ten behoeve van de kinderen in de 
logopedische praktijk. Marjo dank je wel voor de vriendschap en voor alle fijne gesprekken 
die we hebben. Laten we het leven blijven vieren met onze mannen erbij!
Lieve Sandra, trots dat je als paranimf naast me staat vandaag. Je bent mijn directe 
droolingteam-collega en samen hebben we regelmatig kunnen brainstormen over 
ontwikkelingen of ‘speekselverlies’ vraagstukken. Jouw betrokkenheid is hartverwarmend 
en ik ervaar het als bijzonder dat we samen steeds vaker internationaal op pad gaan om 
lezingen te geven op congressen. Daarnaast ben jij mijn maatje als docent bij de workshops 
die we als team hebben ontwikkeld en bij de modules kinderneurorevalidatie. Prachtig zoals 
jij met je haarscherpe analyses en mensenkennis het leven interessanter maakt. Door jouw 
enthousiasme voor het geven en ontwikkelen van onderwijs worden mijn eigen lessen ook 
steeds beter. Dank je wel dat je me altijd steunt en voor me klaarstaat. Op naar nog vele 
mooie jaren en een fijne samenwerking.
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Lieve Leenke, wat mooi om jou te zien groeien van stagiaire tot zeer deskundige collega 
en mede-promovenda. Wat hebben we veel aan elkaar gehad tijdens onze gezamenlijke 
schrijfdagen. Prachtig zoals jij het leven ziet en over het leven nadenkt. Altijd rustig aanwezig 
met een eigen mening en scherpe geest. Geduldig en nauwgezet. Fijn dat we elkaar altijd 
vinden op momenten dat we even willen brainstormen. Mooi ook dat we samen binnen de 
genetica optrekken om dat stuk van ons vakgebied verder te ontwikkelen. Leenke, op naar 
jouw promotie!
Lieve Marloes, onze ‘jongste’ collega maar eentje die zich vliegensvlug de academische 
taken eigen heeft gemaakt. Als collega, mede droolingteam-lid en promovenda ben je 
zeer waardevol voor ons als team. Je hebt inmiddels al een onmiskenbare plek! Nieuwe 
ontwikkelingen pik je razendsnel op en zo help je ons verder (zoals bijvoorbeeld bij het 
omzetten van de droolingdatabase naar Castor). Fijn zoals jij nieuwe energie aan het team 
geeft!
Beste overige drooling-team leden, wat mooi zoals we elkaar in de loop der jaren hebben 
gevonden en de zorg voor het kind met speekselcontrole problemen hebben uitgebouwd. 
In de rij met promoties rondom dit onderwerp ben ik de vijfde, Peter Jongerius, Jan van 
der Burg, Corrie Erasmus, Arthur Scheffer zijn mij voorgegaan en na mij zullen er nog zeker 
3 volgen; Corinne Delsing, Saskia Kok en Stijn Bekkers. Ik kijk uit naar jullie promoties! Fijn 
zoals we elkaar kunnen helpen en samen kunnen nadenken over het ‘speeksel’ probleem.
Dr. van den Hoogen, beste Frank, vanuit de KNO ben jij de stimulator voor vele promoties 
binnen jullie afdeling. Ik weet dat dit stuk van je vakgebied ook een beetje “hobby” is, 
we delen de liefde voor deze groep kinderen en hun ouders. Met je deskundige blik maar 
ook met je ongedwongen humor ben je een belangrijk teamlid. Dank voor je bijdragen als 
medeauteur van een aantal artikelen. Ontzettend fijn dat de KNO de taak van Peter heeft 
overgenomen en dat jullie naast de chirurgische interventies ook de Botuline Toxine injecties 
op jullie hebben genomen. Ik hoop dat we nog lang mogen samenwerken in dit team!
Dr. Scheffer, beste Arthur, dank voor de wijze waarop je onze kennis voor het kind met 
speekselverlies verder hebt gebracht en je bijdragen aan ons team! Het is mooi om te zien 
hoe gegroeid je bent in de afgelopen jaren van jonge assistent tot krachtige KNO arts. Fijn 
dat je ons team blijft versterken.
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Dr. van der Burg, lieve Jan, als orthopedagoog en GZ-psycholoog vanuit de Sint 
Maartenskliniek en de Radboud Universiteit leer jij ons naar de impact van speekselverlies 
kijken voor ouders en kind. Daarnaast is het voor het logopedische vakgebied ontzettend 
leerzaam om jouw zelfmanagement strategieën voor speekselverlies te begrijpen en te leren 
hoe wij als logopedisten slikgedrag kunnen aanleren. Met je rustige wijze van nadenken en 
je diepzinnige ideeën heb je menig artikel verfraaid.
Fijn dan ook dat we zoveel hebben kunnen samenwerken aan het “impact” artikel. Ik 
hoop nog veel van je te leren en wellicht kunnen we in de toekomst een gezamenlijke 
speekselcontrole interventie gaan ontwikkelen! Dank je wel voor je steunende woorden, 
je nuchtere kijk en je positieve instelling. Met je intellectuele humor heb je me menig keer 
weer gerelativeerd. Onze vriendschap wordt gekoesterd.
Noortje Engbers (voormalig orthopedagoog in SMK) en Jody Sohiers (huidige orthopedagoog), 
dank jullie voor jullie bijdragen aan het team.
Hierbij wil ik ook graag de manuscriptcommissie bestaande uit Prof. C. Noordam, Prof. 
J. Vermeulen en Prof. B. Steenbergen hartelijk bedanken voor de beoordeling van dit 
manuscript.
Lieve dames van het kinderrevalidatie secretariaat, te weten Marieke Peters-Eisenburger, 
Daniëlla Giesbers-Vrins en Christine Teunissen. Altijd staan jullie voor ons klaar. De 
patiëntenzorg maar ook de zorg voor ons als paramedici zit in jullie hart. Jullie zijn het 
voorbeeld voor het Amalia ziekenhuis in de persoonsgerichte en kindgerichte zorg. Jullie 
denken mee over de planning en doen er alles aan om ouders en ons tevreden te stellen. 
In het bijzonder wil ik Marieke bedanken die er altijd voor zorgt dat kinderen worden 
opgeroepen op het juiste moment voor metingen, zorgt dat de lijst met kinderen met 
kwijlproblemen (“de droolinglijst”) compleet is en achter de schermen heel veel regelt voor 
het team. Marieke, ik weet als geen ander hoeveel liefde jij in het werk legt en zelfs in 
de nacht, als je een keer niet kunt slapen, zoveel mogelijk namen van kinderen van “de 
droolinglijst” op alfabetische volgorde probeert te bedenken, als een soort schaapjes tellen. 
Marieke fijn om samen te werken, jij maakt het werken voor de kinderrevalidatie een feestje.
Ook dank aan Laurien Honing-Broekland en Dorien Kil, van het stafsecretariaat 
revalidatiegeneeskunde. Dank voor jullie belangeloze hulp bij de praktische zaken rond dit 
proefschrift.
Dr. Feuth, beste Ton, ik leerde je kennen als statisticus toen je na het vertrek van 
Dr. Jan Hendriks zijn taken over nam in de begeleiding van promovendi voor de afdeling 
revalidatie. Ton, jij was in staat om mij te begeleiden in het analyseren van verschillende 
onderzoeken en moeilijke analysen te verrichten waar nodig. Ook al was je met pensioen, 
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je hebt met veel enthousiasme geholpen en je vond het stiekem ook leuk omdat je dochter 
ook logopedist is. Ton, fijn dat ik te allen tijde bij je terecht kon!
Drs. Van der Schaaf, beste Dick, sinds de promotie van Peter maken we gebruik van ‘jouw’ 
database die inmiddels is gevuld met bijna 900 kinderen. Geweldig hoe je via jouw bedrijf 
‘Ooijpolder software’ een databestand hebt gemaakt en het iedere keer hebt aangepast 
zodat nieuwe ontwikkelingen konden worden meegenomen. Inmiddels ben je met pensioen 
(orthopeed SMK) maar ben je altijd bereid om met je fiets naar het Radboud te komen 
om ons uitleg te geven over het aanmaken van o.a. query’s. Dick, “de droolingdatabase’ 
zal waarschijnlijk in 2020 overgaan naar Castor. Nogmaals dank voor al je bruikbare tips 
en hulp. Zonder jou waren er waarschijnlijk niet zoveel data op een gestructureerde wijze 
opgeslagen en dus ook minder artikelen gepubliceerd.
De heer M. Aarts, beste Michel, dank dat je met zoveel enthousiasme ervoor hebt gezorgd 
dat de DRIPS vragenlijst in een werkbaar Excell bestand staat waar vele logopedisten die de 
workshop hebben gevolgd, gebruik van kunnen maken. Dit bestand maakt het werk voor 
logopedisten een stuk eenvoudiger en de uitkomsten van de lijst een stuk overzichtelijker.
Beste mede-auteurs van de verschillende artikelen;
Dr. Lindeboom, beste Robert vanuit de studie EBP heb je meegewerkt aan mijn eerste artikel 
over de Drooling Quotient. Je geduld en je deskundige wijze van lesgeven zijn mij altijd 
bijgebleven.
Prof. Willemsen, beste Michèl, je plek als medeauteur van het artikel over swallowing 
problems bij kinderen met CP laat zien dat jij het werk van Corrie en ons ondersteunt. 
Dank je wel dat je vanuit de kinderneurologie altijd een positief woord hebt voor ons als 
logopedisten en ons werk stimuleert.
Drs. Snik, beste Dorinda, als kinderrevalidatie arts in opleiding hebben we samen hard 
gewerkt aan het EDACS-onderzoek. Wat was het fijn om samen na te denken en stappen 
te zetten. Het was een ingewikkeld onderzoek waarbij we hulp hadden van 30 collega 
logopedisten uit het land en ouders van kinderen met CP. Geweldig hoe iedereen heeft 
meegewerkt. Dank je wel Dorinda en fijn dat je een plek als kinderrevalidatie arts in de Sint 
Maartenskliniek hebt gekregen. Op naar vervolg onderzoek!
Dr. Wortmann en Drs. Blommaert, beste Saskia en Dorian, fijn dat we samen hebben kunnen 
werken aan het artikel over de MEGDEL patiëntjes. We hebben veel van elkaar geleerd!
Drs. C. Kouwenberg, beste Carlyn, als student kwam je voor een wetenschappelijke stage 
bij Corrie Erasmus. Samen hebben we nagedacht over de bijwerkingen van BoNT injecties, 
dank je wel voor je zorgvuldige werk. Succes met je ingeslagen weg.
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Dr. Sellers, dear Diane, thank you for our collaboration during the EDACS study. We stay in 
touch and hopefully we can work together in the future.
Dr. Hughes, Dr. Glader, Dr. Pennington, Dr. Parr and Dr. Reddihough, dear Amy, Laurie, 
Lindsey, Jeremy and Dinah, Thank you all. It is great to collaborate together to improve the 
care for children with saliva loss, in a group of international professionals.
Ook dank voor alle collega’s van de revalidatie, in het bijzonder de collega logopedisten van 
de ‘volwassenkant’ voor hun belangstelling, tips en stimulerende woorden, en de collegae 
(kinder)fysiotherapie en ergotherapie. Zeker ook erkentelijkheid voor Dr. Imelda de Groot, 
Drs. Helma Hijdra, kinderrevalidatie-artsen en voor Gera Peters, physician assistant. Dank 
voor jullie geloof in ons als paramedici en voor de prettige samenwerking! Fijn om steeds 
weer samen na te denken over kinderen.
Collega docenten van de vereniging docenten kinderneurorevalidatie (VDKNR), te weten 
Drs. Ruud Wong Chung, Drs. Florentine Schepers, Drs. Emmeke Faas, Jan Wielders, Caroline 
Scheijmans, Sandra de Groot, Harry Crombag, Ingrid van den Tillaar en Ilse Oosterom. Wat 
ben ik blij met zo’n interdisciplinaire docentengroep om samen na te denken en onderwijs 
te ontwikkelen voor kinderen met CP. Door jullie, maar zeker ook door mijn oud docenten, 
Renee Lenaerts-Ernst, Els Geerdink en dr. Pauline Aarts, heb ik geleerd om ‘totaal’ te kijken 
naar een probleem en vanuit die totaalblik naar een oplossing. Jullie hebben mij mede 
aangezet om verder na de denken over deze groep kinderen.
Ook een uiting van dank aan de collega-logopedisten in Nederland die op welke wijze dan 
ook mee hebben gewerkt aan onze onderzoeken en me hebben geïnspireerd. Onderzoek 
doe je om de praktijk vooruit te brengen en om de zorg voor het kind met eet-/drink- en 
slikproblemen te verbeteren. Ik hoop met dit proefschrift een stapje in die richting te 
hebben gezet.
Zeker een woord van dank voor alle medewerkers binnen het Amalia kinderziekenhuis. Fijn 
om te voelen dat we allemaal een warm hart hebben voor de complexe groep kinderen en 
dat we elkaar vinden als het nodig is!
Dat buren van onschatbare waarden zijn blijkt wel weer uit het feit dat buurvrouw Mariëtte 
van den Berg-Kersten de cover heeft gemaakt van dit boek. Dank voor jullie warme aandacht 
allemaal.
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Naast alle mensen binnen mijn werkveld, gaat mijn dankbaarheid ook uit naar al onze 
vrienden en familie. Op belangrijke en moeilijke momenten in mijn en ons leven waren en 
zijn jullie er altijd! Vriendschap betekent voor mij vertrouwen en onvoorwaardelijk er voor 
elkaar zijn. Samen het leven delen, plezier maken en nadenken over dingen die op ons pad 
komen. Dit gepaard met lekkere etentjes en borreltjes dan kan vriendschap niet stuk.
Mijn allergrootste dank gaat naar mijn overleden ouders (overleden in 2011 en 2017). Zij 
zijn het geweest die altijd klaar stonden voor mij en gestimuleerd hebben om na te denken 
en om nieuwsgierig te blijven. Ik weet dat zij trots zouden zijn en genoten zouden hebben 
van deze dag.
Lieve pap en mam, dit boek draag ik op aan jullie!
Marc, lieve broer, wij gaan samen verder, de liefde voor elkaar en onze overleden broer 
Robert blijft ons verbinden. Wat ben ik blij met zo’n vrolijke, hardwerkende broer met zo’n 
groot hart. Ik houd van de wijze waarop jij iedereen omarmt.
Mw. A. van Hooft, lieve Annie, dank voor je liefde en belangstelling voor ons.
Wat is het mooi om dit proces te volbrengen als je kinderen al ouder zijn en begrijpen 
wat het is om ambities te hebben. Ieder op hun eigen wijze hebben zij mij gesteund en 
gestimuleerd.
Lieve Michiel, fantastisch zoals jij in het leven staat en samen met Felicia en kleine Axel 
geniet. Ik bewonder je talent om naar mensen te kijken, je analytische vermogen en je 
snelle denken. Dank je wel voor het maken van Visio stroomdiagrammen, jij was het die 
mijn ‘simpele’ diagrammen omzette in flowcharts zoals het hoorde. Daarbij bleek ook je 
belangstelling voor mijn vakgebied en konden we echt samen nadenken over de logistiek 
van interventies. Mooi om deze dag te laten samenvallen met jouw 31e verjaardag; proficiat!
Lieve Francesca, wat heb ik je zien groeien als persoonlijkheid. Ik zie je steeds meer stappen 
zetten in het nemen van verantwoordelijkheid en dat past je. Ik bewonder de wijze waarop 
jij, zonder oordeel, klaarstaat voor iedereen. Met je creatieve geest kun je alles of het nu 
gaat om bakken of meubels maken, bloemschikken of schilderen. Een rijkdom om zoveel 
talenten te hebben! Ik zie René en jou altijd hard werken! Fijn dat jij deel uit maakt van ons 
gezin.
Lieve Luuk, met je tomeloze energie, liefde en humor. Mooi om te zien hoe trouw jij bent 
aan je vrienden en familie. Jij bent het die mij verrast met lieve, attente appjes of lekkere 
kopjes koffie. Ik bewonder de wijze waarop je gegroeid bent de laatste jaren. Ik weet zeker 
dat jij nog veel geluk gaat tegenkomen als je zo onbevangen en spontaan in het leven blijft 
staan. Dank je wel voor je fijngevoelige rol in ons gezin.
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Lieve Rosanne, de jongste, mijn paranimf vandaag. Ik heb je niet zomaar gevraagd om deze 
rol op je te nemen. Jij was het die jarenlang in de vakanties de “droolingdatabase” heeft 
ingevuld. Dat deed je zorgvuldig en met belangstelling voor mijn vakgebied. Precies zoals je 
bent: liefdevol, nadenkend, hulpvaardig, spontaan en geïnteresseerd. Ik herken veel in je en 
samen delen we de liefde voor de zorg. Mooi dat we in 2019 eerst jouw bruiloft met Wout 
konden vieren en nu weer een feestje. Ik ben zo trots dat je naast me staat vandaag!
Als laatste een woord van grote dank voor mijn lieve Peter. Zonder jou was dit proefschrift 
er nooit gekomen. Jij was het die mij stimuleerde om niet naast je op de bank te komen 
zitten toen onze toekomst er anders uit ging zien dan we misschien hadden bedacht. Jij 
was het die altijd in mij geloofde en de lekkerste maaltijden voor me neerzette na hard 
werken. Van ‘buitenaf’ keek je mee en kon ik altijd even reflecteren waarbij jij met je 
overview en mensenkennis zinvolle commentaren gaf. Ik bewonder je positieve instelling 
en je doorzettingsvermogen. Ondanks alles hebben we een rijk leven; samen hebben we 
het goed!
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Curriculum vitae
Karen van Hulst was born in Oss, the Netherlands, on December 5th, 1962. She graduated 
from secondary school (VWO, Titus Brandsma Lyceum  in Oss) in 1981 and, thereafter, started 
her bachelor training in Speech and Language Therapy at the Hogeschool Arnhem-Nijmegen 
(HAN) in Nijmegen. Since 1985 she has worked as a speech language therapist in a pediatric 
SLT team, first at the department of Pediatric Neurology and since 2011 at the department 
of Rehabilitation of the Radboud university medical center, Amalia Children’s Hospital, in 
Nijmegen. The pediatric SLT team is involved in research and diagnostic assessment and 
treatment of infants and children with complex oral motor disorders and speech and 
language disorders. Based on scientific research the team has developed several disease 
specific assessment and treatment trajectories for children with neurologic disorders and 
syndromes. The team is working for children all over the country and combines patient care 
with scientific research, that resulted in several studies and publications.
Karen is a member of the swallowing and saliva-control team of the Radboudumc also a 
member and is specialized in dysphagia and drooling in children with neurodevelopmental 
disabilities. The swallowing and saliva controle team integrates pediatric neurology, 
radiology, otorhinolaryngology and rehabilitation and collaborates with the pediatric 
rehabilitation department of the Sint Maartenskliniek, Nijmegen. Since 2000 she has been 
involved in several PhD projects of the saliva control team members. 
Karen obtained her Master of Science (MSc) in Evidence-Based Practice in 2010 at the 
University of Amsterdam (2008-2010). In 2012 she started her PhD training in combination 
with clinical work. In parallel, she has contributed to the development of a national 
evidence-based guideline for the diagnosis and treatment of children with spasticity (under 
the leadership of the Dutch Institute for Health Improvement, 2006, revision 2015) and to 
the development of the national diet-treatment guideline for people with cerebral palsy 
(2018).
In addition, Karen is lecturing and runs courses for healthcare professionals in pediatric 
rehabilitation in the Netherlands via the Vereniging Docenten Kinderneurorevalidatie 
(VDKNR), organized in collaboration with the Radboud Health Academy. She is also a member 
of the board of the Dutch Academy of Childhood Disability. During her PhD, Karen presented 
her work at several (inter)national conferences. After her PhD defense, Karen will continue 
to combine her clinical work with scientific research in her inspiring and enthusiastic SLT 
team.
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PhD Portfolio
Courses
Courses and workshops Year ECTS 
Master of science EBP, University of Amsterdam 2010 95
Donders introduction course, Radboud university medical center 2015 0.6
Academic writing, Radboud university medical center 2015 3
Writing week, department of Rehabilitation, Radboud university medical center 2017 and 2018 4
TOTAL 102.6
Lectures and conferences (part of them)
Year ECTS 
Proof of teaching at the HAN 2011-2018 40
Prelogopedie symposia Nijmegen (organization and speaker) 2011-2015 6
International Cerebral Palsy Conference (speaker) 2012 1
American Academy Cerebral Palsy Developmental Medicine (AACPDM) Milwaukee 
(speaker mini symposium)
2013 1
Dutch-ACD, Learn to move symposium (speaker workshop) 2014 1
EMG platform (speaker) 2014 0.3
NVAVG teaching course (speaker) 2015 0.5
Gruppo Italiano de Studio della Disfagia (GISD) (speaker) 2015 1
European Society for Swallowing Disorders (ESSD) (speaker) 2014, 2015,
2016, 2018
4
European Academy Childhood Disabilities (speaker and poster presentations) 2014, 2015,
2017, 2019
8
Vlaamse Vereniging voor Logopedie, Brussel (speaker) 2017 0.5
Symposium Samen Eten, Samen sterk, Rotterdam  (speaker) 2017 0.5
Tutor at the pediatric Neurorehabilitation Course the Netherlands 2012-2018 40
TOTAL 103.8
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Data management form
General information about the data collection
This research project involves human subject data. Oral or written informed consent for 
collecting such data was obtained from the participants and/or from their parents (or legal 
representatives) for those younger than 18 years old. All studies have been reviewed by 
the ethics committee on the basis of the Dutch Code of conduct for health research, the 
Dutch Code of conduct for responsible use, the Dutch Personal Data Protection Act, and the 
Medical Treatment Agreement Act. 
FAIR  principles
Findable: 
New data were collected and stored in a secure “drooling” database (named DROOLING_
TBL_2007.MDB), on a protected server at the department of Rehabilitation of the Radboud 
university medical center. The datasets are named: DB_DRIPS, DB_EDACS, DB_DQ5, 
DB_NEGEFFBoNT and DB_CHANGEIMPACT. Documentation (i.e. read me file) to describe 
the datasets is provided on the department server. At the end of 2019, the ACCESS database 
Drooling.version 2.0.9. will be converted to CASTOR.
Accessible: 
Only members of the research group have access to the database. Paper records are stored 
in the department’s archive. It is not yet possible to make the data available in a public 
repository. However, all data will be available on request by contacting the staff secretary of 
the department of Rehabilitation of the Radboud university medical center (secretariaatstaf.
reval@radboudumc.nl). 
Interpretable: 
Documentation has been added to the datasets to make them interpretable. The 
documentation contains links to publications, references to the location of the datasets, and 
a description of the datasets. The data are stored in SPSS format. No existing data standards 
have been used such as vocabularies, ontology’s or thesauri.
Reusable: 
The data will be stored for at least 10 years and can therefore also be reused in this time 
period. There is no embargo on the accessibility of the data.
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established 
the Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially 
recognised as a national graduate school in 2009. The Graduate School covers training at 
both Master’s and PhD level and provides an excellent educational context fully aligned with 
the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. Positions outside 
academia spread among the following sectors: specialists in a medical environment, mainly 
in genetics, geriatrics, psychiatry and neurology. Specialists in a psychological environment, 
e.g. as specialist in neuropsychology, psychological diagnostics or therapy. Positions in higher 
education as coordinators or lecturers. A smaller percentage enters business as research 
consultants, analysts or head of research and development. Fewer graduates  stay in a 
research environment as lab coordinators, technical support or policy advisors. Upcoming 
possibilities are positions in the IT sector and management position in pharmaceutical 
industry. In general, the PhDs graduates almost invariably continue with high-quality 
positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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